Drug Name,Generic Name,Brand Name,Company Name,Therapy Area,Indication,Development Stage,Drug Geography
lenalidomide,lenalidomide,Revlimid,Celgene Switzerland LLC,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Switzerland
lenalidomide,lenalidomide,Revlimid,Celgene BVBA,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Belgium
lenalidomide,lenalidomide,Revlimid,Celgene Corp,Oncology, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma); Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-cell Lymphoma; Nodal Marginal Zone B-Cell Lymphoma; Splenic Marginal Zone B-Cell Lymphoma,Marketed,United States
lenalidomide,lenalidomide,Revlimid,Celgene Pty Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Marketed,Australia
lenalidomide,lenalidomide,Revlimid,Neopharm Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Israel
lenalidomide,lenalidomide,Revlimid,Celgene International Sarl,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Marketed,EU; France
lenalidomide,lenalidomide,Revlimid,Celgene Inc,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Relapsed Multiple Myeloma,Marketed,Canada
lenalidomide,lenalidomide,Revlimid,BeiGene (Beijing) Co Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,China
lenalidomide,lenalidomide,Revlimid,Celgene GmbH,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Marketed,Germany
lenalidomide,lenalidomide,Revlimid,Celgene Srl,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Marketed,Italy
lenalidomide,lenalidomide,Lenalidomide,Bristol-Myers Squibb SA,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Switzerland
lenalidomide,lenalidomide,Revlimid,Celgene New Zealand Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,New Zealand
lenalidomide,lenalidomide,Revlimid,Key Oncologics (Pty) Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,South Africa
lenalidomide,lenalidomide,Revlimid,Celgene KK,Oncology, Follicular Lymphoma; Marginal Zone B-cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Refractory Multiple Myeloma; Relapsed Multiple Myeloma; T-Cell Leukemia; T-Cell Lymphomas,Marketed,Japan
lenalidomide,lenalidomide,Revlimid,Celgene Corp,Oncology, Refractory Multiple Myeloma,Marketed,Russia; South Korea
lenalidomide,lenalidomide,Revlimid,Celgene Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Austria; United Kingdom
lenalidomide,lenalidomide,Revlimid,Celgene SL,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Marketed,Spain
lenalidomide,lenalidomide,Revlimid,Celgene ApS,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Denmark
lenalidomide,lenalidomide,Revlimid,Celgene International Sarl,Oncology, Follicular Lymphoma,Marketed,EU
lenalidomide,lenalidomide,Revlimid,Celgene Ltd,Oncology, Relapsed Multiple Myeloma,Marketed,United Kingdom
lenalidomide,lenalidomide,Revlimid,Celgene Pharmaceuticals Brazil Ltda,Oncology, Myelodysplastic Syndrome; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Marketed,Brazil
lenalidomide,lenalidomide,Revlimid,Celgene Corp,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,South Korea; United States
lenalidomide,lenalidomide,Revlimid,Celgene Corp,Oncology, Relapsed Multiple Myeloma,Marketed,Russia; South Korea; United States
lenalidomide,lenalidomide,Revlimid,Asofarma De Mexico SA De CV,Oncology, Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Marketed,Mexico
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, B-Cell Chronic Lymphocytic Leukemia,Phase III,EU; Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, B-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Phase III,Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, Anaplastic Large Cell Lymphoma (ALCL); Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Peripheral T-Cell Lymphomas (PTCL); Plasma Cell Neoplasm; Primary CNS Lymphoma,Phase II,Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, T-Cell Leukemia; T-Cell Lymphomas,Phase I,Global
lenalidomide,lenalidomide,,Bristol-Myers Squibb Co,Oncology, Primary CNS Lymphoma; Secondary CNS Lymphoma,Phase I,Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, Marginal Zone B-cell Lymphoma,Inactive,China; EU
lenalidomide,lenalidomide,,Bristol-Myers Squibb Co,Oncology, Follicular Lymphoma,Inactive,Global; Japan
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Gastrointestinal, Crohn's Disease (Regional Enteritis),Inactive,Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, Follicular Lymphoma,Inactive,China
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Central Nervous System, Cancer Pain; Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy),Inactive,Global
lenalidomide,lenalidomide,,Bristol-Myers Squibb Co,Oncology, Diffuse Large B-Cell Lymphoma,Inactive,Japan
lenalidomide,lenalidomide,,Bristol-Myers Squibb Co,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy; Cutaneous T-Cell Lymphoma; Follicular Thyroid Cancer; Marginal Zone B-cell Lymphoma; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Myelofibrosis; Ovarian Cancer; Papillary Thyroid Cancer; Peripheral T-Cell Lymphomas (PTCL); Peritoneal Cancer; Primary Mediastinal B-Cell Lymphoma; T-Cell Lymphomas",Inactive,Global
lenalidomide,lenalidomide,,Bristol-Myers Squibb Co,Oncology, Myelodysplastic Syndrome,Inactive,Global; United States
lenalidomide,lenalidomide,,Bristol-Myers Squibb Co,Central Nervous System, Radiculopathy,Inactive,Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Immunology, Immunoglobulin G4-Related Disease (IgG4-RD),Inactive,Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Cutaneous T-Cell Lymphoma; Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer); Non-Small Cell Lung Cancer; Plasma Cell Neoplasm; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia; Transitional Cell Cancer (Urothelial Cell Cancer); Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)",Inactive,Global
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, B-Cell Chronic Lymphocytic Leukemia,Inactive,Global; United States
lenalidomide,lenalidomide,Revlimid,Bristol-Myers Squibb Co,Oncology, Diffuse Large B-Cell Lymphoma,Inactive,EU; United States
aflibercept,aflibercept,Eylea,Bayer New Zealand Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,New Zealand
aflibercept,aflibercept,Eylea,Bayer Plc,Metabolic Disorders, Diabetic Macular Edema,Marketed,United Kingdom
aflibercept,aflibercept,Eylea,Bayer SpA,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Italy
aflibercept,aflibercept,Eylea,Bayer Zydus Pharma Pvt Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,India
aflibercept,aflibercept,Eylea,Bayer Healthcare Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,China
aflibercept,aflibercept,Eylea,PT. Bayer Indonesia,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Indonesia
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United States
aflibercept,aflibercept,Aflibercept,Bayer Yakuhin Ltd,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization; Macular Edema; Neovascular Glaucoma,Marketed,Japan
aflibercept,aflibercept,Eylea,Bayer (Pty) Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,South Africa
aflibercept,aflibercept,Eylea,Bayer Australia Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Australia
aflibercept,aflibercept,Eylea,Bayer Australia Ltd,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Australia
aflibercept,aflibercept,Eylea,Bayer Sante SAS,Metabolic Disorders, Diabetic Macular Edema,Marketed,France
aflibercept,aflibercept,Eylea,Bayer Israel Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Israel
aflibercept,aflibercept,Eylea,PT. Bayer Indonesia,Metabolic Disorders, Diabetic Macular Edema,Marketed,Indonesia
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy; Non-Proliferative Diabetic Retinopathy (NPDR),Marketed,United States
aflibercept,aflibercept,Eylea,Bayer New Zealand Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,New Zealand
aflibercept,aflibercept,Eylea,Bayer Hispania SL,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Spain
aflibercept,aflibercept,Eylea,Bayer Yakuhin Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Neovascular Glaucoma; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Japan
aflibercept,aflibercept,Eylea,Bayer Yakuhin Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Japan
aflibercept,aflibercept,Eylea,Bayer Korea Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,South Korea
aflibercept,aflibercept,Eylea,Bayer AG,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Austria; Belgium; Denmark; EU; Germany
aflibercept,aflibercept,Eylea,Bayer Healthcare Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,China
aflibercept,aflibercept,Eylea,JSC Bayer,Metabolic Disorders, Diabetic Macular Edema,Marketed,Russia
aflibercept,aflibercept,Eylea,Bayer (Pty) Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,South Africa
aflibercept,aflibercept,Eylea,Bayer Inc,Metabolic Disorders, Diabetic Macular Edema,Marketed,Canada
aflibercept,aflibercept,Eylea,Bayer (Schweiz) AG,Metabolic Disorders, Diabetic Macular Edema,Marketed,Switzerland
aflibercept,aflibercept,Eylea,Bayer Sante SAS,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,France
aflibercept,aflibercept,Eylea,Bayer AG,Metabolic Disorders, Diabetic Macular Edema,Marketed,Austria; Belgium; Denmark; EU; Germany
aflibercept,aflibercept,Eylea,Bayer Israel Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Israel
aflibercept,aflibercept,Eylia,Bayer SA (Brazil),Metabolic Disorders, Diabetic Macular Edema,Marketed,Brazil
aflibercept,aflibercept,Eylea,Bayer Plc,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United Kingdom
aflibercept,aflibercept,Eylea,Bayer (Schweiz) AG,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Switzerland
aflibercept,aflibercept,Wetlia,Bayer de Mexico SA de CV,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Mexico
aflibercept,aflibercept,Aflibercept,Bayer Yakuhin Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Japan
aflibercept,aflibercept,Eylea,Bayer Hispania SL,Metabolic Disorders, Diabetic Macular Edema,Marketed,Spain
aflibercept,aflibercept,Eylea,Bayer Inc,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Canada
aflibercept,aflibercept,Eylea,Bayer Korea Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,South Korea
aflibercept,aflibercept,Eylea,Bayer SpA,Metabolic Disorders, Diabetic Macular Edema,Marketed,Italy
aflibercept,aflibercept,Eylea,JSC Bayer,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Russia
aflibercept,aflibercept,Eylia,Bayer SA (Brazil),Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Brazil
aflibercept,aflibercept,Wetlia,Bayer de Mexico SA de CV,Metabolic Disorders, Diabetic Macular Edema,Marketed,Mexico
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Metabolic Disorders, Non-Proliferative Diabetic Retinopathy (NPDR),Pre-Registration,United States
aflibercept,aflibercept,,Regeneron Pharmaceuticals Inc,Ophthalmology, Retinopathy Of Prematurity,Pre-Registration,EU; Japan
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema,Phase III,Global
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Metabolic Disorders, Diabetic Retinopathy,Phase III,Japan
aflibercept,aflibercept,,Regeneron Pharmaceuticals Inc,Ophthalmology, Retinopathy Of Prematurity,Phase III,Japan
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Ophthalmology, Retinopathy Of Prematurity,Phase III,Global; South Korea; United States
aflibercept,aflibercept,,Regeneron Pharmaceuticals Inc,Ophthalmology, Age Related Macular Degeneration,Phase III,Global
aflibercept,aflibercept,,Regeneron Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,United States
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Ophthalmology, Optic Neuropathy; Retinopathy,Phase II,Global
aflibercept,aflibercept,,Regeneron Pharmaceuticals Inc,Ophthalmology, Graves' Ophthalmopathy,Phase I,Global
aflibercept,aflibercept,Eylea,Regeneron Pharmaceuticals Inc,Ophthalmology, Corneal Neovascularization,Inactive,Global
ranibizumab,ranibizumab,Lucentis,Novartis Healthcare Pvt Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,India
ranibizumab,ranibizumab,Lucentis,Novartis Australia Pty Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Australia
ranibizumab,ranibizumab,Lucentis,Novartis Biociencias SA,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Brazil
ranibizumab,ranibizumab,Lucentis,Novartis Farmaceutica SA de CV,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Mexico
ranibizumab,ranibizumab,Lucentis,Novartis Farmaceutica SA,Metabolic Disorders, Diabetic Macular Edema,Marketed,Spain
ranibizumab,ranibizumab,Lucentis,Shanghai Novartis Trading Ltd,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Marketed,China
ranibizumab,ranibizumab,Lucentis,Novartis South Africa Pty Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,South Africa
ranibizumab,ranibizumab,Lucentis,Novartis UK Ltd,Ophthalmology, Retinopathy Of Prematurity,Marketed,EU
ranibizumab,ranibizumab,Lucentis,Novartis Pharma BV,Metabolic Disorders, Diabetic Macular Edema,Marketed,Belgium
ranibizumab,ranibizumab,Lucentis,Genentech USA Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy; Non-Proliferative Diabetic Retinopathy (NPDR); Proliferative Diabetic Retinopathy (PDR),Marketed,United States
ranibizumab,ranibizumab,Lucentis,Novartis Pharmaceuticals UK Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United Kingdom
ranibizumab,ranibizumab,Lucentis,Novartis South Africa Pty Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,South Africa
ranibizumab,ranibizumab,Lucentis,Novartis Healthcare Pvt Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,India
ranibizumab,ranibizumab,Lucentis,Novartis Healthcare A/S,Metabolic Disorders, Diabetic Macular Edema,Marketed,Denmark
ranibizumab,ranibizumab,Lucentis,Novartis Pharma AG,Metabolic Disorders, Diabetic Macular Edema,Marketed,Russia
ranibizumab,ranibizumab,Lucentis,Novartis UK Ltd,Metabolic Disorders, Proliferative Diabetic Retinopathy (PDR),Marketed,EU
ranibizumab,ranibizumab,Lucentis,Novartis Israel Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Israel
ranibizumab,ranibizumab,Lucentis,Genentech USA Inc,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United States
ranibizumab,ranibizumab,Lucentis,Novartis Pharma KK,Ophthalmology, Choroidal Neovascularization; Macular Edema; Retinopathy Of Prematurity; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Japan
ranibizumab,ranibizumab,Lucentis,Novartis Healthcare A/S,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Denmark
ranibizumab,ranibizumab,Lucentis,Novartis Biociencias SA,Ophthalmology, Choroidal Neovascularization; Macular Edema; Retinopathy Of Prematurity; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Brazil
ranibizumab,ranibizumab,Lucentis,Novartis Farmaceutica SA de CV,Metabolic Disorders, Diabetic Macular Edema,Marketed,Mexico
ranibizumab,ranibizumab,Lucentis,Novartis New Zealand Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,New Zealand
ranibizumab,ranibizumab,Lucentis,Novartis New Zealand Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,New Zealand
ranibizumab,ranibizumab,Lucentis,Novartis Pharma Schweiz AG,Metabolic Disorders, Diabetic Macular Edema,Marketed,Switzerland
ranibizumab,ranibizumab,Lucentis,Novartis Sante Familiale SAS,Metabolic Disorders, Diabetic Macular Edema,Marketed,France
ranibizumab,ranibizumab,Lucentis,Novartis Pharmaceuticals UK Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,United Kingdom
ranibizumab,ranibizumab,Lucentis,Novartis Pharmaceuticals Canada Inc,Metabolic Disorders, Diabetic Macular Edema,Marketed,Canada
ranibizumab,ranibizumab,Lucentis,Novartis Pharma AG,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Russia
ranibizumab,ranibizumab,Lucentis,Novartis UK Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Austria; EU; Germany; Italy
ranibizumab,ranibizumab,Lucentis,Novartis Pharma BV,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Belgium
ranibizumab,ranibizumab,Lucentis,Novartis Sante Familiale SAS,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,France
ranibizumab,ranibizumab,Patizra,PT Novartis Indonesia,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Indonesia
ranibizumab,ranibizumab,Lucentis,Novartis Pharma KK,Metabolic Disorders, Diabetic Macular Edema,Marketed,Japan
ranibizumab,ranibizumab,Lucentis,Novartis Farmaceutica SA,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Spain
ranibizumab,ranibizumab,Lucentis,Novartis Korea Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,South Korea
ranibizumab,ranibizumab,Lucentis,Novartis Pharmaceuticals Canada Inc,Ophthalmology, Choroidal Neovascularization; Macular Edema; Retinopathy Of Prematurity; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Canada
ranibizumab,ranibizumab,Lucentis,Novartis Israel Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Israel
ranibizumab,ranibizumab,Lucentis,Novartis Korea Co Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,South Korea
ranibizumab,ranibizumab,Lucentis,Shanghai Novartis Trading Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Retinopathy Of Prematurity; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,China
ranibizumab,ranibizumab,Lucentis,Novartis UK Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Austria; EU; Germany; Italy
ranibizumab,ranibizumab,Lucentis,Novartis Australia Pty Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Australia
ranibizumab,ranibizumab,Lucentis,Novartis Pharma Schweiz AG,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Switzerland
ranibizumab,ranibizumab,,F. Hoffmann-La Roche Ltd,Ophthalmology, Retinopathy Of Prematurity,Phase III,Australia; Global
ranibizumab,ranibizumab,Lucentis,F. Hoffmann-La Roche Ltd,Ophthalmology, Corneal Neovascularization; Cystoid Macular Edema; Polypoidal Choroidal Vasculopathy; Pterygium; Uveitis,Inactive,Global
ranibizumab,ranibizumab,Lucentis,F. Hoffmann-La Roche Ltd,Ear Nose Throat Disorders, Epistaxis,Inactive,Global
bevacizumab,bevacizumab,Avastin,Produtos Roche Quimicos e Farmaceuticos S/A,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Brazil
bevacizumab,bevacizumab,Avastin,Roche Registration Ltd,Oncology, Metastatic Ovarian Cancer; Renal Cell Carcinoma,Marketed,France
bevacizumab,bevacizumab,Avastin,Chugai Pharmaceutical Co Ltd,Oncology, Cervical Cancer; Malignant Glioma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Hepatocellular Carcinoma (HCC); Metastatic Ovarian Cancer; Non-Small Cell Lung Cancer,Marketed,Japan
bevacizumab,bevacizumab,Avastin,Roche Products Pty Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Malignant Glioma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Australia
bevacizumab,bevacizumab,Avastin,PT Menarini Indria Laboratories,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Indonesia
bevacizumab,bevacizumab,Avastin,Hoffmann-La Roche Ltd,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Canada
bevacizumab,bevacizumab,Avastin,Roche Pharmaceuticals (Israel) Ltd,Oncology, Breast Cancer; Cervical Cancer; Glioblastoma Multiforme (GBM); Lung Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Ovarian Cancer,Marketed,Israel
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Peritoneal Cancer,Marketed,EU
bevacizumab,bevacizumab,Avastin,Roche Products (NZ) Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Malignant Glioma ,Marketed,New Zealand
bevacizumab,bevacizumab,Avastin,Genentech USA Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Colorectal Cancer; Metastatic Hepatocellular Carcinoma (HCC); Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,United States
bevacizumab,bevacizumab,Avastin,Roche Registration Ltd,Oncology, Metastatic Renal Cell Carcinoma; Ovarian Cancer,Marketed,Italy; Spain; United Kingdom
bevacizumab,bevacizumab,Avastin,Cipla Ltd,Oncology, Lung Cancer,Marketed,India
bevacizumab,bevacizumab,Avastin,Roche Korea Co Ltd,Oncology, Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Peritoneal Cancer,Marketed,South Korea
bevacizumab,bevacizumab,Avastin,Roche Austria GmbH,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Austria
bevacizumab,bevacizumab,Avastin,Productos Roche SA de CV,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer,Marketed,Mexico
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Colorectal Cancer; Glioma,Marketed,Russia
bevacizumab,bevacizumab,Avastin,Shanghai Roche Pharmaceutical Co Ltd,Oncology, Breast Cancer; Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Lung Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,China
bevacizumab,bevacizumab,Avastin,Roche Registration Ltd,Oncology, Cervical Cancer,Marketed,France; Germany; Spain; United Kingdom
bevacizumab,bevacizumab,Avastin,Roche Registration Ltd,Oncology, Fallopian Tube Cancer; Metastatic Colorectal Cancer; Peritoneal Cancer,Marketed,France; Germany; Italy; Spain; United Kingdom
bevacizumab,bevacizumab,Avastin,PT Boehringer Ingelheim Indonesia,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Indonesia
bevacizumab,bevacizumab,Avastin,Roche Pharma (Schweiz) AG,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Switzerland
bevacizumab,bevacizumab,Avastin,Roche Registration Ltd,Oncology, Metastatic Breast Cancer; Non-Small Cell Lung Cancer,Marketed,France; Italy; Spain; United Kingdom
bevacizumab,bevacizumab,Avastin,Roche a/s,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Denmark
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma,Marketed,EU; Russia
bevacizumab,bevacizumab,Avastin,NV Roche SA,Oncology, Cervical Cancer; Colorectal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Ovarian Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Marketed,Belgium
bevacizumab,bevacizumab,Avastin,Roche Registration Ltd,Oncology, Epithelial Ovarian Cancer,Marketed,Germany
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Melanoma,Phase III,United States
bevacizumab,bevacizumab,,F. Hoffmann-La Roche Ltd,Oncology, Cervical Cancer; Malignant Pleural Mesothelioma,Phase III,Global
bevacizumab,bevacizumab,Avastin,Chugai Pharmaceutical Co Ltd,Oncology, Hepatocellular Carcinoma,Phase III,Japan
bevacizumab,bevacizumab,,Chugai Pharmaceutical Co Ltd,Oncology, Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Small-Cell Lung Cancer,Phase III,Japan
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Hepatocellular Carcinoma; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Non-Small Cell Lung Cancer,Phase III,Global
bevacizumab,bevacizumab,,F. Hoffmann-La Roche Ltd,Oncology, Anal Cancer; Bile Duct Cancer (Cholangiocarcinoma) ; Endometrial Cancer; Pancreatic Ductal Adenocarcinoma; Penile Cancer; Recurrent Glioblastoma Multiforme (GBM); Small-Cell Lung Cancer; Vaginal Cancer; Vulvar Cancer,Phase II,Global
bevacizumab,bevacizumab,,F. Hoffmann-La Roche Ltd,Oncology, Hepatocellular Carcinoma,Phase II,Global; Japan
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Hepatocellular Carcinoma,Phase II,Spain
bevacizumab,bevacizumab,,Chugai Pharmaceutical Co Ltd,Oncology, Hepatocellular Carcinoma; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer),Phase II,Japan
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Malignant Mesothelioma; Merkel Cell Carcinoma; Metastatic Hepatocellular Carcinoma (HCC); Nasopharyngeal Cancer; Neuroblastoma; Non-Small Cell Lung Cancer; Pancreatic Endocrine Tumor; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Phase II,Global
bevacizumab,bevacizumab,,F. Hoffmann-La Roche Ltd,Oncology, Metastatic Colorectal Cancer; Small-Cell Lung Cancer,Phase I,Global
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Glioblastoma Multiforme (GBM),Inactive,EU
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Gastrointestinal Tumor; Meningioma; Metastatic Pancreatic Cancer; Oligodendroglioma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Inactive,Global
bevacizumab,bevacizumab,,F. Hoffmann-La Roche Ltd,Oncology, Bladder Cancer; Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Metastatic Liver Cancer; Non-Rhabdomyosarcoma; Rhabdomyosarcoma,Inactive,Global
bevacizumab,bevacizumab,Avastin,F. Hoffmann-La Roche Ltd,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Malignant Pleural Mesothelioma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer,Discontinued,Global
bevacizumab,bevacizumab,,F. Hoffmann-La Roche Ltd,Oncology, Ovarian Cancer,Discontinued,Global
bevacizumab,bevacizumab,,Chugai Pharmaceutical Co Ltd,Oncology, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer),Discontinued,Japan
bevacizumab,bevacizumab,Avastin,Chugai Pharmaceutical Co Ltd,Oncology, Malignant Pleural Mesothelioma; Metastatic Renal Cell Carcinoma,Discontinued,Japan
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Europe Ltd,Oncology, Endometrial Cancer; Hepatocellular Carcinoma,Marketed,Denmark; EU
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai Pharma AG,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Switzerland
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,United Kingdom
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Ltd,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Metastatic Renal Cell Carcinoma; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,Canada
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Farmaceutica SA,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Hepatocellular Carcinoma; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,Spain
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Europe Ltd,Oncology, Follicular Thyroid Cancer; Papillary Thyroid Cancer,Marketed,Denmark; EU; United Kingdom
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Europe Ltd,Oncology, Thyroid Cancer,Marketed,EU; United Kingdom
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai SA/NV,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Hepatocellular Carcinoma; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,Belgium
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Australia Pty Ltd,Oncology, Follicular Thyroid Cancer; Papillary Thyroid Cancer,Marketed,Australia
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Ltd,Oncology, Hepatocellular Carcinoma,Marketed,Canada; United Kingdom
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Korea Inc,Oncology, Follicular Thyroid Cancer; Hepatocellular Carcinoma; Papillary Thyroid Cancer; Renal Cell Carcinoma; Thyroid Cancer,Marketed,South Korea
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai Europe Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Denmark; EU
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai China Inc,Oncology, Hepatocellular Carcinoma,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Inc,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Thyroid Cancer,Marketed,United States
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Srl,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Hepatocellular Carcinoma; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,Italy
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai Farmaceutica SA,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Spain
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai GesmbH,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Austria
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai SAS,Oncology, Metastatic Renal Cell Carcinoma,Marketed,France
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Co Ltd,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Thyroid Cancer; Thymic Carcinoma,Marketed,Japan
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Pharma AG,Oncology, Hepatocellular Carcinoma; Thyroid Cancer,Marketed,Switzerland
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Neopharm Ltd,Oncology, Follicular Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Thyroid Cancer,Marketed,Israel
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Laboratorios S de RL de CV,Oncology, Follicular Thyroid Cancer; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,Mexico
lenvatinib mesylate,lenvatinib mesylate,Lenvima,United Medical Ltda,Oncology, Follicular Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,Brazil
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai SAS,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Hepatocellular Carcinoma; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,France
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai GesmbH,Oncology, Follicular Thyroid Cancer; Papillary Thyroid Cancer,Marketed,Austria
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai GmbH,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Germany; Italy
lenvatinib mesylate,lenvatinib mesylate,Kisplyx,Eisai SA/NV,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Belgium
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Ltd,Oncology, Follicular Thyroid Cancer; Papillary Thyroid Cancer; Thyroid Cancer,Marketed,Russia
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Australia Pty Ltd,Oncology, Endometrial Cancer; Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Thyroid Cancer,Marketed,Australia; New Zealand
lenvatinib mesylate,lenvatinib mesylate,Lenvima,PT Eisai Indonesia,Oncology, Follicular Thyroid Cancer; Hepatocellular Carcinoma; Papillary Thyroid Cancer,Marketed,Indonesia
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai GmbH,Oncology, Endometrial Cancer; Follicular Thyroid Cancer; Hepatocellular Carcinoma; Papillary Thyroid Cancer; Thyroid Cancer,Withdrawn,Germany
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction,Phase III,China; EU; Global
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,EU; Global; Japan; United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Renal Cell Carcinoma,Phase III,EU
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Gastric Cancer,Phase III,China; EU; Global; Japan; United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Metastatic Melanoma,Phase III,China; EU; United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Colorectal Cancer,Phase III,EU; United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Endometrial Cancer; Esophageal Squamous Cell Carcinoma (ESCC); Metastatic Transitional (Urothelial) Tract Cancer; Recurrent Head And Neck Cancer Squamous Cell Carcinoma,Phase III,China; EU; Japan; United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Phase III,Global
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Metastatic Renal Cell Carcinoma,Phase III,United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Bladder Cancer,Phase III,China; EU; Global; United States
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Co Ltd,Oncology, Esophageal Squamous Cell Carcinoma (ESCC); Metastatic Renal Cell Carcinoma,Phase III,Global
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Gastric Cancer; Glioblastoma Multiforme (GBM); Melanoma; Ovarian Cancer; Triple-Negative Breast Cancer (TNBC),Phase II,EU; Global; United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Head And Neck Cancer Squamous Cell Carcinoma; Lung Adenocarcinoma,Phase II,United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Endometrial Cancer; Metastatic Biliary Tract Cancer; Metastatic Melanoma; Non-Small Cell Lung Cancer; Pancreatic Cancer; Transitional Cell Cancer (Urothelial Cell Cancer),Phase II,EU; United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Head And Neck Cancer,Phase II,EU
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Adenoid Cystic Carcinoma (ACC); Anaplastic Thyroid Cancer; Breast Cancer; Colorectal Cancer; Ewing Sarcoma; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; High-Grade Glioma; Hypopharyngeal Cancer; Laryngeal Cancer; Merkel Cell Carcinoma; Oral Cavity (Mouth) Cancer; Oropharyngeal Cancer; Osteosarcoma; Pancreatic Ductal Adenocarcinoma; Pediatric Diffuse Intrinsic Pontine Glioma; Primitive Neuroectodermal Tumor (PNET); Prostate Cancer; Recurrent Head And Neck Cancer Squamous Cell Carcinoma; Rhabdomyosarcoma; Salivary Gland Cancer; Small-Cell Lung Cancer; Thymic Carcinoma,Phase II,Global
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Co Ltd,Oncology, Head And Neck Cancer Squamous Cell Carcinoma,Phase II,EU
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology," Adenocarcinoma Of The Gastroesophageal Junction; Adrenocortical Carcinoma (Adrenal Cortex Cancer); Epithelial Ovarian Cancer; Fallopian Tube Cancer; Gastric Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis); Malignant Pleural Mesothelioma; Oral Cavity (Mouth) Cancer; Oropharyngeal Cancer; Pancreatic Ductal Adenocarcinoma; Paranasal Sinus And Nasal Cavity Cancer; Peritoneal Cancer; Recurrent Head And Neck Cancer Squamous Cell Carcinoma; Squamous Cell Carcinoma",Phase I,Global
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Solid Tumor,Phase I,China
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Infectious Disease, Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma),Phase I,Global
lenvatinib mesylate,lenvatinib mesylate,Lenvima,Eisai Co Ltd,Oncology, Melanoma,Phase I,Global
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Endometrial Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Hepatocellular Carcinoma; Melanoma; Renal Cell Carcinoma; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Phase I,Japan
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase I,Global; Japan
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Gastrointestinal, Liver Fibrosis,Inactive,Global
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Melanoma; Recurrent Glioblastoma Multiforme (GBM),Inactive,Global
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Non-Small Cell Lung Cancer,Inactive,China
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Bladder Cancer; Metastatic Biliary Tract Cancer,Inactive,Japan
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Lung Adenocarcinoma,Inactive,Asia-Pacific; EU; Japan
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Recurrent Malignant Glioma ,Discontinued,United States
lenvatinib mesylate,lenvatinib mesylate,,Eisai Co Ltd,Oncology, Non-Small Cell Lung Cancer,Discontinued,EU; United States
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen NV,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,Belgium
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen Biopharmaceuticals Canada Inc,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Thyroid Cancer,Marketed,Canada
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen Pharma GmbH,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,Austria; EU; Germany
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen SpA,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,Italy
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen SA,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma,Marketed,New Zealand
Cabometyx,cabozantinib s-malate,Cabometyx,Medison Pharma Ltd,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma,Marketed,Israel
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen Pty Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Australia
Cabometyx,cabozantinib s-malate,Cabometyx,Future Health Pharma GmbH,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Switzerland
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,United States
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen Korea Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,South Korea
Cabometyx,cabozantinib s-malate,Cabometyx,Takeda Pharmaceutical Co Ltd,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma,Marketed,Japan
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen Pharma SA,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,Denmark; Spain
Cabometyx,cabozantinib s-malate,Aptimetyx,Ipsen Mexico S de RL de CV,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Mexico
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen Ltd,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma,Marketed,United Kingdom
Cabometyx,cabozantinib s-malate,Cabometyx,Beaufour Ipsen Farmaceutica Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Brazil
Cabometyx,cabozantinib s-malate,Cabometyx,Ipsen Innovation SAS,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,France
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology, Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Carcinoma,Phase III,Global
Cabometyx,cabozantinib s-malate,,Takeda Pharmaceutical Co Ltd,Oncology," Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Non-Small Cell Lung Cancer",Phase III,Japan
Cabometyx,cabozantinib s-malate,,Exelixis Inc,Oncology, Metastatic Renal Cell Carcinoma,Phase III,Global
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology," Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer",Phase III,United States
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology, Adrenocortical Carcinoma (Adrenal Cortex Cancer); Endometrial Cancer; Epithelial Ovarian Cancer; Esophageal Squamous Cell Carcinoma (ESCC); Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Head And Neck Cancer Squamous Cell Carcinoma; High-Grade Glioma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Muscle Invasive Bladder Cancer (MIBC); Neuroendocrine Carcinoma; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Neuroendocrine Tumors; Soft Tissue Sarcoma; Transitional Cell Cancer (Urothelial Cell Cancer); Triple-Negative Breast Cancer (TNBC),Phase II,Global
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology, Gastrointestinal Stromal Tumor (GIST); Leiomyosarcoma; Uterine Cancer,Phase II,EU
Cabometyx,cabozantinib s-malate,,Exelixis Inc,Oncology," Adrenocortical Carcinoma (Adrenal Cortex Cancer); Bladder Cancer; Cervical Cancer; Esophageal Cancer; Ewing Sarcoma; Fallopian Tube Cancer; Follicular Thyroid Cancer; Germ Cell Tumors; High-Grade Glioma; Laryngeal Cancer; Lip Cancer; Medulloblastoma; Metastatic Biliary Tract Cancer; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Metastatic Melanoma; Nasopharyngeal Cancer; Neuroblastoma; Non-Rhabdomyosarcoma; Non-Small Cell Lung Cancer; Oral Cavity (Mouth) Cancer; Oropharyngeal Cancer; Osteosarcoma; Pancreatic Cancer; Papillary Thyroid Cancer; Paranasal Sinus And Nasal Cavity Cancer; Pediatric Diffuse Intrinsic Pontine Glioma; Peritoneal Cancer; Rhabdomyosarcoma; Salivary Gland Cancer; Soft Tissue Sarcoma; Transitional Cell Carcinoma (Urothelial Cell Carcinoma); Ureter Cancer; Urethral Cancer; Wilms' Tumor (Nephroblastoma)",Phase II,Global
Cabometyx,cabozantinib s-malate,,Takeda Pharmaceutical Co Ltd,Oncology, Metastatic Colorectal Cancer,Phase II,Japan
Cabometyx,cabozantinib s-malate,,Exelixis Inc,Oncology, Ewing Sarcoma; Germ Cell Tumors; Hepatocellular Carcinoma; Leukemia; Lymphoma; Melanoma; Osteosarcoma; Prostate Cancer; Renal Cell Carcinoma; Soft Tissue Sarcoma; Solid Tumor,Phase I,Global
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology, Melanoma,Phase I,Global
Cabometyx,cabozantinib s-malate,,Exelixis Inc,Oncology, Adenoid Cystic Carcinoma (ACC),Inactive,Global
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology, Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Salivary Gland Cancer,Inactive,Global
Cabometyx,cabozantinib s-malate,Cabometyx,Exelixis Inc,Oncology, Hepatocellular Carcinoma,Inactive,United States
bevacizumab biosimilar,bevacizumab-awwb,Bevacizumab,Daiichi Sankyo Co Ltd,Oncology, Colorectal Cancer,Marketed,Japan
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Canada Inc,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Canada
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen SA,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Spain
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen SpA,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Italy
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Europe BV,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Denmark; EU
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Israel; United States
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Switzerland AG,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Switzerland
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Inc,Oncology, Metastatic Breast Cancer,Marketed,Israel
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen NV,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Belgium
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,PT Pyridam Farma Tbk,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Marketed,Indonesia
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen SAS,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,France
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen GmbH,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Austria; Germany
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Australia Pty Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Marketed,Australia
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,United Kingdom
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen Inc,Oncology, Recurrent Glioblastoma Multiforme (GBM),Marketed,United States
bevacizumab biosimilar,bevacizumab-awwb,Mvasi ,Amgen New Zealand Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Malignant Glioma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Withdrawn,New Zealand
bevacizumab biosimilar,bevacizumab-awwb,,Amgen Inc,Oncology, Non-Small Cell Lung Cancer,Phase I,China
bevacizumab biosimilar,bevacizumab-awwb,Kyomarc,Amgen Inc,Oncology, Breast Cancer; Cervical Cancer; Colon Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Ovarian Cancer; Peritoneal Cancer; Rectal Cancer,Inactive,EU
ramucirumab,ramucirumab,Cyramza,Lilly Netherlands BV,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Austria; EU; Spain
ramucirumab,ramucirumab,Cyramza,Eli Lilly Italia SpA,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Italy
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Company Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,United Kingdom
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Co,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Indonesia; United States
ramucirumab,ramucirumab,Cyramza,Eli Lilly Australia Pty Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Australia
ramucirumab,ramucirumab,Cyramza,Eli Lilly do Brasil Ltda,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Brazil
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Co,Oncology, Hepatocellular Carcinoma,Marketed,United States
ramucirumab,ramucirumab,Cyramza,Eli Lilly (SA) (PTY) Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,South Africa
ramucirumab,ramucirumab,Cyramza,Eli Lilly Denmark A/S,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Denmark
ramucirumab,ramucirumab,Cyramza,Eli Lilly Israel,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Israel
ramucirumab,ramucirumab,Cyramza,Eli Lilly Mexico SA CV,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Mexico
ramucirumab,ramucirumab,Cyramza,Eli Lilly Canada Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Canada
ramucirumab,ramucirumab,Cyramza,Eli Lilly Japan KK,Oncology, Gastric Cancer; Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Japan
ramucirumab,ramucirumab,Cyramza,Eli Lilly Benelux SA,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Belgium
ramucirumab,ramucirumab,Cyramza,Lilly France SAS,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,France
ramucirumab,ramucirumab,Cyramza,Lilly Deutschland GmbH,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,Germany
ramucirumab,ramucirumab,Cyramza,Lilly Korea Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction,Marketed,South Korea
ramucirumab,ramucirumab,Cyramza,Eli Lilly (Suisse) SA,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Switzerland
ramucirumab,ramucirumab,Ramucirumab,Eli Lilly International Trading Shanghai Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Marketed,China
ramucirumab,ramucirumab,Cyramza,Lilly Netherlands BV,Oncology, Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,EU
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Co (NZ) Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction,Withdrawn,New Zealand
ramucirumab,ramucirumab,,Eli Lilly and Co,Oncology, Metastatic Colorectal Cancer,Phase III,Global
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Co,Oncology, Adenocarcinoma Of The Gastroesophageal Junction,Phase III,EU; Japan; United States
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Co,Oncology, Malignant Pleural Mesothelioma,Phase II,Global
ramucirumab,ramucirumab,,Eli Lilly and Co,Oncology, Esophageal Cancer; Gallbladder Cancer; Gastric Cancer; Metastatic Adenocarcinoma of The Pancreas; Metastatic Biliary Tract Cancer; Neuroendocrine Tumors; Soft Tissue Sarcoma; Synovial Sarcoma; Thymic Carcinoma,Phase II,Global
ramucirumab,ramucirumab,,Eli Lilly and Co,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Bladder Cancer; Central Nervous System (CNS) Tumor; Gastric Cancer; Hepatocellular Carcinoma; Metastatic Biliary Tract Cancer; Non-Small Cell Lung Cancer; Solid Tumor; Squamous Non-Small Cell Lung Cancer; Transitional Cell Carcinoma (Urothelial Cell Carcinoma); Urethral Cancer,Phase I,Global
ramucirumab,ramucirumab,,Eli Lilly and Co,Oncology, Small-Cell Lung Cancer,Phase I,Japan
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Co,Oncology, Non-Small Cell Lung Cancer,Inactive,Japan
ramucirumab,ramucirumab,,Eli Lilly and Co,Oncology," Epithelial Ovarian Cancer; Fallopian Tube Cancer; Gastric Cancer; Hepatocellular Carcinoma; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Mantle Cell Lymphoma; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Peritoneal Tumor; Recurrent Glioblastoma Multiforme (GBM); Signet Ring Cell Squamous Cell Carcinoma ; Solid Tumor",Inactive,Global
ramucirumab,ramucirumab,Cyramza,Eli Lilly and Co,Oncology, Metastatic Transitional (Urothelial) Tract Cancer,Discontinued,EU; Japan; United States
ramucirumab,ramucirumab,,Eli Lilly and Co,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer),Discontinued,Global
ramucirumab,ramucirumab,,Eli Lilly and Co,Oncology, Gastric Cancer,Discontinued,EU; Japan; United States
axitinib,axitinib,Inlyta,Pfizer SA de CV,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Mexico
axitinib,axitinib,Inlyta,Pfizer (China) Research and Development Co Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,China
axitinib,axitinib,Inlyta,Pfizer Ltd (UK),Oncology, Metastatic Renal Cell Carcinoma,Marketed,EU; United Kingdom
axitinib,axitinib,Inlyta,Pfizer SL,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Spain
axitinib,axitinib,Inlyta,Pfizer ApS,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Denmark
axitinib,axitinib,Inlyta,Pfizer Corporation Austria Gesellschaft mbH,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Austria
axitinib,axitinib,Inlyta,Pfizer Pharmaceuticals Korea Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,South Korea
axitinib,axitinib,Inlyta,Pfizer Canada Inc,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Canada
axitinib,axitinib,Inlyta,Pfizer Australia Pty Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Australia
axitinib,axitinib,Inlyta,Laboratorios Pfizer Ltda,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Brazil
axitinib,axitinib,Inlyta,Pfizer Pharma GmbH,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Germany
axitinib,axitinib,Inlyta,Pfizer Holding France (SCA),Oncology, Metastatic Renal Cell Carcinoma,Marketed,France
axitinib,axitinib,Inlyta,Pfizer AG,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Switzerland
axitinib,axitinib,Inlyta,Pfizer NV/SA,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Belgium
axitinib,axitinib,Inlita ,Pfizer HCP Corp,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Russia
axitinib,axitinib,Inlyta,Pfizer Inc,Oncology, Metastatic Renal Cell Carcinoma,Marketed,United States
axitinib,axitinib,Inlyta,PT. Pfizer Indonesia,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Indonesia
axitinib,axitinib,Inlyta,Pfizer Pharmaceuticals Israel Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Israel
axitinib,axitinib,Inlyta,Pfizer New Zealand Limited,Oncology, Metastatic Renal Cell Carcinoma,Marketed,New Zealand
axitinib,axitinib,Inlyta,Pfizer Japan Inc,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Japan
axitinib,axitinib,Inlyta,Pfizer Italia Srl,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Italy
axitinib,axitinib,,Pfizer Inc,Oncology, Neuroendocrine Tumors,Phase III,Global
axitinib,axitinib,Inlyta,Pfizer Inc,Oncology, Angiosarcoma; Chondrosarcoma; Ductal Carcinoma; Ewing Sarcoma; Gastrointestinal Stromal Tumor (GIST); Leiomyosarcoma; Melanoma; Non-Small Cell Lung Cancer; Osteosarcoma; Peripheral Nerve Sheath Tumor (Neurofibrosarcoma); Pleomorphic Liposarcoma; Prostate Cancer; Rhabdomyosarcoma; Salivary Gland Cancer; Soft Tissue Sarcoma; Spindle Cell Squamous Cell Carcinoma ; Synovial Sarcoma,Phase II,Global
axitinib,axitinib,,Pfizer Inc,Oncology, Bladder Cancer; Chordoma; Clear Cell Squamous Cell Carcinoma  ; Gastrointestinal Stromal Tumor (GIST); Metastatic Melanoma; Metastatic Transitional (Urothelial) Tract Cancer; Paraganglioma (Glomus Jugulare Tumor); Recurrent Glioblastoma Multiforme (GBM); Sarcomas; Ureter Cancer; Urethral Cancer,Phase II,Global
axitinib,axitinib,,Pfizer Inc,Dermatology, Atopic Dermatitis (Atopic Eczema),Unknown,China
axitinib,axitinib,Inlyta,Pfizer Inc,Oncology, Hepatocellular Carcinoma,Inactive,Global
axitinib,axitinib,Inlyta,Pfizer Inc,Infectious Disease, Kaposi Sarcoma,Inactive,Global
axitinib,axitinib,,Pfizer Inc,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Adrenocortical Carcinoma (Adrenal Cortex Cancer); Gastric Cancer; Glioblastoma Multiforme (GBM); Head And Neck Cancer Squamous Cell Carcinoma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Uveal Melanoma; Myelodysplastic Syndrome; Non-Small Cell Lung Cancer",Inactive,Global
axitinib,axitinib,,Pfizer Inc,Oncology, Thyroid Cancer,Inactive,United States
axitinib,axitinib,,Pfizer Inc,Oncology, Metastatic Hepatocellular Carcinoma (HCC),Discontinued,Global
axitinib,axitinib,,Pfizer Inc,Oncology, Metastatic Pancreatic Cancer,Discontinued,United States
axitinib,axitinib,Inlyta,Pfizer Inc,Oncology, Renal Cell Carcinoma,Discontinued,Asia-Pacific
regorafenib,regorafenib,Stivarga,Bayer (Pty) Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer,Marketed,South Africa
regorafenib,regorafenib,Stivarga,Bayer Australia Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Australia
regorafenib,regorafenib,Stivarga,Bayer (Schweiz) AG,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Switzerland
regorafenib,regorafenib,Stivarga,Bayer Hispania SL,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer,Marketed,Spain
regorafenib,regorafenib,Nublexa,Bayer Pharmaceuticals Pvt Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,India
regorafenib,regorafenib,Stivarga,Bayer Sante SAS,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer,Marketed,France
regorafenib,regorafenib,Stivarga,Bayer Yakuhin Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Japan
regorafenib,regorafenib,Stivarga,Bayer Korea Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer,Marketed,South Korea
regorafenib,regorafenib,Stivarga,Bayer SpA,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer,Marketed,Italy
regorafenib,regorafenib,Stivarga,Bayer AG,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer,Marketed,Austria; EU; Germany
regorafenib,regorafenib,Stivarga,Bayer SA (Brazil),Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Brazil
regorafenib,regorafenib,Stivarga,Bayer NV,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Belgium
regorafenib,regorafenib,Stivarga,Bayer A / S,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Denmark
regorafenib,regorafenib,Stivarga,Bayer Israel Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Israel
regorafenib,regorafenib,Stivarga,PT. Bayer Indonesia,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Indonesia
regorafenib,regorafenib,Stivarga,Bayer (China) Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,China
regorafenib,regorafenib,Stivarga,Bayer de Mexico SA de CV,Oncology, Metastatic Colorectal Cancer,Marketed,Mexico
regorafenib,regorafenib,Stivarga,Bayer Plc,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,United Kingdom
regorafenib,regorafenib,Stivarga,Bayer Healthcare LLC,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,United States
regorafenib,regorafenib,Stivarga,Bayer Inc,Oncology, Gastrointestinal Stromal Tumor (GIST); Hepatocellular Carcinoma; Metastatic Colorectal Cancer,Marketed,Canada
regorafenib,regorafenib,Stivarga,Bayer AG,Oncology, Hepatocellular Carcinoma,Marketed,Austria; EU
regorafenib,regorafenib,Stivarga,Bayer New Zealand Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer,Withdrawn,New Zealand
regorafenib,regorafenib,Stivarga,Bayer AG,Oncology, Recurrent Glioblastoma Multiforme (GBM),Phase III,United States
regorafenib,regorafenib,,Bayer AG,Oncology, Gliosarcoma; Metastatic Colorectal Cancer; Osteosarcoma; Recurrent Glioblastoma Multiforme (GBM),Phase III,Global
regorafenib,regorafenib,Stivarga,Bayer AG,Oncology, Glioblastoma Multiforme (GBM),Phase III,EU
regorafenib,regorafenib,,Bayer AG,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Adenoid Cystic Carcinoma (ACC); Anaplastic Astrocytoma; Bile Duct Cancer (Cholangiocarcinoma) ; Chondrosarcoma; Chordoma; Esophageal Cancer; Esophageal Squamous Cell Carcinoma (ESCC); Ewing Sarcoma; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Gastrointestinal Stromal Tumor (GIST); Glioblastoma Multiforme (GBM); Head And Neck Cancer Squamous Cell Carcinoma; Liposarcoma ; Metastatic Adenocarcinoma of The Pancreas; Metastatic Biliary Tract Cancer; Metastatic Colorectal Cancer; Oropharyngeal Cancer; Pancreatic Ductal Adenocarcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Solid Tumor; Transitional Cell Cancer (Urothelial Cell Cancer),Phase II,Global
regorafenib,regorafenib,Stivarga,Bayer AG,Oncology, Hepatocellular Carcinoma; Medullary Thyroid Cancer; Metastatic Hepatocellular Carcinoma (HCC),Phase II,Global
regorafenib,regorafenib,Stivarga,Bayer AG,Oncology, Myelodysplastic Syndrome; Myelofibrosis; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia,Phase I,Global
regorafenib,regorafenib,,Bayer AG,Oncology, Head And Neck Cancer Squamous Cell Carcinoma; Metastatic Hepatocellular Carcinoma (HCC),Phase I,Global
regorafenib,regorafenib,,Bayer AG,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer; Renal Cell Carcinoma,Inactive,Global
regorafenib,regorafenib,,Bayer AG,Oncology, Solid Tumor,Inactive,China; Japan
regorafenib,regorafenib,,Bayer AG,Oncology, Metastatic Colorectal Cancer,Inactive,Asia-Pacific
regorafenib,regorafenib,,Bayer AG,Oncology, Metastatic Colorectal Cancer,Discontinued,Global
regorafenib,regorafenib,,Bayer AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer ApS,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Denmark
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Canada Inc,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Canada
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Australia Pty Ltd,Oncology, Cervical Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer; Squamous Non-Small Cell Lung Cancer,Marketed,Australia
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Italia Srl,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Italy
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer AG,Oncology, Cervical Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Switzerland
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Ltd (UK),Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,EU; United Kingdom
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Pharmaceuticals Israel Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Israel
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer SL,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Spain
bevacizumab biosimilar,bevacizumab-bvzr,Bevacizumab,Pfizer Japan Inc,Oncology, Metastatic Colorectal Cancer,Marketed,Japan
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,United States
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Holding France (SCA),Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,France
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Corporation Austria Gesellschaft mbH,Oncology, Cervical Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Austria
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer NV/SA,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Belgium
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Brasil,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Brazil
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer Germany GmbH,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Germany
bevacizumab biosimilar,bevacizumab-bvzr,Zirabev,Pfizer New Zealand Limited,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Malignant Glioma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Withdrawn,New Zealand
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,PT Sydna Farma,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Indonesia
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Denmark A/S,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Denmark
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Medison Pharma Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Israel
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier (Suisse) SA,Oncology, Metastatic Colorectal Cancer,Marketed,Switzerland
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Laboratories SA (Pty) Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,South Africa
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Taiho Pharmaceutical Co Ltd,Oncology, Gastric Cancer,Marketed,Japan
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Taiho Pharma Canada Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Canada
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Taiho Oncology Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,United States
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Laboratories of Brazil Ltda,Oncology, Metastatic Colorectal Cancer,Marketed,Brazil
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Jeil Pharmaceutical Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,South Korea
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Laboratories Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,United Kingdom
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Laboratorios Servier SL,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Spain
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Deutschland GmbH,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Germany
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Les Laboratoires Servier SAS,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Austria; EU; France
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Taiho Pharmaceutical Co Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,China; Japan
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Benelux SA,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Belgium
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Italia SpA,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Marketed,Italy
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Servier Laboratories (Aust) Pty Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,Australia
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Orcantas,Servier Laboratories (Aust) Pty Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,Australia
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Orcantas,Servier Laboratories SA (Pty) Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,South Africa
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Taiho Oncology Inc,Oncology, Metastatic Colorectal Cancer,Phase III,Global
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),,Les Laboratoires Servier SAS,Oncology, Metastatic Colorectal Cancer,Phase III,EU; Global
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),,Les Laboratoires Servier SAS,Oncology, Metastatic Colorectal Cancer,Phase II,Global
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),,Taiho Oncology Inc,Oncology, Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma) ; Basaloid Squamous Cell Carcinoma ; Bile Duct Cancer (Cholangiocarcinoma) ; Esophageal Cancer; Gallbladder Cancer; Metastatic Adenocarcinoma of The Pancreas; Metastatic Transitional (Urothelial) Tract Cancer; Neuroendocrine Carcinoma; Squamous Cell Carcinoma; Squamous Non-Small Cell Lung Carcinoma,Phase II,Global
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),,Taiho Oncology Inc,Oncology, Breast Cancer; Colorectal Cancer; Gastrointestinal Tumor; Pancreatic Endocrine Tumor; Rectal Cancer,Phase I,Global
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),,3SBio Inc,Oncology, Metastatic Colorectal Cancer,Inactive,China
(tipiracil hydrochloride + trifluridine),(tipiracil hydrochloride + trifluridine),Lonsurf,Taiho Oncology Inc,Oncology, Small-Cell Lung Cancer,Discontinued,EU; Japan
lurbinectedin,lurbinectedin,Zepzelca,Specialised Therapeutics Australia Pty Ltd,Oncology, Small-Cell Lung Cancer,Marketed,Australia
lurbinectedin,lurbinectedin,Zepzelca,Jazz Pharmaceuticals Inc,Oncology, Small-Cell Lung Cancer,Marketed,United States
lurbinectedin,lurbinectedin,Zepzelca,Jazz Pharmaceuticals Plc,Oncology, Small-Cell Lung Cancer,Marketed,Canada
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Small-Cell Lung Cancer,Pre-Registration,United Kingdom
lurbinectedin,lurbinectedin,,Luye Pharma Group Ltd,Oncology, Small-Cell Lung Cancer,Pre-Registration,China; Hong Kong
lurbinectedin,lurbinectedin,,Jazz Pharmaceuticals Plc,Oncology, Small-Cell Lung Cancer,Phase III,United States
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Small-Cell Lung Cancer,Phase III,EU; Global; Middle East and Africa
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Ewing Sarcoma; Gastric Cancer; Germ Cell Tumors; Glioblastoma Multiforme (GBM); Head And Neck Carcinoma; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Leiomyosarcoma; Malignant Pleural Mesothelioma; Metastatic Colorectal Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Pancreatic Cancer; Sarcomas; Soft Tissue Sarcoma,Phase II,Global
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Malignant Mesothelioma,Phase II,EU
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Endometrial Cancer,Phase II,EU; Global
lurbinectedin,lurbinectedin,,Jazz Pharmaceuticals Plc,Oncology, Endometrial Cancer; Esophageal Cancer; Gastric Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Biliary Tract Cancer; Metastatic Pancreatic Cancer; Neuroendocrine Cancer; Solid Tumor; Transitional Cell Cancer (Urothelial Cell Cancer); Triple-Negative Breast Cancer (TNBC),Phase II,United States
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Solid Tumor,Phase I,Japan
lurbinectedin,lurbinectedin,,Luye Pharma Group Ltd,Oncology, Solid Tumor,Phase I,China
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology," Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia); Bladder Cancer; Bone Cancer; Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia); Hematological Tumor; Hepatocellular Carcinoma; Leukemia; Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia",Phase I,Global
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Small-Cell Lung Cancer,Inactive,Israel; Switzerland
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Metastatic Pancreatic Cancer,Inactive,Global
lurbinectedin,lurbinectedin,,Pharma Mar SA,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Inactive,EU; United States
brolucizumab,brolucizumab,Beovu,Novartis Healthcare A/S,Metabolic Disorders, Diabetic Macular Edema,Marketed,Denmark
brolucizumab,brolucizumab,Beovu,Novartis Pharma KK,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Japan
brolucizumab,brolucizumab,Beovu,Novartis Pharma SAS,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,France
brolucizumab,brolucizumab,Beovu,Novartis Israel Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Israel
brolucizumab,brolucizumab,Beovu,Novartis Pharmaceuticals Corp,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United States
brolucizumab,brolucizumab,Pagenax,PT Novartis Indonesia,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Indonesia
brolucizumab,brolucizumab,Vizcu,Novartis Pharma LLC,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Russia
brolucizumab,brolucizumab,Beovu,Novartis Pharma NV SA,Metabolic Disorders, Diabetic Macular Edema,Marketed,Belgium
brolucizumab,brolucizumab,Beovu,Novartis Pharma SAS,Metabolic Disorders, Diabetic Macular Edema,Marketed,France
brolucizumab,brolucizumab,Beovu,Novartis Farma SpA,Metabolic Disorders, Diabetic Macular Edema,Marketed,Italy
brolucizumab,brolucizumab,Beovu,Novartis Farma SpA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Italy
brolucizumab,brolucizumab,Beovu,Novartis Korea Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,South Korea
brolucizumab,brolucizumab,Beovu,Novartis Pharmaceuticals Canada Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Canada
brolucizumab,brolucizumab,Beovu,Novartis Pharmaceuticals Australia Pty Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Australia
brolucizumab,brolucizumab,Vsiqq,Novartis Pharmaceuticals Australia Pty Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Australia
brolucizumab,brolucizumab,Beovu,Novartis Farmaceutica SA,Metabolic Disorders, Diabetic Macular Edema,Marketed,Spain
brolucizumab,brolucizumab,Beovu,Novartis Pharma GmbH,Metabolic Disorders, Diabetic Macular Edema,Marketed,Germany
brolucizumab,brolucizumab,Beovu,Novartis Pharmaceuticals Corp,Metabolic Disorders, Diabetic Macular Edema,Marketed,United States
brolucizumab,brolucizumab,Beovu,Novartis Pharma KK,Metabolic Disorders, Diabetic Macular Edema,Marketed,Japan
brolucizumab,brolucizumab,Beovu,Novartis UK Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,EU
brolucizumab,brolucizumab,Beovu,Novartis Healthcare A/S,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Denmark
brolucizumab,brolucizumab,Beovu,Novartis UK Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,EU; United Kingdom
brolucizumab,brolucizumab,Beovu,Novartis Pharma NV SA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Belgium
brolucizumab,brolucizumab,Vsiqq,Novartis Biociencias SA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Brazil
brolucizumab,brolucizumab,Beovu,Novartis Austria GmbH,Metabolic Disorders, Diabetic Macular Edema,Marketed,Austria
brolucizumab,brolucizumab,Beovu,Novartis Farmaceutica SA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Spain
brolucizumab,brolucizumab,Beovu,Novartis Pharma GmbH,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Germany
brolucizumab,brolucizumab,Beovu,Novartis Austria GmbH,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Austria
brolucizumab,brolucizumab,Beovu,Novartis Pharma Schweiz AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Switzerland
brolucizumab,brolucizumab,Vsiqq,Sandoz South Africa (Pty) Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,South Africa
brolucizumab,brolucizumab,Beovu,Novartis New Zealand Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,New Zealand
brolucizumab,brolucizumab,,Novartis AG,Metabolic Disorders, Diabetic Macular Edema,Phase III,China; Global
brolucizumab,brolucizumab,,Novartis AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,China
brolucizumab,brolucizumab,,Novartis AG,Metabolic Disorders, Proliferative Diabetic Retinopathy (PDR),Phase III,Global
brolucizumab,brolucizumab,,Kuur Therapeutics Ltd,Infectious Disease, Kaposi Sarcoma,Inactive,Global
brolucizumab,brolucizumab,,Kuur Therapeutics Ltd,Dermatology, Keloids; Rosacea,Inactive,Global
brolucizumab,brolucizumab,,Novartis AG,Ophthalmology, Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion,Inactive,Global
brolucizumab,brolucizumab,,Kuur Therapeutics Ltd,Oncology, Glioblastoma Multiforme (GBM),Inactive,Global
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,AVEO Pharmaceuticals Inc,Oncology, Metastatic Renal Cell Carcinoma,Marketed,United States
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,Recordati SpA,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Austria; Belgium; Denmark; EU; Italy
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,Recordati Espana Sl,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Spain
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,Recordati Orphan Drugs SAS,Oncology, Metastatic Renal Cell Carcinoma,Marketed,France
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,Recordati Pharma GmbH,Oncology, Metastatic Renal Cell Carcinoma,Marketed,Germany
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,Recordati Pharmaceuticals Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,United Kingdom
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,Link Pharmaceuticals Ltd,Oncology, Metastatic Renal Cell Carcinoma,Withdrawn,New Zealand
tivozanib hydrochloride,tivozanib hydrochloride,,AVEO Pharmaceuticals Inc,Oncology, Renal Cell Carcinoma,Phase III,Global
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,AVEO Pharmaceuticals Inc,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Gallbladder Cancer; Neuroendocrine Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Soft Tissue Sarcoma,Phase II,Global
tivozanib hydrochloride,tivozanib hydrochloride,,Recordati SpA,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ,Phase II,Global
tivozanib hydrochloride,tivozanib hydrochloride,,AVEO Pharmaceuticals Inc,Oncology, Fallopian Tube Cancer; Metastatic Hepatocellular Carcinoma (HCC); Ovarian Cancer; Peritoneal Cancer,Phase II,Global
tivozanib hydrochloride,tivozanib hydrochloride,,Recordati SpA,Undisclosed, Unspecified,IND/CTA Filed,Japan
tivozanib hydrochloride,tivozanib hydrochloride,,Pharmstandard,Oncology, Renal Cell Carcinoma,Inactive,Russia
tivozanib hydrochloride,tivozanib hydrochloride,,AVEO Pharmaceuticals Inc,Oncology, Hepatocellular Carcinoma; Renal Cell Carcinoma,Inactive,Global
tivozanib hydrochloride,tivozanib hydrochloride,,AVEO Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
tivozanib hydrochloride,tivozanib hydrochloride,Tivopath,AVEO Pharmaceuticals Inc,Oncology, Non-Small Cell Lung Cancer,Inactive,Global
tivozanib hydrochloride,tivozanib hydrochloride,Fotivda,AVEO Pharmaceuticals Inc,Oncology, Breast Cancer; Vulvar Cancer,Discontinued,Global
tivozanib hydrochloride,tivozanib hydrochloride,,AVEO Pharmaceuticals Inc,Oncology, Metastatic Colorectal Cancer,Discontinued,EU; United States
tivozanib hydrochloride,tivozanib hydrochloride,Tivopath,AVEO Pharmaceuticals Inc,Oncology, Metastatic Breast Cancer,Discontinued,EU; United States
tivozanib hydrochloride,tivozanib hydrochloride,,Recordati SpA,Oncology, Solid Tumor,Discontinued,Japan
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Ipsen Ltd,Oncology, Medullary Thyroid Cancer,Marketed,United Kingdom
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Ipsen NV,Oncology, Medullary Thyroid Cancer,Marketed,Belgium
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Ipsen Pharma SA,Oncology, Medullary Thyroid Cancer,Marketed,Denmark; Spain
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Ipsen Innovation SAS,Oncology, Medullary Thyroid Cancer,Marketed,France
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Exelixis Inc,Oncology, Medullary Thyroid Cancer,Marketed,United States
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Ipsen SpA,Oncology, Medullary Thyroid Cancer,Marketed,Italy
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Ipsen Pharma GmbH,Oncology, Medullary Thyroid Cancer,Marketed,Austria; EU; Germany
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology," Carcinoid Tumor; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)",Phase III,Global
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Metastatic Renal Cell Carcinoma,Phase II,Japan
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Non Malignant Disorders, Plexiform Neurofibroma,Phase II,Global
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Phase II,Global; United States
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Cervical Cancer; Meningioma; Metastatic Melanoma; Non-Small Cell Lung Cancer; Papillary Renal Cell Carcinoma; Penile Cancer; Recurrent Head And Neck Cancer Squamous Cell Carcinoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Soft Tissue Sarcoma; Squamous Cell Carcinoma,Phase II,Global
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Bladder Cancer; Breast Cancer; Endometrial Cancer; Epithelial Ovarian Cancer; Ewing Sarcoma; Fallopian Tube Cancer; Merkel Cell Carcinoma; Metastatic Adenocarcinoma of The Pancreas; Metastatic Colorectal Cancer; Metastatic Uveal Melanoma; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Non-Rhabdomyosarcoma; Osteosarcoma; Paraganglioma (Glomus Jugulare Tumor); Peritoneal Cancer; Pheochromocytoma; Rhabdomyosarcoma; Thyroid Cancer; Ureter Cancer; Urethral Cancer; Wilms' Tumor (Nephroblastoma),Phase II,United States
cabozantinib s-malate,cabozantinib s-malate,Cometriq,Exelixis Inc,Oncology, Melanoma; Small-Cell Lung Cancer; Triple-Negative Breast Cancer (TNBC),Phase I,Global
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer; Metastatic Transitional (Urothelial) Tract Cancer,Phase I,Global
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Hepatocellular Carcinoma,Phase I,Global; United States
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Anaplastic Thyroid Cancer; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia,Inactive,United States
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Oncology, Astrocytoma; Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Glioblastoma Multiforme (GBM); Small-Cell Lung Cancer,Inactive,Global
cabozantinib s-malate,cabozantinib s-malate,,Exelixis Inc,Genito Urinary System And Sex Hormones, Renal Failure,Inactive,Global
tirbanibulin,tirbanibulin,Klisyri,Almirall Hermal GmbH,Dermatology, Actinic (Solar) Keratosis,Marketed,Germany
tirbanibulin,tirbanibulin,Klisyri,Almirall SAS,Dermatology, Actinic (Solar) Keratosis,Marketed,France
tirbanibulin,tirbanibulin,Klisyri,Almirall Prodesfarma SA,Dermatology, Actinic (Solar) Keratosis,Marketed,Spain
tirbanibulin,tirbanibulin,Klisyri,Almirall Ltd,Dermatology, Actinic (Solar) Keratosis,Marketed,United Kingdom
tirbanibulin,tirbanibulin,Klisyri,Almirall NV,Dermatology, Actinic (Solar) Keratosis,Marketed,Belgium
tirbanibulin,tirbanibulin,Klisyri,Almirall SpA,Dermatology, Actinic (Solar) Keratosis,Marketed,Italy
tirbanibulin,tirbanibulin,Klisyri,Almirall LLC,Dermatology, Actinic (Solar) Keratosis,Marketed,United States
tirbanibulin,tirbanibulin,Klisyri,Almirall GmbH,Dermatology, Actinic (Solar) Keratosis,Marketed,Austria
tirbanibulin,tirbanibulin,Klisyri,Almirall ApS,Dermatology, Actinic (Solar) Keratosis,Marketed,Denmark
tirbanibulin,tirbanibulin,Klisyri,Almirall SA,Dermatology, Actinic (Solar) Keratosis,Marketed,EU
tirbanibulin,tirbanibulin,Klisyri,Almirall AG,Dermatology, Actinic (Solar) Keratosis,Marketed,Switzerland
tirbanibulin,tirbanibulin,,PharmaEssentia Corp,Dermatology, Actinic (Solar) Keratosis,Pre-Registration,Malaysia; Taiwan; Vietnam
tirbanibulin,tirbanibulin,,PharmaEssentia Japan KK,Dermatology, Actinic (Solar) Keratosis,Pre-Registration,South Korea
tirbanibulin,tirbanibulin,,Almirall SA,Dermatology, Actinic (Solar) Keratosis,Phase III,United States
tirbanibulin,tirbanibulin,,PharmaEssentia Japan KK,Dermatology, Actinic (Solar) Keratosis,Phase III,Japan
tirbanibulin,tirbanibulin,,PharmaEssentia Corp,Immunology, Plaque Psoriasis (Psoriasis Vulgaris),Phase I,China; Hong Kong; Malaysia; Singapore; Taiwan
tirbanibulin,tirbanibulin,,Athenex Inc,Oncology, Blood Cancer; Ovarian Cancer,Inactive,Taiwan
tirbanibulin,tirbanibulin,,Hanmi Pharmaceuticals Co Ltd,Oncology, Breast Cancer; Gastric Cancer,Inactive,South Korea
tirbanibulin,tirbanibulin,,Athenex Inc,Oncology, Lymphoma; Skin Cancer,Inactive,Global
tirbanibulin,tirbanibulin,,PharmaEssentia Corp,Oncology, Solid Tumor,Inactive,South Korea
tirbanibulin,tirbanibulin,,Athenex Inc,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Solid Tumor",Inactive,United States
tirbanibulin,tirbanibulin,,Athenex Inc,Gastrointestinal, Liver Fibrosis,Inactive,United States
tirbanibulin,tirbanibulin,,Hanmi Pharmaceuticals Co Ltd,Oncology, Solid Tumor,Discontinued,South Korea
ranibizumab SR,ranibizumab,Susvimo,Genentech USA Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United States
ranibizumab SR,ranibizumab,,F. Hoffmann-La Roche Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Pre-Registration,EU
ranibizumab SR,ranibizumab,,F. Hoffmann-La Roche Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase III,EU; United States
ranibizumab SR,ranibizumab,,F. Hoffmann-La Roche Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
ranibizumab SR,ranibizumab,,F. Hoffmann-La Roche Ltd,Ophthalmology, Macular Edema,Phase III,EU; United States
ranibizumab SR,ranibizumab,,F. Hoffmann-La Roche Ltd,Metabolic Disorders, Diabetic Retinopathy,Phase III,Global
ranibizumab SR,ranibizumab,,F. Hoffmann-La Roche Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Japan
ranibizumab SR,ranibizumab,,F. Hoffmann-La Roche Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase II,Japan
anlotinib hydrochloride,,Focus V,Chia Tai Tianqing Pharmaceutical Group Co Ltd,Oncology, Medullary Thyroid Cancer; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Soft Tissue Sarcoma; Thyroid Cancer,Marketed,China
anlotinib hydrochloride,,,Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Breast Cancer; Endometrial Cancer; Esophageal Cancer; Fallopian Tube Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Melanoma; Metastatic Colorectal Cancer; Nasopharyngeal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Peritoneal Cancer; Renal Cell Carcinoma; Soft Tissue Sarcoma; Triple-Negative Breast Cancer (TNBC),Phase III,China
anlotinib hydrochloride,,,Advenchen Laboratories LLC,Oncology, Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Phase III,Global
anlotinib hydrochloride,,,Advenchen Laboratories LLC,Oncology, Leiomyosarcoma; Ovarian Cancer; Soft Tissue Sarcoma; Synovial Sarcoma,Phase III,United States
anlotinib hydrochloride,,,Chia Tai Tianqing Pharmaceutical Group Co Ltd,Oncology, Salivary Gland Cancer,Phase II,China
anlotinib hydrochloride,,,Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd,Oncology, Anaplastic Large Cell Lymphoma (ALCL); Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy; Angiosarcoma; Bile Duct Cancer (Cholangiocarcinoma) ; Chondrosarcoma; Esophageal Squamous Cell Carcinoma (ESCC); Ewing Sarcoma; Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Tumor; Giant Cell Tumor Of Bone; Glioblastoma Multiforme (GBM); Head And Neck Cancer Squamous Cell Carcinoma; Hepatocellular Carcinoma; High-Grade Glioma; Liposarcoma ; Malignant Pleural Mesothelioma; Metastatic Colorectal Cancer; Metastatic Hepatocellular Carcinoma (HCC); Metastatic Transitional (Urothelial) Tract Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Osteosarcoma; Peripheral T-Cell Lymphomas (PTCL); Peritoneal Cancer; Primitive Neuroectodermal Tumor (PNET); Recurrent Glioblastoma Multiforme (GBM); Small-Cell Lung Cancer; Squamous Non-Small Cell Lung Cancer; Thymic Carcinoma; Thyroid Cancer; Triple-Negative Breast Cancer (TNBC),Phase II,China
anlotinib hydrochloride,,,Advenchen Laboratories LLC,Oncology, Metastatic Ovarian Cancer; Metastatic Pancreatic Cancer; Nasopharyngeal Cancer; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Soft Tissue Sarcoma; Solid Tumor,Phase II,Global
anlotinib hydrochloride,,,Chia Tai Tianqing Pharmaceutical Group Co Ltd,Oncology, Metastatic Colorectal Cancer,Phase II,Global
anlotinib hydrochloride,,,Chia Tai Tianqing Pharmaceutical Group Co Ltd.,Oncology, Fallopian Tube Cancer,Phase II,China
anlotinib hydrochloride,,,Advenchen Laboratories LLC,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer),Phase I,China
anlotinib hydrochloride,,,Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd,Oncology, Bladder Cancer; Cervical Cancer; Diffuse Large B-Cell Lymphoma; Hepatocellular Carcinoma; Metastatic Transitional (Urothelial) Tract Cancer; Nasopharyngeal Cancer; Neuroblastoma; Non-Small Cell Lung Cancer; Pleomorphic Liposarcoma; Renal Cell Carcinoma; Solid Tumor; Ureter Cancer; Urethral Cancer,Phase I,China
anlotinib hydrochloride,,,Advenchen Laboratories LLC,Oncology, Adenocarcinoma; Squamous Cell Carcinoma; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Inactive,Global
anlotinib hydrochloride,,,Advenchen Laboratories LLC,Oncology, Colon Cancer,Inactive,United States
anlotinib hydrochloride,,,Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd,Oncology, Adipocytic Sarcoma; Fibrosarcoma; Leiomyosarcoma; Malignant Fibrous Histiocytoma; Synovial Sarcoma,Inactive,China
apatinib mesylate,apatinib mesylate,Aitan,Jiangsu Hengrui Medicine Co Ltd,Oncology, Gastric Cancer; Hepatocellular Carcinoma,Marketed,China
apatinib mesylate,apatinib mesylate,,HLB Life Science Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer,Phase III,EU; Japan; South Korea; Taiwan; United States
apatinib mesylate,apatinib mesylate,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Colorectal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Thyroid Cancer,Phase III,China
apatinib mesylate,apatinib mesylate,,HLB Life Science Co Ltd,Oncology, Hepatocellular Carcinoma,Phase III,Global
apatinib mesylate,apatinib mesylate,,HLB Life Science Co Ltd,Oncology, Metastatic Colorectal Cancer,Phase II,Global
apatinib mesylate,apatinib mesylate,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Angiosarcoma; Bile Duct Cancer (Cholangiocarcinoma) ; Cervical Cancer; Colon Cancer; Endometrial Cancer; Epithelial Ovarian Cancer; Esophageal Squamous Cell Carcinoma (ESCC); Ewing Sarcoma; Fibrosarcoma; Gallbladder Cancer; Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Head And Neck Cancer Squamous Cell Carcinoma; Hepatocellular Carcinoma; High-Grade Glioma; Leiomyosarcoma; Liposarcoma ; Lung Adenocarcinoma; Melanoma; Metastatic Biliary Tract Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Nasopharyngeal Cancer; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Osteosarcoma; Recurrent Glioblastoma Multiforme (GBM); Rhabdomyosarcoma; Sarcomas; Small-Cell Lung Cancer; Soft Tissue Sarcoma; Solid Tumor; Synovial Sarcoma; Thymoma (Thymic Epithelial Tumor); Thyroid Cancer; Triple-Negative Breast Cancer (TNBC),Phase II,China
apatinib mesylate,apatinib mesylate,,Elevar Therapeutics Inc,Oncology, Metastatic Colorectal Cancer,Phase II,Global
apatinib mesylate,apatinib mesylate,,Jiangsu Hengrui Medicine Co Ltd,Infectious Disease, Epstein–Barr Virus (HHV-4) Infections,Phase II,China
apatinib mesylate,apatinib mesylate,,Jiangsu Hengrui Medicine Co Ltd,Toxicology, Radiation Injury,Phase II,China
apatinib mesylate,apatinib mesylate,,Advenchen Laboratories LLC,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Pancreatic Cancer; Recurrent Glioblastoma Multiforme (GBM); Triple-Negative Breast Cancer (TNBC),Phase II,Global
apatinib mesylate,apatinib mesylate,,HLB Life Science Co Ltd,Oncology, Adenoid Cystic Carcinoma (ACC),Phase II,United States
apatinib mesylate,apatinib mesylate,,HLB Life Science Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Angiosarcoma; Breast Cancer; Leiomyosarcoma; Melanoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Synovial Sarcoma,Phase I,Global
apatinib mesylate,apatinib mesylate,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Choriocarcinoma (Gestational Trophoblastic Neoplasia); Epithelial Ovarian Cancer; Fallopian Tube Cancer; Follicular Thyroid Cancer; Gastric Cancer; High-Grade Glioma; Medullary Thyroid Cancer; Neuroblastoma; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Papillary Thyroid Cancer; Peritoneal Cancer,Phase I,China
apatinib mesylate,apatinib mesylate,,Advenchen Laboratories LLC,Oncology, Anaplastic Large Cell Lymphoma (ALCL); Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy; Gastroesophageal (GE) Junction Carcinomas; Hepatocellular Carcinoma; Peripheral T-Cell Lymphomas (PTCL); T-Cell Lymphomas,Phase I,Global
apatinib mesylate,apatinib mesylate,,Bukwang Pharmaceutical Co Ltd,Oncology, Colorectal Cancer; Gastrointestinal Stromal Tumor (GIST); Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Triple-Negative Breast Cancer (TNBC),Inactive,South Korea
apatinib mesylate,apatinib mesylate,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Adenocarcinoma; Gastric Cancer; Non-Small Cell Lung Cancer,Inactive,China
apatinib mesylate,apatinib mesylate,,HLB Life Science Co Ltd,Oncology, Metastatic Colorectal Cancer; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Inactive,Global
apatinib mesylate,apatinib mesylate,,Elevar Therapeutics Inc,Oncology, Hepatocellular Carcinoma,Inactive,United States
axitinib,axitinib,Axitinib,Shandong New Time Pharmaceutical Co Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,China
axitinib,axitinib,Axinib,AMPS Biotech Pvt Ltd,Oncology, Metastatic Renal Cell Carcinoma,Marketed,India
bevacizumab biosimilar,,Versavo,Dr. Reddy's Laboratories Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,India
bevacizumab biosimilar,,,Dr. Reddy's Laboratories Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Inactive,EU; United States
bevacizumab biosimilar,,Boyounuo,Shandong Boan Biotechnology Co Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,China
bevacizumab biosimilar,,Bevaciptin,Cipla Australia Pty Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Australia
bevacizumab biosimilar,,Bevacip,Cipla Australia Pty Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Australia
bevacizumab biosimilar,,Ankada,Qilu Pharmaceutical Co Ltd,Oncology, Cervical Cancer; Glioma; Kidney Cancer (Renal Cell Cancer); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer,Marketed,China
bevacizumab biosimilar,,Avegra,Biocad,Oncology, Cervical Cancer; Colorectal Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Lung Cancer; Mammary Ductal Carcinoma; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Russia
bevacizumab biosimilar,,,Biocad,Oncology, Non-Small Cell Lung Cancer,Phase III,India
bevacizumab biosimilar,,,Biocad,Oncology, Colorectal Cancer; Non-Small Cell Lung Cancer,Preclinical,China
bevacizumab biosimilar,,,Biocad,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
bevacizumab biosimilar,,Advamab,Alkem Laboratories Ltd,Oncology, Colorectal Cancer; Ovarian Cancer,Marketed,India
bevacizumab biosimilar,,Bevacizumab,Betta Pharmaceuticals Co Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,China
bevacizumab biosimilar,,,Beijing Mabworks Biotech Co Ltd,Oncology, Unspecified Cancer,Inactive,China
bevacizumab biosimilar,,,Beijing Mabworks Biotech Co Ltd,Oncology, Ovarian Cancer,Inactive,Global
bevacizumab biosimilar,,Bevatas ,Intas Pharmaceuticals Ltd,Oncology, Cervical Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,India
bevacizumab biosimilar,,Hanbeitai,Shanghai Henlius Biotech Inc,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,China
bevacizumab biosimilar,,,Shanghai Henlius Biotech Inc,Oncology, Hepatocellular Carcinoma; Recurrent Glioblastoma Multiforme (GBM),Pre-Registration,China
bevacizumab biosimilar,,,Essex Bio-Technology Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Australia; China; EU; Global
bevacizumab biosimilar,,,Essex Bio-Technology Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Spain; United States
bevacizumab biosimilar,,,Shanghai Henlius Biotech Inc,Oncology, Metastatic Hepatocellular Carcinoma (HCC),Phase II,Global
bevacizumab biosimilar,,,Shanghai Henlius Biotech Inc,Oncology, Solid Tumor,Phase I,China
bevacizumab biosimilar,,,Essex Bio-Technology Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Singapore
bevacizumab biosimilar,,,Shanghai Henlius Biotech Inc,Oncology, Hepatocellular Carcinoma,Phase I,Global
bevacizumab biosimilar,,,Essex Bio-Technology Ltd,Metabolic Disorders, Diabetic Retinopathy,IND/CTA Filed,China
bevacizumab biosimilar,,Aybintio,Samsung Bioepis Co Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Austria; Belgium; Canada; Denmark
bevacizumab biosimilar,,Aybintio,Merck Sharp & Dohme de Espana SAU,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Spain
bevacizumab biosimilar,,Aybintio,Samsung Bioepis UK Ltd,Oncology, Cervical Cancer; Colorectal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Denmark
bevacizumab biosimilar,,Aybintio,Merck Sharp & Dohme GmbH,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Germany
bevacizumab biosimilar,,Aybintio,MSD Italia SRL,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Italy
bevacizumab biosimilar,,Aybintio,Organon Pharma (UK) Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,United Kingdom
bevacizumab biosimilar,,Aybintio,Biogen Idec Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,EU
bevacizumab biosimilar,,Aybintio,MSD France,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,France
bevacizumab biosimilar,,Onbevzi,Samsung Bioepis UK Ltd,Oncology, Cervical Cancer; Colorectal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Austria; Belgium; EU; France; Germany; Italy; Spain; United Kingdom
bevacizumab biosimilar,,Aybintio,Samsung Bioepis Co Ltd,Oncology, Malignant Glioma,Marketed,Canada
bevacizumab biosimilar,,Onbevzi,Samsung Bioepis Co Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,South Korea
bevacizumab biosimilar,,Aybintio,Samsung Bioepis Co Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer,Marketed,Austria; Belgium; Denmark
bevacizumab biosimilar,,,Samsung Bioepis Co Ltd,Oncology, Metastatic Colorectal Cancer,Inactive,China
bevacizumab biosimilar,,,Samsung Bioepis Co Ltd,Oncology, Non-Small Cell Lung Cancer,Inactive,China; United States
bevacizumab biosimilar,,Pobevcy,BeiGene Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,China
bevacizumab biosimilar,,,Bio-Thera Solutions Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer,Pre-Registration,EU
bevacizumab biosimilar,,,Bio-Thera Solutions Ltd,Oncology, Non-Small Cell Lung Cancer,Pre-Registration,EU; United Kingdom; United States
bevacizumab biosimilar,,,Bio-Thera Solutions Ltd,Oncology, Hepatocellular Carcinoma,Phase II,China
bevacizumab biosimilar,,,Bio-Thera Solutions Ltd,Oncology, Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Ovarian Cancer,Phase I,Global
bevacizumab biosimilar,,,Bio-Thera Solutions Ltd,Oncology, Renal Cell Carcinoma,Inactive,Global
bevacizumab biosimilar,,Equidacent ,Centus Biotherapeutics Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Austria; Belgium; Italy; Spain
bevacizumab biosimilar,,Equidacent ,Centus Biotherapeutics Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Withdrawn,Denmark; EU
bevacizumab biosimilar,,,Centus Biotherapeutics Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,Global; Japan; United States
bevacizumab biosimilar,,,Centus Biotherapeutics Ltd,Oncology, Cervical Cancer; Colorectal Cancer,Phase I,Global
bevacizumab biosimilar,,,Centus Biotherapeutics Ltd,Oncology, Colorectal Cancer; Non-Small Cell Lung Cancer; Solid Tumor,Inactive,United Kingdom
bevacizumab biosimilar,,Avamab,PT Kalbe Farma Tbk,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer; Triple-Negative Breast Cancer (TNBC),Marketed,Indonesia
bevacizumab biosimilar,,Zumab,Eris Lifesciences Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,India
bevacizumab biosimilar,,Bevazza,Lupin Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,India
bevacizumab biosimilar,,Bevagen,PT Etana Biotechnologies,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer; Triple-Negative Breast Cancer (TNBC),Marketed,Indonesia
bevacizumab biosimilar,,Byvasda,Innovent Biologics Inc,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,China
bevacizumab biosimilar,,,Innovent Biologics Inc,Oncology, Hepatocellular Carcinoma; Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Innovent Biologics Inc,Oncology, Metastatic Colorectal Cancer,Phase III,Global
bevacizumab biosimilar,,,Innovent Biologics Inc,Oncology, Endometrial Cancer; Hepatocellular Carcinoma,Phase II,Global
bevacizumab biosimilar,,,Innovent Biologics Inc,Infectious Disease, Recurrent Respiratory Papillomatosis (Juvenile Laryngeal Papilloma or Laryngeal Papilloma),Phase I,Global
bevacizumab biosimilar,,,Innovent Biologics Inc,Oncology, Gastric Cancer,Preclinical,Global
bevacizumab biosimilar,,,Coherus BioSciences Inc,Oncology, Non-Small Cell Lung Cancer,Discontinued,United States
bevacizumab biosimilar,,BevaciRel,Reliance Life Sciences Pvt Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,India
bevacizumab biosimilar,bevacizumab-maly,Oyavas,Thornton & Ross Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,United Kingdom
bevacizumab biosimilar,bevacizumab-maly,Alymsys ,Mabxience Holding SL,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,EU
bevacizumab biosimilar,bevacizumab-maly,Oyavas,Stada Arzneimittel GmbH,Oncology, Cervical Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Austria
bevacizumab biosimilar,bevacizumab-maly,Oyavas,Mabxience Holding SL,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,EU
bevacizumab biosimilar,bevacizumab-maly,Alymsys ,G.L. Pharma GmbH,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Austria
bevacizumab biosimilar,bevacizumab-maly,Oyavas,Spirig HealthCare AG,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Switzerland
bevacizumab biosimilar,bevacizumab-maly,Alymsys ,Servier Deutschland GmbH,Oncology, Cervical Cancer; Colorectal Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Germany
bevacizumab biosimilar,bevacizumab-maly,Oyavas,STADApharm GmbH,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Germany
bevacizumab biosimilar,bevacizumab-maly,Alymsys ,Amneal Pharmaceuticals Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,United States
bevacizumab biosimilar,bevacizumab-maly,Oyavas,Eg Spa,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Italy
bevacizumab biosimilar,bevacizumab-maly,Alymsys ,Mabxience Research SL,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Belgium; Denmark; France; Spain; United Kingdom
bevacizumab biosimilar,bevacizumab-maly,Oyavas,STADA Nordic ApS,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Denmark
bevacizumab biosimilar,bevacizumab-maly,Oyavas,Laboratorio STADA SL,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Spain
bevacizumab biosimilar,bevacizumab-maly,Alymsys ,Zentiva Italy Srl,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Italy
bevacizumab biosimilar,bevacizumab-maly,Oyavas,Stada Arzneimittel AG,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,France
bevacizumab biosimilar,bevacizumab-maly,Oyavas,SA Eurogenerics NV,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Belgium
bevacizumab biosimilar,bevacizumab-maly,,Insud Pharma,Oncology, Non-Small Cell Lung Cancer,Phase III,Global
bevacizumab biosimilar,bevacizumab-maly,,Insud Pharma,Oncology, Metastatic Colorectal Cancer,Phase I,Global; Japan
bevacizumab biosimilar,bevacizumab-maly,,Insud Pharma,Oncology, Non-Small Cell Lung Cancer,Phase I,Japan
bevacizumab biosimilar,,Abevmy,Mylan Pharmaceuticals ULC,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Canada
bevacizumab biosimilar,,Abevmy,Mylan dura GmbH,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,Germany
bevacizumab biosimilar,,Abevmy,Mylan ApS,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,Denmark
bevacizumab biosimilar,,Abevmy,PT Indofarma Tbk,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer; Triple-Negative Breast Cancer (TNBC),Marketed,Indonesia
bevacizumab biosimilar,,Abevmy,Mylan SAS,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,France
bevacizumab biosimilar,,Abevmy,Alphapharm Pty Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Australia
bevacizumab biosimilar,,Abevmy,Mylan Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,United Kingdom
bevacizumab biosimilar,,Abevmy,Mylan SpA,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,Italy
bevacizumab biosimilar,,Abevmy,Mylan BVBA,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,Belgium
bevacizumab biosimilar,,Bevacizumab,Mylan (Proprietary) Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,South Africa
bevacizumab biosimilar,,Abevmy,Mylan Pharmaceuticals SL,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,Spain
bevacizumab biosimilar,,Abevmy,Mylan (Proprietary) Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,South Africa
bevacizumab biosimilar,,Bevamyl,Mylan (Proprietary) Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,South Africa
bevacizumab biosimilar,,Abevmy,Mylan Austria GmbH,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,Austria
bevacizumab biosimilar,,Abevmy,Mylan Pharmaceuticals Pvt Ltd,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,India
bevacizumab biosimilar,,Abevmy,Mylan Pharma Group Ltd,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Marketed,EU
bevacizumab biosimilar,,Lextemy,Mylan Pharma Group Ltd,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,EU
bevacizumab biosimilar,,Lextemy,Mylan SpA,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,Italy
bevacizumab biosimilar,,Lextemy,Mylan Austria GmbH,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,Austria
bevacizumab biosimilar,,Lextemy,Mylan ApS,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,Denmark
bevacizumab biosimilar,,Abevmy,Mylan New Zealand Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Malignant Glioma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Withdrawn,New Zealand
bevacizumab biosimilar,,Lextemy,Mylan dura GmbH,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,Germany
bevacizumab biosimilar,,Lextemy,Mylan Pharmaceuticals SL,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,Spain
bevacizumab biosimilar,,Lextemy,Mylan SAS,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,France
bevacizumab biosimilar,,Lextemy,Mylan BVBA,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Carcinoma; Ovarian Cancer,Withdrawn,Belgium
bevacizumab biosimilar,,Abevmy,Viatris Inc,Oncology, Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Carcinoma; Ovarian Cancer,Inactive,United Kingdom
bevacizumab biosimilar,,Abevmy,Viatris Inc,Oncology, Cervical Cancer; Colorectal Cancer; Metastatic Breast Cancer,Inactive,United Kingdom; United States
bevacizumab biosimilar,,Abevmy,Viatris Inc,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,United States
bevacizumab biosimilar,,Bevacizumab,Nichi-Iko Pharmaceutical Co Ltd,Oncology, Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,Japan
bevacizumab biosimilar,,Elovie,Libbs Farmaceutica Ltda,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,Brazil
bevacizumab biosimilar,,Bevaas,PT Amarox Pharma Global,Oncology, Metastatic Colorectal Cancer,Marketed,Indonesia
bevacizumab biosimilar,,Cizumab,Hetero Drugs Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,India
bevacizumab biosimilar,,Vegzelma,Celltrion Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Austria; Belgium; Denmark; EU; France; Germany; Italy; Spain
bevacizumab biosimilar,,,Celltrion Inc,Oncology, Fallopian Tube Cancer; Peritoneal Cancer; Squamous Non-Small Cell Lung Cancer,Pre-Registration,EU
bevacizumab biosimilar,,,Celltrion Inc,Oncology, Metastatic Colorectal Cancer,Phase III,South Korea
bevacizumab biosimilar,,,Celltrion Inc,Oncology, Lung Adenocarcinoma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer,Phase III,Global
bevacizumab biosimilar,,Bevarest,Emcure Pharmaceuticals Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,India
bevacizumab biosimilar,,Bevacizumab ,Teva Pharma AG,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,Switzerland
bevacizumab biosimilar,,Bevacizumab,Suzhou Shengdia Biomedical Co Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Marketed,China
bevacizumab biosimilar,,Bambevi,Apobiologix,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Malignant Glioma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,Canada
bevacizumab biosimilar,,,Apotex Inc,Oncology, Cervical Cancer; Fallopian Tube Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer,Inactive,Canada; EU; United States
bevacizumab biosimilar,,,Apotex Inc,Oncology, Glioblastoma Multiforme (GBM),Inactive,United States
bevacizumab biosimilar,,,Apotex Inc,Oncology, Epithelial Ovarian Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Inactive,EU; United States
bevacizumab biosimilar,,,Apotex Inc,Oncology, Recurrent Glioblastoma Multiforme (GBM),Inactive,Canada; EU
bevacizumab biosimilar,,Pusintin,Jiangxi Jemincare Pharmaceutical Co Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Marketed,China
bevacizumab biosimilar,,,TOT Biopharm Co Ltd,Undisclosed, Unspecified,IND/CTA Filed,China
bevacizumab biosimilar,,,TOT Biopharm Co Ltd,Oncology, Colorectal Cancer; Solid Tumor,Inactive,Global
bevacizumab biosimilar,,Krabeva,Biocon Ltd,Oncology, Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer,Marketed,India
bevacizumab biosimilar,,,Biocon Ltd,Oncology, Metastatic Colorectal Cancer,Phase III,Global
bevacizumab biosimilar,,,Biocon Ltd,Oncology, Cervical Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Recurrent Glioblastoma Multiforme (GBM),Inactive,United States
bevacizumab biosimilar,,,Biocon Ltd,Oncology, Non-Small Cell Lung Cancer,Inactive,Global; United States
bevacizumab biosimilar,,Bryxta,Zydus Healthcare Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Marketed,India
bucillamine,bucillamine [INN],Balumin,Samik Pharmaceutical Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,South Korea
bucillamine,bucillamine [INN],K Lamine,Kolmar Korea Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,South Korea
bucillamine,bucillamine [INN],Rimatil,AYUMI Pharmaceutical Corp,Immunology, Rheumatoid Arthritis,Marketed,Japan
bucillamine,bucillamine [INN],Rimatil,Chong Kun Dang Pharmaceutical Corporation,Immunology, Rheumatoid Arthritis,Marketed,South Korea
bucillamine,bucillamine [INN],Lamin,Hanlim Pharm Co Ltd,Central Nervous System, Rheumatoid Arthritis Pain,Marketed,South Korea
bucillamine,bucillamine [INN],Boomiq,Kuhnil Pharmaceutical Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,South Korea
bucillamine,bucillamine [INN],Bucillamine,Nichi-Iko Pharmaceutical Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,Japan
bucillamine,bucillamine [INN],Bucillate,Nichi-Iko Pharmaceutical Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,Japan
bucillamine,bucillamine [INN],Lemalc,Teva Takeda Yakuhin Ltd,Immunology, Rheumatoid Arthritis,Marketed,Japan
bucillamine,bucillamine [INN],Bucillamine,Towa Pharmaceutical Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,Japan
bucillamine,bucillamine [INN],Bucilant,Kobayashi Kako Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,Japan
bucillamine,bucillamine [INN],Bucillamine,Kobayashi Kako Co Ltd,Immunology, Rheumatoid Arthritis,Marketed,Japan
bucillamine,bucillamine [INN],Bucillamine,Optimus Pharma Pvt Ltd,Immunology, Rheumatoid Arthritis,Marketed,India
cabozantinib s-malate,cabozantinib s-malate,Cabotres,Cipla Ltd,Oncology, Hepatocellular Carcinoma; Renal Cell Carcinoma,Marketed,India
conbercept,conbercept [INN],Langmu,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Ophthalmology, Age Related Macular Degeneration,Marketed,China
conbercept,conbercept [INN],,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Ophthalmology, Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
conbercept,conbercept [INN],,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase III,Global
conbercept,conbercept [INN],,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Oncology, Retinoblastoma,Phase II,Global
everolimus,everolimus,Everolimus,Teva Pharmaceuticals USA Inc,Genetic Disorders, Tuberous Sclerosis,Marketed,United States
everolimus,everolimus,Everolimus,Teva Canada Ltd,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Renal Cell Carcinoma; Subependymal Giant Cell Astrocytoma  ,Marketed,Canada
everolimus,everolimus,Everolimus,Teva Italy SRL,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Renal Cell Carcinoma,Marketed,Italy
everolimus,everolimus,Everolimus,ratiopharm GmbH,Oncology, Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Germany
everolimus,everolimus,Everolimus,Teva Denmark A/S,Oncology, Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Denmark
everolimus,everolimus,Everolimus,ratiopharm Arzneimittel Vertriebs GmbH,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Austria
everolimus,everolimus,Everolimus,Teva Pharma Belgium NV,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Renal Cell Carcinoma,Marketed,Belgium
everolimus,everolimus,Everolimus,Teva Pharma AG,Oncology, Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Switzerland
everolimus,everolimus,Everolimus,Teva Pharmaceuticals USA Inc,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Neuroendocrine Tumors; Renal Cell Carcinoma; Subependymal Giant Cell Astrocytoma  ,Marketed,United States
everolimus,everolimus,Everolimus,Teva Pharmaceuticals USA Inc,Non Malignant Disorders, Angiomyolipoma (AML),Marketed,United States
everolimus,everolimus,Everolimus,Teva UK Ltd,Oncology, Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,United Kingdom
everolimus,everolimus,Everolimus,Teva Sante SAS,Oncology, Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,France
everolimus,everolimus,Everolimus,Teva Pharma SLU,Oncology, Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Withdrawn,Spain
everolimus,everolimus,Everolimus,Taro International Ltd,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Renal Cell Carcinoma; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Neuroendocrine Tumors; Pancreatic Endocrine Tumor; Subependymal Giant Cell Astrocytoma  ,Marketed,Israel
everolimus,everolimus,Everolimus,Taro International Ltd,Non Malignant Disorders, Angiomyolipoma (AML),Marketed,Israel
everolimus,everolimus,Everolimus,Taro International Ltd,Genetic Disorders, Tuberous Sclerosis,Marketed,Israel
everolimus,everolimus,Everolimus,Cristers SAS,Oncology, Kidney Cancer (Renal Cell Cancer); Metastatic Breast Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,France
everolimus,everolimus,Everofin ,TAD Pharma GmbH,Oncology, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Germany
everolimus,everolimus,Everolimus,Krka dd Novo Mesto,Oncology, Hormone Sensitive Breast Cancer; Metastatic Renal Cell Carcinoma,Marketed,Belgium
everolimus,everolimus,Everolimus,Krka dd Novo Mesto,Oncology, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Belgium; Denmark
everolimus,everolimus,Everolimus,TAD Pharma GmbH,Oncology, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Spain
everolimus,everolimus,Everolimus,HCS BVBA,Oncology, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET),Marketed,Austria; France; Italy; United Kingdom
faricimab,faricimab-svoa,Vabysmo,Genentech USA Inc,Metabolic Disorders, Diabetic Macular Edema,Marketed,United States
faricimab,faricimab-svoa,Vabysmo,Chugai Pharmaceutical Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Japan
faricimab,faricimab-svoa,Vabysmo,Roche Pharma (Schweiz) AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Switzerland
faricimab,faricimab-svoa,Vabysmo,Chugai Pharmaceutical Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Japan
faricimab,faricimab-svoa,Vabysmo,Roche Pharma (Schweiz) AG,Metabolic Disorders, Diabetic Macular Edema,Marketed,Switzerland
faricimab,faricimab-svoa,Vabysmo,Roche Products Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United Kingdom
faricimab,faricimab-svoa,Vabysmo,Hoffmann-La Roche Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Canada
faricimab,faricimab-svoa,Vabysmo,Hoffmann-La Roche Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Canada
faricimab,faricimab-svoa,Vabysmo,Roche Products Pty Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Australia
faricimab,faricimab-svoa,Vabysmo,Roche Products Pty Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Australia
faricimab,faricimab-svoa,Vabysmo,Genentech USA Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United States
faricimab,faricimab-svoa,Vabysmo,Roche Products Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,United Kingdom
faricimab,faricimab-svoa,,F. Hoffmann-La Roche Ltd,Metabolic Disorders, Diabetic Macular Edema,Pre-Registration,EU
faricimab,faricimab-svoa,,F. Hoffmann-La Roche Ltd,Metabolic Disorders, Diabetic Retinopathy,Pre-Registration,United States
faricimab,faricimab-svoa,,F. Hoffmann-La Roche Ltd,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Pre-Registration,EU
faricimab,faricimab-svoa,,F. Hoffmann-La Roche Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase III,Global
faricimab,faricimab-svoa,,F. Hoffmann-La Roche Ltd,Ophthalmology, Branch Retinal Vein Occlusion,Phase III,EU; United States
faricimab,faricimab-svoa,,Chugai Pharmaceutical Co Ltd,Ophthalmology, Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion,Phase III,Japan
faricimab,faricimab-svoa,,F. Hoffmann-La Roche Ltd,Ophthalmology, Central Retinal Vein Occlusion; Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
fruquintinib,fruquintinib,Elunate,Hutchison Whampoa Pharmaceutical Shanghai Co Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,China
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Endometrial Cancer; Gastric Cancer,Pre-Registration,China
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Metastatic Colorectal Cancer,Pre-Registration,EU; Japan; United States
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction,Phase III,China
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Solid Tumor,Phase II,China; South Korea; United States
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Endometrial Cancer; Metastatic Colorectal Cancer,Phase II,China; United States
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Triple-Negative Breast Cancer (TNBC),Phase II,United States
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Angiosarcoma; Metastatic Pancreatic Cancer; Soft Tissue Sarcoma,Phase II,Global
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Breast Cancer; Cervical Cancer; Colorectal Cancer; Gastrointestinal Tumor; Hepatocellular Carcinoma; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Ovarian Cancer; Thymic Carcinoma,Phase II,China
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Triple-Negative Breast Cancer (TNBC),Phase I,United States
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma,Phase I,China
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Meningioma; Metastatic Adenocarcinoma of The Pancreas; Rectal Cancer,Phase I,Global
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Hepatocellular Carcinoma,Inactive,United States
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Metastatic Biliary Tract Cancer,Inactive,Global
fruquintinib,fruquintinib,,Hutchison MediPharma Ltd,Oncology, Non-Small Cell Lung Cancer,Discontinued,China
lenalidomide,lenalidomide,Relidomide,Reliance Life Sciences Pvt Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Teva UK Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide Hydrochloride,Abic Marketing Ltd,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Israel
lenalidomide,lenalidomide,Lenalidomide,Teva Pharma AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Switzerland
lenalidomide,lenalidomide,Lenalidomide Hydrochloride,Teva Pharmaceuticals Australia Pty Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Lenalidomide,Teva Pharma Italia Srl,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Italy
lenalidomide,lenalidomide,Lenalidomide,ratiopharm Arzneimittel Vertriebs GmbH,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Teva Pharma SLU,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Teva Denmark A/S,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide Hydrochloride Hydrate,Teva Pharma Belgium NV,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Belgium
lenalidomide,lenalidomide,Lenalidomide,Teva Sante SAS,Oncology, Multiple Myeloma (Kahler Disease),Marketed,France
lenalidomide,lenalidomide,Lenalidomide,ratiopharm GmbH,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Tecnimede Espana Industria Farmaceutica SA,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Spain
lenalidomide,lenalidomide,Leblikin,Boryung Pharmaceutical Co Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,South Korea
lenalidomide,lenalidomide,Lenalidomide,Genericon Pharma Gesellschaft mbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Tarbis Farma SL,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Heumann Pharma GmbH & Co Generica KG,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Torrent Pharma (UK) Ltd,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Te Arai BioFarma Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,New Zealand
lenalidomide,lenalidomide,Lenalidomide,Mylan SpA,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Italy
lenalidomide,lenalidomide,Lenalidomide,Generics UK Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Mylan SAS,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,France
lenalidomide,lenalidomide,Lenalidomide,Mylan Austria GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Mylan Pharmaceuticals SL,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Mylan Pharma Gmbh,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Switzerland
lenalidomide,lenalidomide,Lenalidomide,Mylan Ltd,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,EU
lenalidomide,lenalidomide,Lenalidomide,Mylan dura GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Mylan BVBA,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Belgium
lenalidomide,lenalidomide,Lenalidomide,Mylan ApS,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,Mylan Inc,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,United States
lenalidomide,lenalidomide,Lenalidomide,Apotex Inc,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Canada
lenalidomide,lenalidomide,Lenalidomide,Apotex Corp,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,United States
lenalidomide,lenalidomide,Lenalidomide,Flagship Biotech International Pvt Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Humix,Biocon Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Biocon Pharma Ltd,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Eurofarma Laboratorios SA,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Brazil
lenalidomide,lenalidomide,Nuvyor,Eurofarma Laboratorios SA,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Brazil
lenalidomide,lenalidomide,Lenalidomide,Beijing Pharmaceutical Group Co Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,China
lenalidomide,lenalidomide,Lidmed,Arechar Healthcare LLP,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenabdor,Interdos Pharma BV,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Interdos Pharma BV,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenif,Florencia Healthcare Pvt Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenaglob,Globela Pharma Pvt Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Kern Pharma SL,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Yangtze River Pharmaceutical Group,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,China
lenalidomide,lenalidomide,Lenalidomide,Krka dd Novo Mesto,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Belgium; EU; Germany
lenalidomide,lenalidomide,Lenalidomide,Krka Pharmaceuticals Milano Srl,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Italy
lenalidomide,lenalidomide,Lenalidomide,Krka France Eurl,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,France
lenalidomide,lenalidomide,Lenalidomide Hydrochloride,Krka dd Novo Mesto,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Denmark; United Kingdom
lenalidomide,lenalidomide,Lenalidomide,KRKA Pharma GmbH,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,KRKA Farmaceutica SL,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Spain
lenalidomide,lenalidomide,Lenid,United Biotech (P) Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Mydolen ,Miracalus Pharma Pvt Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,V. S. International Pvt Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,India
lenalidomide,lenalidomide,Mylomid,Forrester Pharma (Pty) Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,South Africa
lenalidomide,lenalidomide,Lenalidomide,Forrester Pharma (Pty) Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,South Africa
lenalidomide,lenalidomide,Lomylemide,Forrester Pharma (Pty) Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,South Africa
lenalidomide,lenalidomide,Lenalidomide,Orion Pharma A/S,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,JAMP Pharma Corp,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Canada
lenalidomide,lenalidomide,Lenalidomide,Medical Valley Invest AB,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Denmark; Germany
lenalidomide,lenalidomide,Mmlinoda,Alkem Laboratories Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Medac Pharma Srl,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Italy
lenalidomide,lenalidomide,Lenalid,Samyang Biopharmaceuticals Corp,Oncology, Multiple Myeloma (Kahler Disease),Marketed,South Korea
lenalidomide,lenalidomide,Lenalidomide,Reddy US Therapeutics Inc,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,United States
lenalidomide,lenalidomide,Lenalidomide,Dr. Reddy's Laboratories (Pty) Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,South Africa
lenalidomide,lenalidomide,Lenalidomide,Dr Reddy’s Laboratories Canada Inc,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Canada
lenalidomide,lenalidomide,Lenalidomide,Reddy Pharma Iberia SA,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,betapharm Arzneimittel GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Dr. Reddy's Laboratories (UK) Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Reddy Pharma SAS,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,France
lenalidomide,lenalidomide,Lenangio,Dr. Reddy's Laboratories Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Dr. Reddy's Laboratories Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia; China
lenalidomide,lenalidomide,Lenalidomide,Nativa,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Russia
lenalidomide,lenalidomide,Lenalidomide,G.L. Pharma GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Myeloma,Zuvius Lifesciences Pvt Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Wockhardt UK Holdings Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Taro Pharmaceuticals Inc,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Canada
lenalidomide,lenalidomide,Lenalidomide,Sun Pharmaceuticals Spain SLU,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Sun Pharmaceutical Industries Europe BV,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,Basics GmbH,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Germany
lenalidomide,lenalidomide,Vilena,PT Pratapa Nirmala,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Indonesia
lenalidomide,lenalidomide,Lenalidomide,Aliud Pharma GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,SA Eurogenerics NV,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Belgium
lenalidomide,lenalidomide,Lenalidomide,STADApharm GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,EG Labo EuroGenerics,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,France
lenalidomide,lenalidomide,Lenalidomide,Laboratorio STADA SL,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Stada Arzneimittel AG,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,Stada Arzneimittel GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Grindeks AS,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Belgium; Spain
lenalidomide,lenalidomide,Lenalidomide,Grindeks AS,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Myelodysplastic Syndrome,Marketed,Belgium
lenalidomide,lenalidomide,Lenalidomide Ammonium Chloride,Grindeks AS,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Austria; Denmark; France; United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Accord A/S,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,Accord Healthcare GmbH Austria,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Accord Healthcare France SAS,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,France
lenalidomide,lenalidomide,Lenalidomide,Accord Healthcare Ltd,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,EU
lenalidomide,lenalidomide,Lenalidomide,Accord Healthcare AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Switzerland
lenalidomide,lenalidomide,Lenalidomide,Accord Healthcare Italia srl,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Italy
lenalidomide,lenalidomide,Lenome,Intas Pharmaceuticals Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Accord Healthcare GmbH,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Accord-UK Ltd,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Accord Healthcare SLU,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Belgium; Spain
lenalidomide,lenalidomide,Lenalidomide,Beijing SL Pharmaceutical Co Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,China
lenalidomide,lenalidomide,Lenalidomide,Natco Pharma (Canada) Inc,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Canada
lenalidomide,lenalidomide,Lenalid,Natco Pharma Ltd,Oncology, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma); Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Nodal Marginal Zone B-Cell Lymphoma; Splenic Marginal Zone B-Cell Lymphoma,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Teva Pharmaceuticals USA Inc,Oncology, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma); Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome; Nodal Marginal Zone B-Cell Lymphoma; Splenic Marginal Zone B-Cell Lymphoma,Marketed,United States
lenalidomide,lenalidomide,Lidamide,CMG Biotech Pvt Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Aurobindo Pharma Ltd,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Belgium
lenalidomide,lenalidomide,Lenalidomide,Aurovitas Spain SA,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Arrow Generiques SAS,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,France
lenalidomide,lenalidomide,Lenalidomide,PUREN Pharma GmbH and Co KG,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Aurobindo Pharma USA Inc,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Archived,United States
lenalidomide,lenalidomide,Lenalidomide,Changzhou Pharmaceutical Factory Co Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,China
lenalidomide,lenalidomide,Lenalex,Juno Pharmaceuticals Pty Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Lenalide,Juno Pharmaceuticals Pty Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Lenalidomide,Juno Pharmaceuticals Pty Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Tolreso,Acino France SAS,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,France
lenalidomide,lenalidomide,Levimid,Acino Pharma AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Switzerland
lenalidomide,lenalidomide,Lenalidomide,Acino France SAS,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,France
lenalidomide,lenalidomide,Lenalidomide,Acino International AG,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany; Spain
lenalidomide,lenalidomide,Xin'an,Jiangsu Hansoh Pharmaceutical Group Co Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,China
lenalidomide,lenalidomide,Lenalidomide,Zentiva France,Oncology, Multiple Myeloma (Kahler Disease),Marketed,France
lenalidomide,lenalidomide,Lenalidomide,Zentiva Pharma UK Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Helvepharm AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Switzerland
lenalidomide,lenalidomide,Lenalidomide,Zentiva Group AS,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,Zentiva Pharma Gmbh,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,SP Accure Labs Pvt Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Fresenius Kabi France SAS,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,France
lenalidomide,lenalidomide,Lenalidomide,Fresenius Kabi Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Fresenius Kabi Espana SA,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Fresenius Kabi Austria GmbH,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Fresenius Kabi NV SA,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Belgium
lenalidomide,lenalidomide,Lenalidomide,Fresenius Kabi AB,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Midolan,Helm AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,Helm AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Elmistal ,Helm Iberica SA,Oncology, Multiple Myeloma (Kahler Disease),Withdrawn,Spain
lenalidomide,lenalidomide,Lenalidomide,Helm AG,Oncology, Multiple Myeloma (Kahler Disease),Withdrawn,Denmark; France
lenalidomide,lenalidomide,Lenalidomide,Aristo Pharma GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Austria; Denmark; Germany; Spain
lenalidomide,lenalidomide,Lenalidomide,Glenmark Pharmaceuticals Europe Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Glenmark Arzneimittel GmbH,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Denmark; Germany; Spain
lenalidomide,lenalidomide,Lenalidomide,Cipla Australia Pty Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Australia
lenalidomide,lenalidomide,Lenalidomide,Cipla Europe NV,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Austria; Italy; Spain
lenalidomide,lenalidomide,Lenalidomide,Cipla Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,France
lenalidomide,lenalidomide,Lenalicip,Cipla Australia Pty Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Myelid,Cipla Medpro (Pty) Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,South Africa
lenalidomide,lenalidomide,Lenalidomide,Cipla Australia Pty Ltd,Hematological Disorders, Anemia,Marketed,Australia
lenalidomide,lenalidomide,Lenalimid,Cipla Australia Pty Ltd,Oncology, Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Lenalidomide,Cipla (EU) Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Germany; United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Cipla Europe NV,Oncology, Follicular Lymphoma,Marketed,Italy
lenalidomide,lenalidomide,Lenalidomide,Devatis GmbH,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Devatis AG,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Switzerland
lenalidomide,lenalidomide,Lenalidomide,Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,China
lenalidomide,lenalidomide,Lenalidomide,Sandoz Farmaceutica SA,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Spain
lenalidomide,lenalidomide,Lenalidomide,Sandoz Pty Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Lenalidomide,Sandoz Canada Inc,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Canada
lenalidomide,lenalidomide,Lenalidomide,Sandoz International GmbH,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Austria
lenalidomide,lenalidomide,Lenalidomide,Sandoz SAS,Oncology, Multiple Myeloma (Kahler Disease),Marketed,France
lenalidomide,lenalidomide,Lenalidomide,Sandoz NV,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Belgium
lenalidomide,lenalidomide,Lenalidomide,Sandoz A/S,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Denmark
lenalidomide,lenalidomide,Lenalidomide,Sandoz Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Hexal AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Germany
lenalidomide,lenalidomide,Lenalidomide,Sandoz Pharmaceuticals AG,Oncology, Multiple Myeloma (Kahler Disease),Marketed,Switzerland
lenalidomide,lenalidomide,Lenomust,Panacea Biotec Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,India
lenalidomide,lenalidomide,Lenalidomide,Luminarie Pty Ltd,Oncology, Mantle Cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Marketed,Australia
lenalidomide,lenalidomide,Chippy,Qilu Pharmaceutical Co Ltd,Oncology, Multiple Myeloma (Kahler Disease),Marketed,China
lenalidomide,lenalidomide,Lenalidomide,Ohre Pharma,Oncology, Multiple Myeloma (Kahler Disease),Marketed,France; Germany; Spain; United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Ohre Pharma,Oncology, Follicular Lymphoma,Marketed,Germany; Spain
lenalidomide,lenalidomide,Lenaloma,Chong Kun Dang Pharmaceutical Corporation,Oncology, Multiple Myeloma (Kahler Disease),Marketed,South Korea
lenalidomide,lenalidomide,Lenalidomide,Piramal Critical Care BV,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,France; Germany; Spain
lenalidomide,lenalidomide,Lenalidomide,Piramal Healthcare UK Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Lenalidomide,Mercury Pharmaceuticals Ltd,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,United Kingdom
lenalidomide,lenalidomide,Eurolen,Eurolab Pharmaceuticals,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,South Africa
lenalidomide,lenalidomide,Zelvina,Adalvo,Oncology, Follicular Lymphoma; Multiple Myeloma (Kahler Disease),Marketed,Israel
lenvatinib mesilate,lenvatinib mesilate,Lenvatinib Mesilate,CSPC Pharmaceutical Group Ltd,Oncology, Hepatocellular Carcinoma,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Lenvatinib Mesilate,Chia Tai Tianqing Pharmaceutical Group Co Ltd,Oncology, Endometrial Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Fukaite,Sino Biopharmaceutical Ltd,Oncology, Hepatocellular Carcinoma,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Lenvatinib Mesylate,Jiangsu Aosaikang Pharmaceutical Co Ltd,Oncology, Endometrial Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Lenvatinib Mesylate,Jiangxi Shanxiang Pharmaceutical Co Ltd,Oncology, Hepatocellular Carcinoma,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Bdfoie,BDR Pharmaceuticals Internationals Pvt Ltd,Oncology, Metastatic Liver Cancer; Metastatic Renal Cell Carcinoma; Thyroid Cancer,Marketed,India
lenvatinib mesylate,lenvatinib mesylate,Lenvatinib Mesylate,Simcere Pharmaceutical Co Ltd,Oncology, Endometrial Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Lenvatinib Mesylate,Hunan Kelun Pharmaceutical Co Ltd,Oncology, Endometrial Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Lenvatinib Mesylate,Chia Tai Tianqing Pharmaceutical Group Co Ltd,Oncology, Endometrial Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Thyroid Cancer,Marketed,China
lenvatinib mesylate,lenvatinib mesylate,Lenvatol,Cipla Ltd,Oncology, Hepatocellular Carcinoma; Metastatic Renal Cell Carcinoma; Thyroid Cancer,Marketed,India
matrine,,Matrine,Shandong Hualu Pharmaceutical Co Ltd,Oncology, Cancer Anorexia-Cachexia Syndrome,Marketed,China
Neovasculgen,,Neovasculgen,Human Stem Cells Institute,Cardiovascular, Critical Limb Ischemia; Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Marketed,Russia
Neovasculgen,,Neovasculgen,Human Stem Cells Institute,Metabolic Disorders, Diabetic Foot Ulcers,Inactive,Global
Neovasculgen,,Neovasculgen,Human Stem Cells Institute,Cardiovascular, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease),Inactive,Global
Neovasculgen,,Neovasculgen,Human Stem Cells Institute,Central Nervous System, Peripheral Nerve Injury,Inactive,Global
Neovasculgen,,,Human Stem Cells Institute,Cardiovascular, Raynauds Disease,Inactive,Global
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer Japan Inc,Ophthalmology, Age Related Macular Degeneration,Marketed,Japan
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer Pharma GmbH,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,Germany
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer Holding France (SCA),Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,France
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer NV/SA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,Belgium
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer Italia Srl,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,Italy
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer Canada Inc,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization,Withdrawn,Canada
pegaptanib sodium,pegaptanib sodium,Macugen,Bausch Health US LLC,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,United States
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer Ltd (UK),Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,EU; United Kingdom
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer New Zealand Limited,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,New Zealand
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer ApS,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,Denmark
pegaptanib sodium,pegaptanib sodium,Macugen,Bausch & Lomb GmbH,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,Austria
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer SL,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Withdrawn,Spain
pegaptanib sodium,pegaptanib sodium,Macugen,Bausch Health Companies Inc,Metabolic Disorders, Diabetic Macular Edema,Inactive,United States
pegaptanib sodium,pegaptanib sodium,Macugen,Pfizer Inc,Metabolic Disorders, Diabetic Macular Edema,Discontinued,EU
ranibizumab biosimilar,,Razumab,Intas Pharmaceuticals Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,India
ranibizumab biosimilar,,Razumab,Intas Pharmaceuticals Ltd,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Marketed,India
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen France SAS,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,France
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen GmbH,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Germany
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Spain SL,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Spain
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Italia SRL,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Italy
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Inc,Ophthalmology, Choroidal Neovascularization; Macular Edema; Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United States
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Bioepis UK Ltd,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,EU; United Kingdom
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen France SAS,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,France
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Bioepis Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Marketed,Canada
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Biologics Co Ltd,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Switzerland
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen GmbH,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Germany
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Austria GmbH,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Austria
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Belgium NV/SA,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Belgium
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Biologics Co Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Switzerland
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Bioepis UK Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,EU; United Kingdom
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Bioepis AU Pty Ltd,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Australia
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Denmark A/S,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Denmark
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Denmark A/S,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Denmark
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Italia SRL,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Italy
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Spain SL,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Spain
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Austria GmbH,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Austria
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Bioepis AU Pty Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Australia
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Biogen Belgium NV/SA,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Belgium
ranibizumab biosimilar,ranibizumab-nuna,Byooviz,Samsung Bioepis Co Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Canada
ranibizumab biosimilar,ranibizumab-nuna,,Samsung Bioepis Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Pre-Registration,United States
ranibizumab biosimilar,ranibizumab-nuna,,AffaMed Therapeutics US Inc,Metabolic Disorders, Diabetic Macular Edema,Phase I,China; Singapore
ranibizumab biosimilar,ranibizumab-nuna,,AffaMed Therapeutics US Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Phase I,China; Singapore
ranibizumab biosimilar,ranibizumab-nuna,,Samsung Bioepis Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,South Korea
ranibizumab biosimilar,,Ranivisio,Teva Sante SAS,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,France
ranibizumab biosimilar,,Ranivisio,Teva Pharma Italia Srl,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Italy
ranibizumab biosimilar,,Ranivisio,Teva Pharma SLU,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Spain
ranibizumab biosimilar,,Ongavia,Teva Pharmaceuticals Ltd,Metabolic Disorders, Proliferative Diabetic Retinopathy (PDR),Marketed,United Kingdom
ranibizumab biosimilar,,Ranivisio,Midas Pharma GmbH,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,EU
ranibizumab biosimilar,,Ranivisio,Teva Denmark A/S,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Denmark
ranibizumab biosimilar,,Ranivisio,Teva Pharma Belgium NV,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Belgium
ranibizumab biosimilar,,Ranivisio,Teva GmbH,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Germany
ranibizumab biosimilar,,Cimerli,Coherus BioSciences Inc,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization; Cystoid Macular Edema; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United States
ranibizumab biosimilar,,Ranivisio,Teva Pharmaceutical Industries Ltd,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Austria
ranibizumab biosimilar,,Ranivisio,Teva Pharma Belgium NV,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Belgium
ranibizumab biosimilar,,Cimerli,Coherus BioSciences Inc,Metabolic Disorders, Diabetic Retinopathy,Marketed,United States
ranibizumab biosimilar,,Ranivisio,Teva Pharmaceutical Industries Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Austria
ranibizumab biosimilar,,Ranivisio,Teva GmbH,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Germany
ranibizumab biosimilar,,Ranivisio,Teva Pharma Italia Srl,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Italy
ranibizumab biosimilar,,Ranivisio,Midas Pharma GmbH,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,EU
ranibizumab biosimilar,,Ranivisio,Teva Sante SAS,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,France
ranibizumab biosimilar,,Ranivisio,Teva Pharma SLU,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,Spain
ranibizumab biosimilar,,Ranivisio,Teva Denmark A/S,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Marketed,Denmark
ranibizumab biosimilar,,Ongavia,Teva Pharmaceuticals Ltd,Ophthalmology, Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Marketed,United Kingdom
ranibizumab biosimilar,,,Formycon AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
ranibizumab biosimilar,,RanizuRel,Reliance Life Sciences Pvt Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Marketed,India
sirolimus,sirolimus,Rapamune,Pfizer Holding France (SCA),Immunology, Kidney Transplant Rejection,Marketed,France
sirolimus,sirolimus,Rapamune,Pfizer AG,Immunology, Kidney Transplant Rejection,Marketed,Switzerland
sirolimus,sirolimus,Rapamune,Pfizer SL,Immunology, Kidney Transplant Rejection,Marketed,Spain
sirolimus,sirolimus,Sirolimus Greenstone,Greenstone LLC,Respiratory, Lymphangioleiomyomatosis,Marketed,United States
sirolimus,sirolimus,Rapamune,Pfizer Pharmaceuticals Ltd,Immunology, Kidney Transplant Rejection,Marketed,China
sirolimus,sirolimus,Rapamune,Pfizer Australia Pty Ltd,Immunology, Kidney Transplant Rejection,Marketed,Australia
sirolimus,sirolimus,Rapamune,Astellas Pharma Korea Inc,Immunology, Kidney Transplant Rejection,Marketed,South Korea
sirolimus,sirolimus,Rapamune,Pfizer Laboratories (Pty) Ltd,Respiratory, Lymphangioleiomyomatosis,Marketed,South Africa
sirolimus,sirolimus,Rapamune,Laboratorios Pfizer Ltda,Immunology, Kidney Transplant Rejection,Marketed,Brazil
sirolimus,sirolimus,Rapamune,Pfizer ApS,Respiratory, Lymphangioleiomyomatosis,Marketed,Denmark
sirolimus,sirolimus,Sirolimus Greenstone,Greenstone LLC,Immunology, Kidney Transplant Rejection,Marketed,United States
sirolimus,sirolimus,Rapamune,Pfizer Pharmaceuticals Israel Ltd,Immunology, Kidney Transplant Rejection,Marketed,Israel
sirolimus,sirolimus,Rapamune,Pfizer Inc,Immunology, Kidney Transplant Rejection,Marketed,United States
sirolimus,sirolimus,Rapamune,Pfizer Pharma GmbH,Immunology, Kidney Transplant Rejection,Marketed,Germany
sirolimus,sirolimus,Rapamune,Pfizer Italia Srl,Immunology, Kidney Transplant Rejection,Marketed,Italy
sirolimus,sirolimus,Rapamune,Pfizer Ltd India,Immunology, Kidney Transplant Rejection,Marketed,India
sirolimus,sirolimus,Sirolimus,Pfizer Canada Inc,Immunology, Kidney Transplant Rejection,Marketed,Canada
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Respiratory, Lymphangioleiomyomatosis,Marketed,Japan
sirolimus,sirolimus,Rapamune,Pfizer Canada Inc,Immunology, Kidney Transplant Rejection,Marketed,Canada
sirolimus,sirolimus,Rapamune,Pfizer HCP Corp,Immunology, Kidney Transplant Rejection,Marketed,Russia
sirolimus,sirolimus,Rapamune,Pfizer Inc,Respiratory, Lymphangioleiomyomatosis,Marketed,United States
sirolimus,sirolimus,Rapamune,Pfizer ApS,Immunology, Kidney Transplant Rejection,Marketed,Denmark
sirolimus,sirolimus,Rapamune,Pfizer Ltd (UK),Immunology, Kidney Transplant Rejection,Marketed,Austria; EU; United Kingdom
sirolimus,sirolimus,Sirolimus,Pfizer Ireland Pharmaceuticals,Immunology, Kidney Transplant Rejection,Marketed,China
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Non Malignant Disorders, Angiofibroma,Marketed,Japan
sirolimus,sirolimus,Rapamune,Pfizer SA de CV,Immunology, Kidney Transplant Rejection,Marketed,Mexico
sirolimus,sirolimus,Rapamune,Pfizer NV/SA,Respiratory, Lymphangioleiomyomatosis,Marketed,Belgium
sirolimus,sirolimus,Rapamune,Pfizer NV/SA,Immunology, Kidney Transplant Rejection,Marketed,Belgium
sirolimus,sirolimus,Rapamune,Pfizer New Zealand Limited,Immunology, Kidney Transplant Rejection,Marketed,New Zealand
sirolimus,sirolimus,Rapamune,Pfizer Laboratories (Pty) Ltd,Immunology, Kidney Transplant Rejection,Marketed,South Africa
sirolimus,sirolimus,Rapamune,Pfizer Ltd (UK),Respiratory, Lymphangioleiomyomatosis,Marketed,Austria
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Dermatology, Dermatological Disorders,Marketed,Japan
sirolimus,sirolimus,Sirolimus,Wyeth Pharmaceuticals Inc,Immunology, Kidney Transplant Rejection,Marketed,China
sirolimus,sirolimus,Rapalimus,Pfizer Inc,Non Malignant Disorders, Angiofibroma,Pre-Registration,China; EU
sirolimus,sirolimus,,Pfizer Inc,Respiratory, Lymphangioleiomyomatosis,Pre-Registration,EU
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Cardiovascular, Vascular Dysfunction,Phase III,Japan
sirolimus,sirolimus,,Pfizer Inc,Central Nervous System, Cognitive Impairment,Phase III,Global
sirolimus,sirolimus,,Pfizer Inc,Cardiovascular, Vascular Dysfunction,Phase III,Global
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Musculoskeletal Disorders, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva),Phase III,Japan
sirolimus,sirolimus,Rapalimus,Noble Pharma LLC,Immunology, Giant Lymph Node Hyperplasia (Castleman's Disease),Phase III,Japan
sirolimus,sirolimus,,Pfizer Inc,Central Nervous System, Amyotrophic Lateral Sclerosis,Phase II,Global
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Ear Nose Throat Disorders, Acute Sensorineural Hearing Loss,Phase II,Japan
sirolimus,sirolimus,,Nobelpharma Co Ltd,Cardiovascular, Cutaneous Vascular Malformations,Phase II,Japan
sirolimus,sirolimus,,Pfizer Inc,Immunology, Graft Versus Host Disease (GVHD),Phase II,Global
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Central Nervous System, Epilepsy,Phase II,Japan
sirolimus,sirolimus,,Nobelpharma Co Ltd,Genetic Disorders, Primary Immune Deficiency (PID),Phase II,Japan
sirolimus,sirolimus,,Pfizer Inc,Oncology, Chondrosarcoma; Myxoid Liposarcoma,Phase II,Global
sirolimus,sirolimus,,Pfizer Inc,Non Malignant Disorders, Benign Tumor,Phase II,Global
sirolimus,sirolimus,,Pfizer Inc,Cardiovascular, Vascular Dysfunction,Phase II,Global
sirolimus,sirolimus,,Pfizer Inc,Metabolic Disorders, Ageing,Phase I,Global
sirolimus,sirolimus,,Pfizer Inc,Hormonal Disorders, Growth Disorders,Phase I,Global
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Hematological Disorders,,Inactive,Japan
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Dermatology, Sudoriferous (Sweat) Gland Disorders,Inactive,Japan
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Genetic Disorders, Neurofibromatoses Type I (Von Recklinghausen’s Disease),Inactive,Japan
sirolimus,sirolimus,,Pfizer Inc,Immunology, Liver Transplant Rejection,Inactive,Global
sirolimus,sirolimus,Rapalimus,Nobelpharma Co Ltd,Immunology, Graft Versus Host Disease (GVHD),Inactive,Japan
sirolimus albumin-bound,sirolimus,Fyarro,Aadi Bioscience Inc,Oncology, Mesenchymal Tumor,Marketed,United States
sirolimus albumin-bound,sirolimus,,Aadi Bioscience Inc,Oncology, Bladder Cancer; Breast Cancer; Cervical Cancer; Chondrosarcoma; Endometrial Cancer; Ewing Sarcoma; Glioblastoma Multiforme (GBM); Head And Neck Cancer; High-Grade Glioma; Liposarcoma ; Metastatic Colorectal Cancer; Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer); Osteosarcoma; Ovarian Cancer; Pleomorphic Liposarcoma; Renal Cell Carcinoma; Soft Tissue Sarcoma; Unspecified Cancer; Uterine Cancer,Phase II,Global
sirolimus albumin-bound,sirolimus,,Aadi Bioscience Inc,Oncology, Solid Tumor,Phase II,Global; United States
sirolimus albumin-bound,sirolimus,,Aadi Bioscience Inc,Oncology, Epithelial Tumor,Phase II,EU; Global
sirolimus albumin-bound,sirolimus,,Aadi Bioscience Inc,Cardiovascular, Pulmonary Arterial Hypertension,Phase I,Global
sirolimus albumin-bound,sirolimus,,Aadi Bioscience Inc,Genetic Disorders, Subacute Necrotizing Encephalomyelopathy (Leigh Disease),Phase I,Global
sirolimus albumin-bound,sirolimus,,Aadi Bioscience Inc,Central Nervous System, Epilepsy,Phase I,Global
sirolimus albumin-bound,sirolimus,,Aadi Bioscience Inc,Oncology, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Neuroendocrine Tumors; Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Solid Tumor,Inactive,Global
vandetanib,vandetanib,Caprelsa,Sanofi KK,Oncology, Medullary Thyroid Cancer,Marketed,Japan
vandetanib,vandetanib,Caprelsa,Medley Industria Farmaceutica Ltda,Oncology, Medullary Thyroid Cancer,Marketed,Brazil
vandetanib,vandetanib,Caprelsa,Genzyme Europe BV,Oncology, Medullary Thyroid Cancer,Marketed,Austria; Belgium; Denmark; EU; France; Spain
vandetanib,vandetanib,Caprelsa,Genzyme Srl,Oncology, Medullary Thyroid Cancer,Marketed,Italy
vandetanib,vandetanib,Caprelsa,Sanofi-Aventis de Mexico SA de CV,Oncology, Medullary Thyroid Cancer,Marketed,Mexico
vandetanib,vandetanib,Caprelsa,Sanofi-Aventis Canada Inc,Oncology, Medullary Thyroid Cancer,Marketed,Canada
vandetanib,vandetanib,Caprelsa,Sanofi-Aventis Australia Pty Ltd,Oncology, Medullary Thyroid Cancer,Marketed,Australia
vandetanib,vandetanib,Caprelsa,Sanofi-Aventis Suisse SA,Oncology, Medullary Thyroid Cancer,Marketed,Switzerland
vandetanib,vandetanib,Caprelsa,Genzyme Corp,Oncology, Medullary Thyroid Cancer,Marketed,United States
vandetanib,vandetanib,Caprelsa,Sanofi-Aventis Israel,Oncology, Medullary Thyroid Cancer,Marketed,Israel
vandetanib,vandetanib,Caprelsa,Genzyme Therapeutics Ltd (UK),Oncology, Medullary Thyroid Cancer,Marketed,United Kingdom
vandetanib,vandetanib,Caprelsa,Sanofi-Aventis GmbH,Oncology, Medullary Thyroid Cancer,Marketed,Germany
vandetanib,vandetanib,Zactima,Sanofi,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Metastatic Biliary Tract Cancer; Metastatic Colorectal Cancer,Inactive,Global
vandetanib,vandetanib,Zactima,Sanofi,Oncology, Non-Small Cell Lung Cancer,Inactive,United States
vandetanib,vandetanib,,Sanofi,Oncology," Epithelial Ovarian Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Malignant Mesothelioma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Metastatic Pancreatic Cancer; Metastatic Transitional (Urothelial) Tract Cancer; Multiple Myeloma (Kahler Disease); Paraganglioma (Glomus Jugulare Tumor); Pediatric Diffuse Intrinsic Pontine Glioma; Peritoneal Cancer; Pheochromocytoma; Recurrent Glioblastoma Multiforme (GBM); Small-Cell Lung Cancer",Inactive,Global
vandetanib,vandetanib,Caprelsa,Sanofi,Oncology, Follicular Thyroid Cancer; Papillary Thyroid Cancer,Inactive,EU; Japan; United States
vandetanib,vandetanib,,Sanofi,Oncology, Non-Small Cell Lung Cancer,Inactive,EU; Global
vandetanib,vandetanib,Caprelsa,Sanofi,Oncology, Medullary Thyroid Cancer,Discontinued,China; Japan
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis Deutschland GmbH,Oncology, Metastatic Colorectal Cancer,Marketed,Germany
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis SA,Oncology, Metastatic Colorectal Cancer,Marketed,Spain
ziv-aflibercept,ziv-aflibercept [INN],Zalzen,Sanofi-Aventis South Africa (Pty) Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,South Africa
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi UK,Oncology, Metastatic Colorectal Cancer,Marketed,United Kingdom
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-aventis (suisse) sa,Oncology, Metastatic Colorectal Cancer,Marketed,Switzerland
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis Korea Co Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,South Korea
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis Australia Pty Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,Australia
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis Farmaceutica Ltda,Oncology, Metastatic Colorectal Cancer,Marketed,Brazil
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis Denmark A/S,Oncology, Metastatic Colorectal Cancer,Marketed,Denmark
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi Belgium SA NV,Oncology, Metastatic Colorectal Cancer,Marketed,Belgium
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis Groupe SA,Oncology, Metastatic Colorectal Cancer,Marketed,Austria; EU
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis South Africa (Pty) Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,South Africa
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,PT Aventis Pharma,Oncology, Metastatic Colorectal Cancer,Marketed,Indonesia
ziv-aflibercept,ziv-aflibercept [INN],Lidaveg,Sanofi-Aventis Australia Pty Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,Australia
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi KK,Oncology, Metastatic Colorectal Cancer,Marketed,Japan
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis Canada Inc,Oncology, Metastatic Colorectal Cancer,Marketed,Canada
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis US LLC,Oncology, Metastatic Colorectal Cancer,Marketed,United States
ziv-aflibercept,ziv-aflibercept [INN],Aflitiv,Sanofi-Aventis Australia Pty Ltd,Oncology, Metastatic Colorectal Cancer,Marketed,Australia
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis France SA,Oncology, Metastatic Colorectal Cancer,Marketed,France
ziv-aflibercept,ziv-aflibercept [INN],Zaltrapziv,Sanofi-Aventis de Mexico SA de CV,Oncology, Metastatic Colorectal Cancer,Marketed,Mexico
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi SpA,Oncology, Metastatic Colorectal Cancer,Withdrawn,Italy
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi-Aventis New Zealand Ltd,Oncology, Metastatic Colorectal Cancer,Withdrawn,New Zealand
ziv-aflibercept,ziv-aflibercept [INN],,Regeneron Pharmaceuticals Inc,Metabolic Disorders, Non-Proliferative Diabetic Retinopathy (NPDR),Phase III,Global
ziv-aflibercept,ziv-aflibercept [INN],,Regeneron Pharmaceuticals Inc,Oncology, Uveal Melanoma,Phase II,Global
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Regeneron Pharmaceuticals Inc,Oncology, Epithelial Ovarian Cancer; Malignant Neoplasms; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Inactive,Global
ziv-aflibercept,ziv-aflibercept [INN],,Regeneron Pharmaceuticals Inc,Oncology, B-Cell Non-Hodgkin Lymphoma,Inactive,Global
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi,Oncology, Metastatic Colorectal Cancer,Inactive,Asia-Pacific
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Sanofi,Oncology, Rectal Cancer,Inactive,Global
ziv-aflibercept,ziv-aflibercept [INN],Zaltrap,Regeneron Pharmaceuticals Inc,Oncology," Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Metastatic Pancreatic Cancer",Discontinued,Global
bucillamine,bucillamine [INN],Bucillamine,HanAll Biopharma Co Ltd,Immunology, Rheumatoid Arthritis,Withdrawn,South Korea
serelaxin,serelaxin,Reasanz,Novartis Pharma LLC,Cardiovascular, Acute Heart Failure,Withdrawn,Russia
serelaxin,serelaxin,,Novartis AG,Cardiovascular, Pre-Eclampsia,Inactive,Global
serelaxin,serelaxin,,Novartis AG,Immunology, Systemic Sclerosis (Scleroderma),Inactive,Japan; United States
serelaxin,serelaxin,,Paladin Labs Inc,Cardiovascular, Acute Heart Failure,Inactive,Canada
serelaxin,serelaxin,,Novartis AG,Women's Health, Cervical Ripening In Pregnant Women Near Term; Labor And Delivery,Inactive,Global
serelaxin,serelaxin,,Novartis AG,Cardiovascular, Acute Heart Failure,Discontinued,EU; Japan; United States
serelaxin,serelaxin,,Paladin Labs Inc,Immunology, Systemic Sclerosis (Scleroderma),Discontinued,Canada
serelaxin,serelaxin,,Novartis AG,Cardiovascular, Chronic Heart Failure,Discontinued,Global
axitinib,axitinib,Axitinib,Teva Pharmaceuticals USA Inc,Oncology, Metastatic Renal Cell Carcinoma,Archived,United States
axitinib,axitinib,Axitinib,Glenmark Pharmaceuticals Inc,Oncology, Metastatic Renal Cell Carcinoma,Archived,United States
axitinib,axitinib,Axitinib,Apotex Corp,Oncology, Metastatic Renal Cell Carcinoma,Archived,United States
lenalidomide,lenalidomide,Lenalidomide,Alvogen Pharma US Inc,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Archived,United States
lenalidomide,lenalidomide,Lenalidomide,Zydus Pharmaceuticals USA Inc,Oncology, Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-cell Lymphoma; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Archived,United States
midostaurin,midostaurin,Midostaurin,Alvogen Inc,Gastrointestinal, Systemic Mastocytosis,Archived,United States
midostaurin,midostaurin,Midostaurin,Alvogen Inc,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)",Archived,United States
bevacizumab biosimilar,,oyavas,STADA Pharmaceuticals (Asia) Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer; Uterine Cancer,Pre-Registration,EU
bevacizumab biosimilar,,,STADA Pharmaceuticals (Asia) Ltd,Oncology, Breast Cancer; Cervical Cancer; Colorectal Cancer; Epithelial Ovarian Cancer; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Peritoneal Cancer,Phase III,United States
bevacizumab biosimilar,,oyavas,STADA Pharmaceuticals (Asia) Ltd,Oncology, Breast Cancer; Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Phase III,United Kingdom
bevacizumab biosimilar,,,STADA Pharmaceuticals (Asia) Ltd,Oncology, Fallopian Tube Cancer,Phase III,Global
bevacizumab biosimilar,,,Nanolek,Oncology, Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Pre-Registration,Russia
bevacizumab-vikg,bevacizumab-vikg [INN],LYTENAVA,Outlook Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Pre-Registration,United States
bevacizumab-vikg,bevacizumab-vikg [INN],,Outlook Therapeutics Inc,Ophthalmology, Branch Retinal Vein Occlusion,Phase III,United States
bevacizumab-vikg,bevacizumab-vikg [INN],,Outlook Therapeutics Inc,Metabolic Disorders, Diabetic Macular Edema,Phase III,United States
bevacizumab-vikg,bevacizumab-vikg [INN],,Outlook Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,EU; Global; Japan; United Kingdom
Carboxyamidotriazole,,,Guangdong Yinzhu Pharmaceutical Technology Co Ltd,Oncology, Non-Small Cell Lung Cancer,Pre-Registration,China
Carboxyamidotriazole,,,Guangdong Yinzhu Pharmaceutical Technology Co Ltd,Oncology, Gastric Cancer; Gastrointestinal Tumor; Ovarian Cancer,Phase II,China
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ,Pre-Registration,Japan; United States
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ,Phase III,EU; Japan; United States
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Metastatic Transitional (Urothelial) Tract Cancer; Non-Small Cell Lung Cancer,Phase II,Global
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Anaplastic Astrocytoma; Glioblastoma Multiforme (GBM); Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Breast Cancer; Multiple Myeloma (Kahler Disease); Oligodendroglioma; Transitional Cell Carcinoma (Urothelial Cell Carcinoma); Triple-Negative Breast Cancer (TNBC),Phase II,EU; United States
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Solid Tumor,Phase II,EU; Global; United States
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Unspecified Cancer,Phase II,EU; Japan; United States
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Endometrial Cancer; Esophageal Cancer; Metastatic Hepatocellular Carcinoma (HCC),Phase I,Global
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Lung Cancer; Unspecified Cancer,Inactive,Global
futibatinib,futibatinib,,Taiho Oncology Inc,Oncology, Breast Cancer,Inactive,Japan
ranibizumab biosimilar,,Xlucane,Xbrane Biopharma AB,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Pre-Registration,EU
ranibizumab biosimilar,,Xlucane,Xbrane Biopharma AB,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Pre-Registration,EU
ranibizumab biosimilar,,Xlucane,Xbrane Biopharma AB,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,United States
ranibizumab biosimilar,,Xlucane,Xbrane Biopharma AB,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Phase III,United States
ranibizumab biosimilar,,Xlucane,Xbrane Biopharma AB,Ophthalmology, Macular Edema,IND/CTA Filed,United States
ranibizumab biosimilar,,Xlucane,Xbrane Biopharma AB,Ophthalmology, Retinal Vein Occlusion,Preclinical,Global
ranibizumab biosimilar,,Xlucane,Xbrane Biopharma AB,Ophthalmology, Macular Edema,Preclinical,EU
abicipar pegol,abicipar pegol,,AbbVie Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Filing rejected/Withdrawn,Japan; United States
abicipar pegol,abicipar pegol,,Molecular Partners AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
abicipar pegol,abicipar pegol,,Molecular Partners AG,Metabolic Disorders, Diabetic Macular Edema,Phase II,Japan; United States
abicipar pegol,abicipar pegol,Rayoqta,Allergan Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,EU
bevacizumab,bevacizumab,Ipique,Rotterdam Biologics BV,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Filing rejected/Withdrawn,EU
9MW-0211,,,Mabwell Shanghai Bioscience Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
aflibercept biosimilar,,,Formycon AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,EU; Global; Japan; United States
aflibercept biosimilar,,,Cinnagen Co,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Middle East and Africa
aflibercept biosimilar,,,Amgen Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
aflibercept biosimilar,,,Johnson & Johnson,Metabolic Disorders, Diabetic Macular Edema,Phase III,EU; Global; United States
aflibercept biosimilar,,,Alvotech SA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
aflibercept biosimilar,,,Hexal AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
aflibercept biosimilar,,,Celltrion Inc,Metabolic Disorders, Diabetic Macular Edema,Phase III,Global
aflibercept biosimilar,,,Sam Chun Dang Pharm Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global; United States
aflibercept biosimilar,,,Mabwell Shanghai Bioscience Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase III,China
aflibercept biosimilar,,,Luye Pharma Group Ltd,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Phase III,China
aflibercept biosimilar,,,Luye Pharma Group Ltd,Ophthalmology, Choroidal Neovascularization; Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Phase III,China
aflibercept biosimilar,,,Luye Pharma Group Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,China
aflibercept biosimilar,,,Luye Pharma Group Ltd,Ophthalmology, Macular Edema,IND/CTA Filed,China
aflibercept biosimilar,,,Luye Pharma Group Ltd,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
aflibercept biosimilar,,,Luye Pharma Group Ltd,Ophthalmology, Choroidal Neovascularization; Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
aflibercept biosimilar,,,Samsung Bioepis Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
aflibercept biosimilar,,,AffaMed Therapeutics US Inc,Metabolic Disorders, Diabetic Macular Edema,Phase I,Singapore
aflibercept biosimilar,,,AffaMed Therapeutics US Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Singapore
aflibercept biosimilar,,,AffaMed Therapeutics US Inc,Metabolic Disorders, Diabetic Macular Edema,IND/CTA Filed,China
aflibercept biosimilar,,,AffaMed Therapeutics US Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,IND/CTA Filed,China
aflibercept biosimilar,,,Alteogen Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global; South Korea
aflibercept biosimilar,,,Alteogen Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,United States
aflibercept biosimilar,,,Kissei Pharmaceutical Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Japan
aganirsen,aganirsen [INN],,Gene Signal International SA,Ophthalmology, Corneal Neovascularization,Phase III,EU
aganirsen,aganirsen [INN],,Gene Signal International SA,Metabolic Disorders, Diabetic Macular Edema,Phase II,Global
aganirsen,aganirsen [INN],,Gene Signal International SA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Global
aganirsen,aganirsen [INN],,Gene Signal International SA,Immunology, Corneal Graft Rejection,Preclinical,United States
aganirsen,aganirsen [INN],,Gene Signal International SA,Oncology, Bladder Cancer,Preclinical,Global
aganirsen,aganirsen [INN],,Gene Signal International SA,Immunology, Corneal Graft Rejection,Inactive,EU
aganirsen,aganirsen [INN],,Gene Signal International SA,Immunology, Psoriasis,Inactive,Global
aganirsen,aganirsen [INN],,Gene Signal International SA,Ophthalmology, Central Retinal Vein Occlusion; Neovascular Glaucoma; Retinopathy Of Prematurity,Inactive,EU
aganirsen,aganirsen [INN],,Gene Signal International SA,Dermatology, Rosacea,Inactive,Global
aganirsen,aganirsen [INN],,Gene Signal International SA,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
APX-003,,,Simcere Pharmaceutical Group Ltd,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Phase III,China
APX-003,,,Simcere Pharmaceutical Group Ltd,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Brenner Tumor; Clear Cell Squamous Cell Carcinoma  ; Colorectal Cancer; Endometrial Cancer; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Solid Tumor; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Phase II,China
APX-003,,,Apexigen Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Global
APX-003,,,Simcere Pharmaceutical Group Ltd,Oncology, Liver Cancer,Phase I,China
APX-003,,,Simcere Pharmaceutical Group Ltd,Oncology, Metastatic Colorectal Cancer,Inactive,China
bevacizumab biosimilar,,,Genor BioPharma Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Genor BioPharma Co Ltd,Oncology, Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer,Phase I,China
bevacizumab biosimilar,,,Anhui Anke Biotechnology (Group) Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Zhejiang Teruisi Pharmaceutical Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Zhejiang Teruisi Pharmaceutical Co Ltd,Oncology, Colorectal Cancer,Phase I,China; United States
bevacizumab biosimilar,,,Zhejiang Teruisi Pharmaceutical Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase I,United States
bevacizumab biosimilar,,,Hualan Biological Engineering Inc,Oncology, Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Boehringer Ingelheim International GmbH,Oncology, Non-Small Cell Lung Cancer,Phase III,Japan
bevacizumab biosimilar,,,Boehringer Ingelheim International GmbH,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Inactive,Global
bevacizumab biosimilar,,,Enzene Biosciences Ltd,Oncology, Metastatic Colorectal Cancer,Phase III,India
bevacizumab biosimilar,,,Enzene Biosciences Ltd,Oncology, Non-Small Cell Lung Cancer,Preclinical,Global
bevacizumab biosimilar,,,Aurobindo Pharma Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,Global
bevacizumab biosimilar,,,Aurobindo Pharma Ltd,Oncology, Metastatic Colorectal Cancer,Phase I,Global
bevacizumab biosimilar,,,Prestige BioPharma Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,EU; Global; United States
bevacizumab biosimilar,,,Prestige BioPharma Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Colorectal Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM),Phase I,EU; United States
bevacizumab biosimilar,,,Prestige BioPharma Ltd,Oncology, Rectal Cancer,Inactive,Global
bevacizumab biosimilar,,,Prestige BioPharma Ltd,Oncology, Metastatic Renal Cell Carcinoma,Inactive,EU; United States
bevacizumab biosimilar,,,SinoCelltech Group Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,China; Global
bevacizumab biosimilar,,,SinoCelltech Group Ltd,Oncology, Hepatocellular Carcinoma,Phase III,Global
bevacizumab biosimilar,,,SinoCelltech Group Ltd,Oncology, Metastatic Colorectal Cancer,Preclinical,Global
bevacizumab biosimilar,,,Shanghai Huaota Biopharmaceutical Co Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Outlook Therapeutics Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,Sino Biopharmaceutical Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Shanghai Institute of Biological Products Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,China
bevacizumab biosimilar,,,Shanghai Institute of Biological Products Co Ltd,Oncology, Metastatic Colorectal Cancer,Phase I,China
bevacizumab biosimilar,,,Laboratorios Sophia SA de CV,Metabolic Disorders, Diabetic Macular Edema,Phase III,Global
bRESCAP,,,Alloksys Life Sciences BV,Immunology, Inflammation,Phase III,Global
bRESCAP,,,Alloksys Life Sciences BV,Genito Urinary System And Sex Hormones, Acute Renal Failure (ARF) (Acute Kidney Injury),Phase III,Global
bRESCAP,,,Alloksys Life Sciences BV,Infectious Disease, Coronavirus Disease 2019 (COVID-19),Phase I,Global
bRESCAP,,,Alloksys Life Sciences BV,Dermatology, Burns,Preclinical,Global
bRESCAP,,,Alloksys Life Sciences BV,Cardiovascular, Ischemia Reperfusion Injury,Inactive,Global
bRESCAP,,,Alloksys Life Sciences BV,Immunology, Rheumatoid Arthritis,Inactive,Global
cediranib maleate,cediranib maleate,,AstraZeneca Plc,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Phase III,United States
cediranib maleate,cediranib maleate,,AstraZeneca Plc,Oncology, Cervical Cancer,Phase II,Global
cediranib maleate,cediranib maleate,,AstraZeneca Plc,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Breast Cancer; Endometrial Cancer; Head And Neck Cancer; Prostate Cancer; Thyroid Cancer",Inactive,Global
cediranib maleate,cediranib maleate,,AstraZeneca Plc,Oncology, Gastric Cancer; Ovarian Cancer,Inactive,Japan
cediranib maleate,cediranib maleate,,AstraZeneca Plc,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Inactive,EU
cediranib maleate,cediranib maleate,,AstraZeneca Plc,Gastrointestinal, Liver Diseases,Inactive,Global
cediranib maleate,cediranib maleate,,AstraZeneca Plc,Oncology, Gastrointestinal Stromal Tumor (GIST); Malignant Pleural Mesothelioma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Soft Tissue Sarcoma; Solid Tumor,Discontinued,Global
cediranib maleate,cediranib maleate,Recentin,AstraZeneca Plc,Oncology, Glioblastoma Multiforme (GBM),Discontinued,United States
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Epithelial Ovarian Cancer; Small-Cell Lung Cancer,Phase III,China
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Peritoneal Cancer,Phase III,Global
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Small-Cell Lung Cancer,Phase II,United States
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Colon Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma; Lung Cancer; Non-Hodgkin Lymphoma,Phase II,Global
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Soft Tissue Sarcoma; Triple-Negative Breast Cancer (TNBC),Phase II,China
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Gastric Cancer; Gastrointestinal Stromal Tumor (GIST); Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Solid Tumor,Phase I,China
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Angiosarcoma; Dedifferentiated Liposarcoma; Dermatofibrosarcoma Protuberans (DFSP); Ewing Sarcoma; Fibrosarcoma; Leiomyosarcoma; Malignant Fibrous Histiocytoma; Peripheral Nerve Sheath Tumor (Neurofibrosarcoma); Pleomorphic Liposarcoma; Rhabdomyosarcoma; Small-Cell Lung Cancer; Soft Tissue Sarcoma; Synovial Sarcoma; Well Differentiated Liposarcoma ,Phase I,Global
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Breast Cancer; Liver Cancer; Ovarian Cancer; Small-Cell Lung Cancer,IND/CTA Filed,United States
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Small-Cell Lung Cancer,Preclinical,Global
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Renal Cell Carcinoma,Inactive,China
CS-2164,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Diffuse Large B-Cell Lymphoma; Peripheral T-Cell Lymphomas (PTCL),Inactive,Global
emvododstat,emvododstat,,PTC Therapeutics Inc,Infectious Disease, Coronavirus Disease 2019 (COVID-19),Phase III,Australia; Brazil; EU; Global; Spain; United States
emvododstat,emvododstat,,PTC Therapeutics Inc,Oncology, Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia,Inactive,United States
emvododstat,emvododstat,,PTC Therapeutics Inc,Oncology, Central Nervous System (CNS) Tumor; Metastatic Breast Cancer,Discontinued,Global
emvododstat,emvododstat,,PTC Therapeutics Inc,Infectious Disease, Kaposi Sarcoma,Discontinued,Global
emvododstat,emvododstat,,PTC Therapeutics Inc,Genetic Disorders, Neurofibromatoses,Discontinued,Global
enzastaurin hydrochloride,enzastaurin hydrochloride,,Denovo Biopharma LLC,Oncology, Glioblastoma Multiforme (GBM),Phase III,Canada; China; Global; United States
enzastaurin hydrochloride,enzastaurin hydrochloride,,Denovo Biopharma LLC,Oncology, Diffuse Large B-Cell Lymphoma,Phase III,Global
enzastaurin hydrochloride,enzastaurin hydrochloride,,Aytu BioPharma Inc,Genetic Disorders, Ehlers-Danlos Syndrome (Cutis Hyperelastica),Phase II,EU; United States
enzastaurin hydrochloride,enzastaurin hydrochloride,,Eli Lilly and Co,Oncology, Non-Small Cell Lung Cancer,Phase II,Global
enzastaurin hydrochloride,enzastaurin hydrochloride,,Denovo Biopharma LLC,Oncology, Colorectal Cancer; Metastatic Colorectal Cancer,Phase II,Global
enzastaurin hydrochloride,enzastaurin hydrochloride,,Denovo Biopharma LLC,Respiratory, Emphysema,Preclinical,Global
enzastaurin hydrochloride,enzastaurin hydrochloride,,Denovo Biopharma LLC,Cardiovascular, Pulmonary Arterial Hypertension,Preclinical,Global
enzastaurin hydrochloride,enzastaurin hydrochloride,,Eli Lilly and Co,Oncology, Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme (GBM),Discontinued,EU; United States
enzastaurin hydrochloride,enzastaurin hydrochloride,,Eli Lilly and Co,Oncology," Cutaneous T-Cell Lymphoma; Follicular Lymphoma; Lung Cancer; Mantle Cell Lymphoma; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Metastatic Renal Cell Carcinoma; Multiple Myeloma (Kahler Disease); Non-Small Cell Lung Cancer; Ovarian Cancer; Peritoneal Tumor; Small-Cell Lung Cancer; Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)",Discontinued,Global
enzastaurin hydrochloride,enzastaurin hydrochloride,,Eli Lilly and Co,Oncology, Advanced Malignancy; Lymphoma; Metastatic Cancer; Solid Tumor,Discontinued,China
gentuximab,,,GeneScience Pharmaceuticals Co Ltd,Oncology, Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas,Phase III,China
gentuximab,,,GeneScience Pharmaceuticals Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase I,Global
gentuximab,,,GeneScience Pharmaceuticals Co Ltd,Oncology, Solid Tumor,Phase I,China
ivonescimab,ivonescimab [INN],,Akeso Inc,Oncology, Non-Small Cell Lung Cancer,Phase III,China
ivonescimab,ivonescimab [INN],,Akeso Inc,Oncology, Cervical Cancer; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Solid Tumor; Triple-Negative Breast Cancer (TNBC),Phase II,China; Global
ivonescimab,ivonescimab [INN],,Akeso Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Colorectal Cancer; Esophageal Squamous Cell Carcinoma (ESCC); Extrahepatic Bile Duct Cancer; Fallopian Tube Cancer; Gallbladder Cancer; Gastric Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Metastatic Biliary Tract Cancer; Metastatic Colorectal Cancer; Oral Cavity (Mouth) Cancer; Oropharyngeal Cancer; Pancreatic Ductal Adenocarcinoma; Peritoneal Cancer; Recurrent Head And Neck Cancer Squamous Cell Carcinoma; Squamous Non-Small Cell Lung Cancer; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Phase II,Global
ivonescimab,ivonescimab [INN],,Akeso Inc,Oncology, Endometrial Cancer; Epithelial Ovarian Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma,Phase II,China
ivonescimab,ivonescimab [INN],,Akeso Inc,Oncology, Hepatocellular Carcinoma; Solid Tumor,Phase I,Australia
ivonescimab,ivonescimab [INN],,Akeso Inc,Oncology, Hepatocellular Carcinoma; Renal Cell Carcinoma; Solid Tumor,IND/CTA Filed,United States
ivonescimab,ivonescimab [INN],,Akeso Inc,Oncology, Renal Cell Carcinoma,Inactive,Australia
lucitanib,lucitanib,,Shanghai Haihe Biopharma Co Ltd,Oncology, Small-Cell Lung Cancer,Phase III,China
lucitanib,lucitanib,,Shanghai Haihe Biopharma Co Ltd,Oncology, Nasopharyngeal Cancer; Thymic Carcinoma,Phase II,China
lucitanib,lucitanib,,Shanghai Haihe Biopharma Co Ltd,Oncology, Gastroesophageal (GE) Junction Carcinomas; Hepatocellular Carcinoma; Nasopharyngeal Cancer,Phase I,China
lucitanib,lucitanib,,Les Laboratoires Servier SAS,Oncology, Solid Tumor; Thymic Carcinoma; Thyroid Cancer,Inactive,Global
lucitanib,lucitanib,,Clovis Oncology Inc,Oncology, Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Gynecological Cancer; Metastatic Transitional (Urothelial) Tract Cancer; Peritoneal Cancer,Inactive,Global
lucitanib,lucitanib,,Clovis Oncology Inc,Oncology, Metastatic Breast Cancer; Squamous Non-Small Cell Lung Cancer,Discontinued,Japan; United States
lucitanib,lucitanib,,Les Laboratoires Servier SAS,Oncology, Metastatic Breast Cancer,Discontinued,Global
OPT-302,,,Opthea Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,EU; Global; United States
OPT-302,,,Opthea Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase II,United States
OPT-302,,,Opthea Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Unknown,United States
OPT-302,,,Opthea Ltd,Oncology, Solid Tumor,Inactive,Global
QL-1207,,,Qilu Pharmaceutical Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
QL-1207,,,Qilu Pharmaceutical Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase I,China
ranibizumab biosimilar,,,Chong Kun Dang Pharmaceutical Corporation,Ophthalmology, Age Related Macular Degeneration,Phase III,South Korea
ranibizumab biosimilar,,,Jecho Biopharmaceuticals Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
ranibizumab biosimilar,,,Jecho Biopharmaceuticals Co Ltd,Ophthalmology, Age Related Macular Degeneration; Unspecified Ophthalmological Disorders,Phase II,Global
ranibizumab biosimilar,,,Enzene Biosciences Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
ranibizumab biosimilar,,,PharmaResearch BIO Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,Global
ranibizumab biosimilar,,,PharmaResearch BIO Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,South Korea
ranibizumab biosimilar,,,Lupin Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,EU; Global; India; United States
RGX-314,,,AbbVie Inc,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Phase III,United States
RGX-314,,,AbbVie Inc,Metabolic Disorders, Diabetic Retinopathy,Phase II,Global
RGX-314,,,AbbVie Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Global
RGX-314,,,AbbVie Inc,Ophthalmology, Unspecified Ophthalmological Disorders,Discovery,Global
SH-1028,,,Nanjing Sanhome Pharmaceutical Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,Global
SH-1028,,,Nanjing Sanhome Pharmaceutical Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase II,China
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Colorectal Cancer,Phase III,Global
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,China
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Respiratory, Idiopathic Pulmonary Fibrosis,Phase III,Global
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Cervical Cancer; Solid Tumor,Phase II,China
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Anaplastic Thyroid Cancer; Bladder Cancer; Endometrial Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Follicular Thyroid Cancer; Gynecological Cancer; Hepatocellular Carcinoma; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Medullary Thyroid Cancer; Metastatic Biliary Tract Cancer; Metastatic Transitional (Urothelial) Tract Cancer; Papillary Thyroid Cancer; Peritoneal Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma; Thyroid Cancer; Triple-Negative Breast Cancer (TNBC); Ureter Cancer; Urethral Cancer,Phase II,Global
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ,Phase I,Global
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Solid Tumor,Phase I,United States
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Genetic Disorders, Familial Adenomatous Polyposis,Preclinical,Global
SHR-1020,,,Jiangsu Hengrui Medicine Co Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST); Metastatic Renal Cell Carcinoma; Nasopharyngeal Cancer; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Osteosarcoma; Pancreatic Endocrine Tumor,Inactive,Global
sitravatinib malate,sitravatinib malate,,BeiGene Ltd,Oncology, Non-Small Cell Lung Cancer,Phase III,Australia; China
sitravatinib malate,sitravatinib malate,,Mirati Therapeutics Inc,Oncology, Non-Small Cell Lung Cancer,Phase III,Global; United States
sitravatinib malate,sitravatinib malate,,Mirati Therapeutics Inc,Oncology, Solid Tumor,Phase III,Global
sitravatinib malate,sitravatinib malate,,BeiGene Ltd,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Gallbladder Cancer,Phase II,South Korea
sitravatinib malate,sitravatinib malate,,Mirati Therapeutics Inc,Oncology, Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Head And Neck Cancer Squamous Cell Carcinoma; Kidney Cancer (Renal Cell Cancer); Liposarcoma ; Metastatic Hepatocellular Carcinoma (HCC); Metastatic Melanoma; Metastatic Transitional (Urothelial) Tract Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Peripheral Nerve Sheath Tumor (Neurofibrosarcoma); Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Squamous Non-Small Cell Lung Cancer; Synovial Sarcoma,Phase II,Global
sitravatinib malate,sitravatinib malate,,BeiGene Ltd,Oncology, Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Hepatocellular Carcinoma; Metastatic Melanoma,Phase II,China
sitravatinib malate,sitravatinib malate,,Mirati Therapeutics Inc,Oncology, Endometrial Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Solid Tumor; Triple-Negative Breast Cancer (TNBC),Phase I,Global
sitravatinib malate,sitravatinib malate,,BeiGene Ltd,Oncology, Oral Cavity (Mouth) Cancer,Phase I,China
sitravatinib malate,sitravatinib malate,,BeiGene Ltd,Oncology, Esophageal Squamous Cell Carcinoma (ESCC),Phase I,Asia-Pacific; China
sitravatinib malate,sitravatinib malate,,BeiGene Ltd,Oncology, Epithelial Ovarian Cancer; Non-Small Cell Lung Cancer; Renal Cell Carcinoma,Phase I,Australia; China
sitravatinib malate,sitravatinib malate,,Mirati Therapeutics Inc,Oncology, Oral Cavity (Mouth) Cancer,Phase 0,Global
sitravatinib malate,sitravatinib malate,,BeiGene Ltd,Oncology, Non-Small Cell Lung Cancer,Preclinical,New Zealand
sitravatinib malate,sitravatinib malate,,Mirati Therapeutics Inc,Oncology," Bone Metastasis; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Thymoma (Thymic Epithelial Tumor)",Inactive,Global
TAB-014,bevacizumab,,Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase III,China
TAB-014,bevacizumab,,TOT Biopharm Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Global
TAB-014,bevacizumab,,TOT Biopharm Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,IND/CTA Filed,United States
tamoxifen citrate,tamoxifen citrate,,University Children's Hospital Basel,Genetic Disorders, Duchenne Muscular Dystrophy,Phase III,EU
tarcocimab tedromer,tarcocimab tedromer [INN],,Kodiak Sciences Inc,Ophthalmology, Choroidal Neovascularization; Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Phase III,EU; United States
tarcocimab tedromer,tarcocimab tedromer [INN],,Kodiak Sciences Inc,Metabolic Disorders, Diabetic Macular Edema,Phase III,EU; United States
tarcocimab tedromer,tarcocimab tedromer [INN],,Kodiak Sciences Inc,Metabolic Disorders, Non-Proliferative Diabetic Retinopathy (NPDR),Phase III,Global; United States
tarcocimab tedromer,tarcocimab tedromer [INN],,Kodiak Sciences Inc,Metabolic Disorders, Diabetic Retinopathy,Phase III,EU
tarcocimab tedromer,tarcocimab tedromer [INN],,Kodiak Sciences Inc,Ophthalmology, Choroidal Neovascularization; Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,China
tarcocimab tedromer,tarcocimab tedromer [INN],,Kodiak Sciences Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Inactive,China
4D-150,,,4D Molecular Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,United States
4D-150,,,4D Molecular Therapeutics Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
4D-150,,,4D Molecular Therapeutics Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
601A anti-VEGF Ab,,,3SBio Inc,Metabolic Disorders, Diabetic Macular Edema,Phase II,Global
601A anti-VEGF Ab,,,3SBio Inc,Ophthalmology, Age Related Macular Degeneration,Phase II,Global
601A anti-VEGF Ab,,,3SBio Inc,Ophthalmology, Central Retinal Vein Occlusion; Choroidal Neovascularization; Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Phase II,China
601A anti-VEGF Ab,,,3SBio Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,China
601A anti-VEGF Ab,,,3SBio Inc,Oncology, Cervical Cancer; Non-Small Cell Lung Cancer,Inactive,China
601A anti-VEGF Ab,,,3SBio Inc,Ophthalmology, Retinal Vein Occlusion,Inactive,China
ABL-001,,,Handok Inc,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Stromal Tumor (GIST); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Solid Tumor,Phase II,South Korea
ABL-001,,,Elpiscience Biopharma Ltd,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Colorectal Cancer; Gastric Cancer; Metastatic Biliary Tract Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer,Phase II,China
ABL-001,,,Compass Therapeutics Inc,Oncology, Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Metastatic Biliary Tract Cancer; Metastatic Colorectal Cancer,Phase I,Global
ABL-001,,,Compass Therapeutics Inc,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Gallbladder Cancer,IND/CTA Filed,United States
ABL-001,,,Elpiscience Biopharma Ltd,Oncology, Endometrial Cancer,IND/CTA Filed,China
AC-701,,,TWi Biotechnology Inc,Dermatology, Rosacea; Skin Rash,Phase II,Taiwan
AG-73305,,,Allgenesis Biotherapeutics Inc,Metabolic Disorders, Diabetic Macular Edema,Phase II,United States
AG-73305,,,Allgenesis Biotherapeutics Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,United States
AG-73305,,,AffaMed Therapeutics US Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,China
AG-73305,,,AffaMed Therapeutics US Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Asia-Pacific
AG-73305,,,AffaMed Therapeutics US Inc,Ophthalmology, Retinal Vein Occlusion,Preclinical,South Korea
AK-109,,,Akeso Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer; Metastatic Hepatocellular Carcinoma (HCC); Non-Small Cell Lung Cancer; Solid Tumor,Phase II,China
AK-109,,,Akeso Inc,Oncology, Lung Cancer; Rectal Cancer,Inactive,China
axitinib,axitinib,,Clearside BioMedical Inc,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Phase II,United States
AXT-107,,,AsclepiX Therapeutics Inc,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Phase II,United States
AXT-107,,,AsclepiX Therapeutics Inc,Metabolic Disorders, Diabetic Macular Edema,Phase II,United States
AXT-107,,,AsclepiX Therapeutics Inc,Ophthalmology, Choroidal Neovascularization,Phase II,Global
AXT-107,,,AsclepiX Therapeutics Inc,Ophthalmology, Retinal Vein Occlusion,Preclinical,United States
AZD-8601,,,Moderna Inc,Metabolic Disorders, Type 2 Diabetes,Phase II,EU
AZD-8601,,,Moderna Inc,Cardiovascular, Congestive Heart Failure (Heart Failure); Myocardial Ischemia,Inactive,EU
BAT-5906,,,Bio-Thera Solutions Ltd,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinal Dysplasia,Phase II,China
BAT-5906,,,Bio-Thera Solutions Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,China
BI-836880,,,Boehringer Ingelheim International GmbH,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Endometrial Cancer; Metastatic Colorectal Cancer; Solid Tumor,Phase II,Global
BI-836880,,,Boehringer Ingelheim International GmbH,Oncology, Hypopharyngeal Cancer; Laryngeal Cancer; Non-Small Cell Lung Cancer; Oral Cavity (Mouth) Cancer; Oropharyngeal Cancer,Phase I,Global
BI-836880,,,Boehringer Ingelheim International GmbH,Oncology, Solid Tumor,Phase I,Japan
BI-836880,,,Boehringer Ingelheim International GmbH,Oncology, Anal Cancer,Inactive,Global
BI-836880,,,Boehringer Ingelheim International GmbH,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
Carboxyamidotriazole Orotate,,Pravitinib,Tactical Therapeutics Inc,Oncology, Glioblastoma Multiforme (GBM); Malignant Glioma,Phase II,United States
Carboxyamidotriazole Orotate,,,Tactical Therapeutics Inc,Oncology, Head And Neck Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Phase I,Global
Carboxyamidotriazole Orotate,,Pravitinib,Tactical Therapeutics Inc,Oncology, Metastatic Melanoma; Prostate Cancer,Preclinical,Global
Carboxyamidotriazole Orotate,,Pravitinib,Tactical Therapeutics Inc,Oncology, Colon Carcinoma; Leiomyosarcoma; Ovarian Cancer; Renal Cell Carcinoma; Small-Cell Lung Cancer; Squamous Non-Small Cell Lung Carcinoma; Synovial Sarcoma,Inactive,Global
Carboxyamidotriazole Orotate,,,Tactical Therapeutics Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
cediranib maleate + olaparib,cediranib maleate + olaparib,,AstraZeneca Plc,Oncology, Ovarian Cancer,Phase II,EU
cediranib maleate + olaparib,cediranib maleate + olaparib,,AstraZeneca Plc,Oncology, Cervical Cancer,Phase II,Global
cediranib maleate + olaparib,cediranib maleate + olaparib,,AstraZeneca Plc,Oncology, Ovarian Cancer,Inactive,Japan
cediranib maleate + olaparib,cediranib maleate + olaparib,,AstraZeneca Plc,Oncology, Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer,Discontinued,Global
cediranib maleate + olaparib,cediranib maleate + olaparib,,AstraZeneca Plc,Oncology, Epithelial Ovarian Cancer,Discontinued,United States
CEND-1,,,Cend Therapeutics Inc,Oncology, Metastatic Colorectal Cancer,Phase II,Global
CEND-1,,,Qilu Pharmaceutical Co Ltd,Oncology, Pancreatic Ductal Adenocarcinoma,Phase II,China
CEND-1,,,Cend Therapeutics Inc,Oncology, Pancreatic Ductal Adenocarcinoma,Phase II,Australia; United States
CEND-1,,,Cend Therapeutics Inc,Oncology, Triple-Negative Breast Cancer (TNBC),Preclinical,China
CEND-1,,,Cend Therapeutics Inc,Oncology, Breast Cancer; Gastric Cancer,Preclinical,Global
CEND-1,,,Cend Therapeutics Inc,Oncology, Breast Cancer; Glioblastoma Multiforme (GBM); Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Prostate Cancer,Inactive,Global
CEP-11981,,,Teva Pharmaceutical Industries Ltd,Oncology," Adenocarcinoma; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer",Phase II,Global
CEP-11981,,,Teva Pharmaceutical Industries Ltd,Oncology, Solid Tumor; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Inactive,Global
CSL-346,,,CSL Ltd,Metabolic Disorders, Diabetic Nephropathy; Lipid Disorders,Phase II,Global
CSL-346,,,CSL Ltd,Oncology, Breast Cancer,Inactive,Global
CSL-346,,,CSL Ltd,Ophthalmology,,Inactive,Global
D-4517,,,Ashvattha Therapeutics LLC,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Global
D-4517,,,Ashvattha Therapeutics LLC,Metabolic Disorders, Diabetic Macular Edema,Phase II,Global
D-4517,,,Ashvattha Therapeutics LLC,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
D-4517,,,Ashvattha Therapeutics LLC,Non Malignant Disorders, Plexiform Neurofibroma,Preclinical,Global
dimesna,dimesna [INN],Tavocept,Lantern Pharma Inc,Oncology, Non-Small Cell Lung Cancer,Phase II,Global
dimesna,dimesna [INN],,Lantern Pharma Inc,Oncology, Lung Adenocarcinoma; Non-Small Cell Lung Cancer,Phase II,Global
dimesna,dimesna [INN],,BioNumerik Pharmaceuticals Inc (Inactive),Central Nervous System, Neurotoxicity Syndromes,Inactive,Global
dimesna,dimesna [INN],Tavocept,BioNumerik Pharmaceuticals Inc (Inactive),Oncology, Lung Adenocarcinoma; Solid Tumor,Inactive,Global
dimesna,dimesna [INN],Tavocept,BioNumerik Pharmaceuticals Inc (Inactive),Oncology, Metastatic Breast Cancer,Inactive,Japan; United States
dimesna,dimesna [INN],,BioNumerik Pharmaceuticals Inc (Inactive),Oncology, Lung Adenocarcinoma,Inactive,Global
dimesna,dimesna [INN],Tavocept,BioNumerik Pharmaceuticals Inc (Inactive),Oncology, Non-Small Cell Lung Cancer,Inactive,EU; Japan; United States
EG-011,,,Trizell Ltd,Cardiovascular, Refractory Angina,Phase II,EU
EG-011,,,Trizell Ltd,Cardiovascular, Critical Limb Ischemia; Myocardial Infarction,Inactive,Global
encoberminogene rezmadenovec,encoberminogene rezmadenovec,,XyloCor Therapeutics Inc,Cardiovascular, Coronary Artery Disease (CAD) (Ischemic Heart Disease),Phase II,Global
encoberminogene rezmadenovec,encoberminogene rezmadenovec,,XyloCor Therapeutics Inc,Cardiovascular, Refractory Angina,Phase II,Global; United States
EXN-407,,,Exonate Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase II,Global
EXN-407,,,Exonate Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
galunisertib monohydrate,galunisertib monohydrate,,Eli Lilly and Co,Oncology," Glioblastoma Multiforme (GBM); Metastatic Adenocarcinoma of The Pancreas; Metastatic Colorectal Cancer; Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Non-Small Cell Lung Cancer; Rectal Cancer",Phase II,Global
galunisertib monohydrate,galunisertib monohydrate,,Eli Lilly and Co,Oncology, Recurrent Glioblastoma Multiforme (GBM),Phase II,EU; United States
galunisertib monohydrate,galunisertib monohydrate,,Eli Lilly and Co,Oncology, Hepatocellular Carcinoma,Phase II,EU; Global; United States
galunisertib monohydrate,galunisertib monohydrate,,Eli Lilly and Co,Oncology, Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Sarcomas; Uterine Cancer,Phase I,Global
galunisertib monohydrate,galunisertib monohydrate,,Eli Lilly and Co,Oncology, Hepatocellular Carcinoma,Inactive,Japan
galunisertib monohydrate,galunisertib monohydrate,,Eli Lilly and Co,Oncology, Malignant Glioma,Inactive,EU; United States
galunisertib monohydrate,galunisertib monohydrate,,Eli Lilly and Co,Oncology, Metastatic Breast Cancer; Metastatic Uveal Melanoma; Myelodysplastic Syndrome,Inactive,Global
HB-0021,,,Huabo Biopharm (Shanghai) Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase II,China
HB-0021,,,Huabo Biopharm (Shanghai) Co Ltd,Oncology, Solid Tumor,Phase II,China
HB-0021,,,Huabo Biopharm (Shanghai) Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Global
HB-0021,,,Huabo Biopharm (Shanghai) Co Ltd,Oncology, Bladder Cancer; Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Gallbladder Cancer; Gastric Cancer; Head And Neck Cancer; Lung Cancer; Metastatic Bile Duct Cancer; Metastatic Ovarian Cancer; Metastatic Pancreatic Cancer; Nasopharyngeal Cancer; Peritoneal Cancer,Phase I,China
HB-0021,,,Huabo Biopharm (Shanghai) Co Ltd,Oncology, Extrahepatic Bile Duct Cancer,Phase I,Global
HB-0021,,,Huabo Biopharm (Shanghai) Co Ltd,Oncology, Breast Cancer; Colorectal Cancer,Inactive,Global
hVEGF-26104,,,Pepscan Therapeutics BV,Oncology, Metastatic Colorectal Cancer; Solid Tumor,Phase II,Global
IBI-302,,,Innovent Biologics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,China
IBI-302,,,Innovent Biologics Inc,Ophthalmology, Unspecified Ophthalmological Disorders,Preclinical,China
IBI-302,,,Innovent Biologics Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
IBI-302,,,Innovent Biologics Inc,Oncology, Solid Tumor,Inactive,Global
IBI-302,,,Innovent Biologics Inc,Metabolic Disorders,,Inactive,Global
ICON-1,,hI-con1,Iconic Therapeutics Inc,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Global
ICON-1,,hI-con1,Iconic Therapeutics Inc,Oncology, Adenocarcinoma; Melanoma; Ovarian Cancer; Prostate Cancer,Inactive,Global
ICON-1,,,Iconic Therapeutics Inc,Oncology, Uveal Melanoma,Inactive,Global
ilorasertib,ilorasertib,,AbbVie Inc,Oncology, Solid Tumor,Phase II,Global
ilorasertib,ilorasertib,,AbbVie Inc,Oncology," Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia); B-Cell Chronic Lymphocytic Leukemia; Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia); Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia",Inactive,Global
ilorasertib,ilorasertib,,AbbVie Inc,Oncology, Ovarian Cancer,Inactive,EU; United States
ilorasertib,ilorasertib,,AbbVie Inc,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)",Inactive,EU; Global; United States
KH-903,,,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer,Phase II,Global
lazucirnon hydrochloride,lazucirnon hydrochloride,,Alkahest Inc,Central Nervous System, Parkinson's Disease,Phase II,Global
lazucirnon hydrochloride,lazucirnon hydrochloride,,Alkahest Inc,Dermatology, Bullous Pemphigoid,Phase II,Global
lazucirnon hydrochloride,lazucirnon hydrochloride,,Alkahest Inc,Immunology, Inflammation,Phase II,Global
lazucirnon hydrochloride,lazucirnon hydrochloride,,Alkahest Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,Global
lazucirnon hydrochloride,lazucirnon hydrochloride,,Alkahest Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
LX-1101,,Lymfactin,Herantis Pharma Plc,Hematological Disorders, Lymphedema,Phase II,Finland; Sweden
MP-0250,,,Molecular Partners AG,Oncology, Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Phase II,Global; United States
MP-0250,,,Molecular Partners AG,Oncology, Advanced Malignancy; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Head And Neck Cancer; Kidney Cancer (Renal Cell Cancer); Liver Cancer; Lung Cancer; Nasopharyngeal Cancer; Pancreatic Cancer,Inactive,Global
MP-0250,,,Molecular Partners AG,Oncology, Non-Small Cell Lung Cancer,Discontinued,United States
MSB-0254,,,Transcenta Holding Ltd,Oncology, Solid Tumor,Phase II,China
MSB-0254,,,Transcenta Holding Ltd,Oncology, Hepatocellular Carcinoma; Neuroendocrine Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma; Thymic Carcinoma,Phase I,China
navicixizumab,navicixizumab,,OncXerna Therapeutics Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Gastric Cancer; Metastatic Colorectal Cancer; Peritoneal Cancer; Triple-Negative Breast Cancer (TNBC),Phase II,Global
navicixizumab,navicixizumab,,OncXerna Therapeutics Inc,Oncology, Breast Cancer; Endometrial Cancer; Pancreatic Cancer; Uterine Cancer,Phase I,Global
navicixizumab,navicixizumab,,OncXerna Therapeutics Inc,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer,Phase I,United States
navicixizumab,navicixizumab,,OncXerna Therapeutics Inc,Oncology, Lung Cancer,Preclinical,Global
navicixizumab,navicixizumab,,OncoMed Pharmaceuticals Inc (Inactive),Oncology, Metastatic Colorectal Cancer,Discontinued,Global
NKT-2152,,,NiKang Therapeutics Inc,Oncology, Metastatic Renal Cell Carcinoma,Phase II,Global
NKT-2152,,,NiKang Therapeutics Inc,Oncology, Renal Cell Carcinoma,Phase I,Global
NKT-2152,,,NiKang Therapeutics Inc,Oncology, Hepatocellular Carcinoma,Preclinical,Global
olinvacimab,olinvacimab [INN],,PharmAbcine Inc,Oncology, Triple-Negative Breast Cancer (TNBC),Phase II,Global
olinvacimab,olinvacimab [INN],,PharmAbcine Inc,Oncology, Colorectal Cancer; Lung Cancer,Preclinical,Global
olinvacimab,olinvacimab [INN],,PharmAbcine Inc,Oncology, Recurrent Glioblastoma Multiforme (GBM),Inactive,United States
olinvacimab,olinvacimab [INN],,3SBio Inc,Oncology, Solid Tumor,Inactive,China
olinvacimab,olinvacimab [INN],,PharmAbcine Inc,Oncology, Gliosarcoma; Hepatocellular Carcinoma,Inactive,Global
palupiprant,,,Adlai Nortye Biopharma Co Ltd,Oncology, Rectal Cancer,Phase II,Global
palupiprant,,,Adlai Nortye Biopharma Co Ltd,Oncology, Cervical Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Solid Tumor; Squamous Non-Small Cell Lung Cancer; Transitional Cell Carcinoma (Urothelial Cell Carcinoma); Triple-Negative Breast Cancer (TNBC),Phase I,Global
palupiprant,,,Adlai Nortye Biopharma Co Ltd,Oncology, Esophageal Cancer; Gastroesophageal (GE) Junction Carcinomas,Phase I,China
palupiprant,,,Eisai Co Ltd,Undisclosed, Unspecified,IND/CTA Filed,China
palupiprant,,,Eisai Co Ltd,Immunology, Rheumatoid Arthritis,Inactive,Global
palupiprant,,,Eisai Co Ltd,Oncology, Adenocarcinoma; Bladder Cancer; Cervical Cancer; Colorectal Cancer; Epithelial Ovarian Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Pancreatic Cancer; Renal Cell Carcinoma; Triple-Negative Breast Cancer (TNBC),Discontinued,EU; United States
PAN-90806,,,PanOptica Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,EU; United States
PAN-90806,,,Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,China; South Korea
PAN-90806,,,Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd,Metabolic Disorders, Diabetic Macular Edema,Preclinical,China; South Korea
PAN-90806,,,PanOptica Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
PAN-90806,,,PanOptica Inc,Metabolic Disorders, Proliferative Diabetic Retinopathy (PDR),Inactive,Global
PBF-1129,,,Palo BioFarma SL,Central Nervous System, Pain,Phase II,Global
PBF-1129,,,Palo BioFarma SL,Respiratory, Idiopathic Pulmonary Fibrosis,Phase II,Global
PBF-1129,,,Palo BioFarma SL,Oncology, Non-Small Cell Lung Cancer; Squamous Non-Small Cell Lung Cancer,Phase I,United States
PBF-1129,,,Palo BioFarma SL,Oncology, Non-Small Cell Lung Cancer,Preclinical,Global
pixatimod,pixatimod [INN],,Zucero Therapeutics Ltd,Oncology, Melanoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Phase II,Global
pixatimod,pixatimod [INN],,Zucero Therapeutics Ltd,Oncology, Metastatic Adenocarcinoma of The Pancreas,Phase I,Global
pixatimod,pixatimod [INN],,Zucero Therapeutics Ltd,Oncology, Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Solid Tumor,Phase I,Australia
pixatimod,pixatimod [INN],,Zucero Therapeutics Ltd,Infectious Disease, Dengue Fever,Preclinical,Global
pixatimod,pixatimod [INN],,Zucero Therapeutics Ltd,Infectious Disease, Coronavirus Disease 2019 (COVID-19),Preclinical,Australia
pixatimod,pixatimod [INN],,Zucero Therapeutics Ltd,Oncology, Solid Tumor,Inactive,Australia
PM-8002,,,Biotheus Inc,Oncology, Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Solid Tumor,Phase II,China
PM-8002,,,Biotheus Inc,Oncology, Hepatocellular Carcinoma; Malignant Mesothelioma; Small-Cell Lung Cancer,Phase I,China
PM-8002,,,Biotheus Inc,Oncology, Triple-Negative Breast Cancer (TNBC),Preclinical,China
RBM-007,,,Ribomic Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,United States
RBM-007,,,Ribomic Inc,Musculoskeletal Disorders, Achondroplasia,Phase I,Japan
RBM-007,,,Ribomic Inc,Musculoskeletal Disorders, Bone Disorders; Osteoporosis,Preclinical,Global
RBM-007,,,Ribomic Inc,Oncology, Lung Cancer,Preclinical,Global
RBM-007,,,Ribomic Inc,Immunology, Rheumatoid Arthritis,Preclinical,Global
RBM-007,,,Ribomic Inc,Central Nervous System, Cancer Pain,Preclinical,Global
RBM-007,,,Ribomic Inc,Respiratory, Idiopathic Pulmonary Fibrosis,Preclinical,Global
RC-28,,,RemeGen Co Ltd,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Phase II,China
RC-28,,,RemeGen Co Ltd,Metabolic Disorders, Diabetic Macular Edema; Non-Proliferative Diabetic Retinopathy (NPDR),Phase II,China
risuteganib,risuteganib,Luminate,Allegro Ophthalmics LLC,Ophthalmology, Dry (Atrophic) Macular Degeneration,Phase II,United States
risuteganib,risuteganib,Luminate,AffaMed Therapeutics US Inc,Ophthalmology, Dry (Atrophic) Macular Degeneration,Phase II,China
risuteganib,risuteganib,Luminate,AffaMed Therapeutics US Inc,Metabolic Disorders, Diabetic Macular Edema,Phase II,China
risuteganib,risuteganib,Luminate,Allegro Ophthalmics LLC,Metabolic Disorders, Diabetic Macular Edema,Phase II,Global
risuteganib,risuteganib,Luminate,Hanmi Pharmaceuticals Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Phase II,South Korea
risuteganib,risuteganib,Luminate,AffaMed Therapeutics US Inc,Ophthalmology, Retinitis Pigmentosa (Retinitis),Phase I,China
risuteganib,risuteganib,Luminate,Allegro Ophthalmics LLC,Ophthalmology, Retinitis Pigmentosa (Retinitis),Phase I,Global
risuteganib,risuteganib,Luminate,Hanmi Pharmaceuticals Co Ltd,Ophthalmology, Retinitis Pigmentosa (Retinitis),Phase I,South Korea
risuteganib,risuteganib,Luminate,Allegro Ophthalmics LLC,Ophthalmology, Vitreomacular Adhesion (VMA); Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
risuteganib,risuteganib,Luminate,Allegro Ophthalmics LLC,Metabolic Disorders, Non-Proliferative Diabetic Retinopathy (NPDR),Inactive,Global
SCT-510A,,,SinoCelltech Group Ltd,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Phase II,China
sirolimus,sirolimus,,Santen Pharmaceutical Co Ltd,Ophthalmology, Blepharitis,Phase II,Japan
sirolimus,sirolimus,,Santen Pharmaceutical Co Ltd,Ophthalmology, Keratoconjunctivitis Sicca (Dry Eye),Inactive,Global; Japan
sirolimus,sirolimus,,Santen Pharmaceutical Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
sirolimus,sirolimus,,Santen Pharmaceutical Co Ltd,Ophthalmology, Choroidal Neovascularization; Geographic Atrophy; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
sirolimus,sirolimus,Opsiria,Santen Pharmaceutical Co Ltd,Ophthalmology, Non-infectious Uveitis,Discontinued,EU
sirolimus,sirolimus,Opsiria,Santen Pharmaceutical Co Ltd,Ophthalmology, Posterior Uveitis,Discontinued,United States
sirolimus,sirolimus,,Santen Pharmaceutical Co Ltd,Ophthalmology, Posterior Uveitis,Discontinued,Asia-Pacific; Japan
taurolidine,taurolidine [INN],PerioSept,Geistlich Pharma AG,Mouth and Dental Disorders, Periodontitis,Phase II,Global
taurolidine,taurolidine [INN],Taurolin,Geistlich Pharma AG,Oncology, Colon Cancer,Inactive,Global
taurolidine,taurolidine [INN],,Geistlich Pharma AG,Oncology, Pancreatic Cancer,Inactive,United States
telatinib,telatinib [INN],,EOC Pharma Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Hepatocellular Carcinoma; Solid Tumor,Phase II,China
telatinib,telatinib [INN],,Eddingpharm Inc,Oncology, Gastric Cancer,Inactive,EU; United States
telatinib,telatinib [INN],,EOC Pharma Ltd,Oncology, Gastric Cancer,Inactive,China
telatinib,telatinib [INN],,Eddingpharm Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Colorectal Cancer,Inactive,Global
Tendoncel,,Tendoncel,Celixir Ltd,Musculoskeletal Disorders, Lateral Epicondylitis(Tennis Elbow),Phase II,Global
Tendoncel,,Tendoncel,Celixir Ltd,Musculoskeletal Disorders, Muscle Injury,Preclinical,Global
THR-317,,,Oncurious NV,Oncology, Medulloblastoma,Phase II,EU
THR-317,,,Oncurious NV,Oncology, Ewing Sarcoma; Neuroblastoma; Rhabdomyosarcoma,Discontinued,EU
THR-317,,,Oxurion NV,Metabolic Disorders, Diabetic Macular Edema,Discontinued,Global
THR-317,,,F. Hoffmann-La Roche Ltd,Oncology, Metastatic Colorectal Cancer; Metastatic Hepatocellular Carcinoma (HCC); Metastatic Ovarian Cancer; Renal Cell Carcinoma,Discontinued,Global
THR-317,,,Oxurion NV,Oncology, Recurrent Glioblastoma Multiforme (GBM),Discontinued,Global
THR-317,,,Oxurion NV,Ophthalmology, Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT),Discontinued,Global
timolol maleate,timolol maleate,,Aucta Pharmaceuticals LLC,Non Malignant Disorders, Infantile Hemangiomas,Phase II,United States
vitamin A palmitate,,,Orphanix GmbH,Respiratory, Bronchopulmonary Dysplasia,Phase II,EU
vitamin A palmitate,,,Orphanix GmbH,Ophthalmology, Retinopathy Of Prematurity,Preclinical,EU; United States
vorolanib,vorolanib [INN],,EyePoint Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase II,United States
vorolanib,vorolanib [INN],,EyePoint Pharmaceuticals Inc,Metabolic Disorders, Diabetic Retinopathy,Phase I,United States
vorolanib,vorolanib [INN],,EyePoint Pharmaceuticals Inc,Metabolic Disorders, Non-Proliferative Diabetic Retinopathy (NPDR),Phase I,Global
vorolanib,vorolanib [INN],,EyePoint Pharmaceuticals Inc,Ophthalmology, Retinal Vein Occlusion,Phase I,United States
vorolanib,vorolanib [INN],,EyePoint Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
vorolanib,vorolanib [INN],,EyePoint Pharmaceuticals Inc,Ophthalmology, Dry (Atrophic) Macular Degeneration,Inactive,Global
YP-01001,,,YaoPharma Co Ltd,Oncology, Solid Tumor,Phase II,China
YP-01001,,,YaoPharma Co Ltd,Oncology, Thyroid Cancer,Phase I,China
YS-1402,,,Osaka University Hospital,Cardiovascular, Ischemic Cardiomyopathy,Phase II,Global
YS-1402,,,Osaka University Hospital,Genito Urinary System And Sex Hormones,Chronic Kidney Disease (Chronic Renal Failure),Preclinical,Global
YS-1402,,,Osaka University Hospital,Cardiovascular, Arteriosclerosis; Cerebral Infarction (Brain Infarction); Dilated Cardiomyopathy; Pulmonary Hypertension,Preclinical,Global
YS-1402,,,Osaka University Hospital,Respiratory, Chronic Obstructive Pulmonary Disease (COPD); Pulmonary Fibrosis,Preclinical,Global
ziv-aflibercept biosimilar,,,Luye Pharma Group Ltd,Oncology, Metastatic Colorectal Cancer,Phase II,China
(enavogliflozin + metformin),(enavogliflozin [INN] + metformin),,Daewoong Pharmaceutical Co Ltd,Metabolic Disorders, Type 2 Diabetes,Phase I,South Korea
3D-011,,,3D Medicines Inc,Oncology," Metastatic Hepatocellular Carcinoma (HCC); Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Renal Cell Carcinoma; Solid Tumor",Phase I,Global
AIV-007,,,AiViva BioPharma Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Global
AIV-007,,,AiViva BioPharma Inc,Male Health, Benign Prostatic Hyperplasia,Preclinical,Global
ALN-VSP,,,Ascletis Pharma Inc,Oncology, Hepatocellular Carcinoma,Phase I,China
ALN-VSP,,,Alnylam Pharmaceuticals Inc,Oncology, Hepatocellular Carcinoma; Solid Tumor,Inactive,United States
ANG-3070,,,Angion Biomedica Corp,Respiratory, Idiopathic Pulmonary Fibrosis,Phase I,Global
ANG-3070,,,Angion Biomedica Corp,Gastrointestinal, Liver Fibrosis; Non-Alcoholic Steatohepatitis (NASH); Pancreatitis,Phase I,Global
ANG-3070,,,Angion Biomedica Corp,Respiratory, Idiopathic Pulmonary Fibrosis,IND/CTA Filed,United States
ANG-3070,,,Angion Biomedica Corp,Genetic Disorders, Alport Syndrome,Preclinical,Global
ANG-3070,,,Angion Biomedica Corp,Immunology, Systemic Sclerosis (Scleroderma),Inactive,Global
ANG-3070,,,Angion Biomedica Corp,Genetic Disorders, Polycystic Kidney Disease,Inactive,United States
ANG-3070,,,Angion Biomedica Corp,Genito Urinary System And Sex Hormones, Chronic Kidney Disease (Chronic Renal Failure); Focal Segmental Glomerulosclerosis (FSGS); IgA Nephropathy (Berger's Disease); Kidney Fibrosis; Proteinuria,Inactive,United States
AR-13503 SR,netarsudil mesylate,,Aerie Pharmaceuticals Inc,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Phase I,United States
AR-13503 SR,netarsudil mesylate,,Aerie Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Phase I,United States
AR-13503 SR,netarsudil mesylate,,Aerie Pharmaceuticals Inc,Ophthalmology, Glaucoma,Preclinical,Global
AROHIF-2,,,Arrowhead Pharmaceuticals Inc,Oncology, Renal Cell Carcinoma,Phase I,United States
AROHIF-2,,,Arrowhead Pharmaceuticals Inc,Oncology, Renal Cell Carcinoma,Inactive,EU
ASKG-712,,,AffaMed Therapeutics US Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,United States
ASKG-712,,,AffaMed Therapeutics US Inc,Metabolic Disorders, Diabetic Macular Edema,IND/CTA Filed,United States
ASKG-712,,,AskGene Pharma Inc,Metabolic Disorders, Diabetic Macular Edema,IND/CTA Filed,China
ASKG-712,,,AskGene Pharma Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,IND/CTA Filed,China
AVI-3207,,,Avixgen Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,South Korea
AVI-3207,,,Avixgen Inc,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
axitinib SR,axitinib,,Ocular Therapeutix Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Australia; United States
axitinib SR,axitinib,,Ocular Therapeutix Inc,Ophthalmology, Retinal Vein Occlusion,Phase I,United States
axitinib SR,axitinib,,Ocular Therapeutix Inc,Metabolic Disorders, Diabetic Macular Edema,Phase I,United States
BC-001,,,Shandong Buchang Pharmaceutical Co Ltd,Oncology, Solid Tumor,Phase I,China
BC-001,,,Shandong Buchang Pharmaceutical Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
bevacizumab + paclitaxel,bevacizumab + paclitaxel,,Sorrento Therapeutics Inc,Oncology, Adenocarcinoma; Cervical Cancer; Clear Cell Squamous Cell Carcinoma  ; Endometrial Cancer; Fallopian Tube Cancer; Melanoma; Ovarian Cancer; Peritoneal Cancer; Squamous Cell Carcinoma,Phase I,Global
bevacizumab biosimilar,,,R-Pharm,Oncology, Breast Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer,Phase I,Global
bevacizumab biosimilar,,,Gedeon Richter Plc,Oncology, Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Phase I,Global
bevacizumab biosimilar,,,Chia Tai Tianqing Pharmaceutical Group Co Ltd,Oncology, Unspecified Cancer,Phase I,China
bevacizumab biosimilar,,,Beijing Eastern Biotech Co Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Phase I,China
bevacizumab biosimilar,,,Beijing Eastern Biotech Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,China
bevacizumab biosimilar,,,Beijing Eastern Biotech Co Ltd,Oncology, Breast Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer),Inactive,China
bevacizumab biosimilar,,,Cipla BioTec Pvt Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Phase I,Global
bevacizumab biosimilar,,,Tanvex BioPharma Inc,Oncology, Lung Cancer; Metastatic Colorectal Cancer,Phase I,United States
bevacizumab biosimilar,,,Synermore Biologics Co Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Peritoneal Cancer; Recurrent Glioblastoma Multiforme (GBM); Squamous Non-Small Cell Lung Cancer,Phase I,Global
bevacizumab biosimilar,,,Synermore Biologics Co Ltd,Oncology, Metastatic Renal Cell Carcinoma,Inactive,Global
Corlicyte,,,Cellresearch Corp Pte Ltd,Metabolic Disorders, Diabetic Foot Ulcers,Phase I,United States
Corlicyte,,,Cellresearch Corp Pte Ltd,Infectious Disease, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome,Preclinical,Global
CU-06,,,Thea Open Innovation SASU,Metabolic Disorders, Diabetic Macular Edema,Phase I,United States
CU-06,,,Thea Open Innovation SASU,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,United States
CU-06,,,Thea Open Innovation SASU,Gastrointestinal, Crohn's Disease (Regional Enteritis); Ulcerative Colitis,Inactive,Global
CU-06,,,Thea Open Innovation SASU,Cardiovascular, Myocardial Infarction; Stroke; Unstable Angina,Inactive,Global
CU-06,,,Thea Open Innovation SASU,Respiratory, Acute Respiratory Distress Syndrome,Inactive,Global
CU-06,,,Thea Open Innovation SASU,Immunology, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency),Inactive,Global
CU-06,,,Thea Open Innovation SASU,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
CX-1003,,,Beijing Konruns Pharmaceutical Co Ltd,Oncology, Gastric Cancer; Medullary Thyroid Cancer; Metastatic Liver Cancer; Metastatic Lung Cancer; Metastatic Prostate Cancer; Metastatic Renal Cell Carcinoma; Thyroid Cancer,Phase I,Global
DFF-332,,,Novartis AG,Oncology, Renal Cell Carcinoma,Phase I,Global
dilpacimab,dilpacimab,,AbbVie Inc,Oncology, Ovarian Cancer; Solid Tumor,Phase I,Global
dilpacimab,dilpacimab,,AbbVie Inc,Oncology, Breast Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Pancreatic Cancer,Inactive,Global
Gene Therapy for Atherosclerosis and Ischemia,,,Qingdao University,Cardiovascular, Atherosclerosis; Ischemia,Phase I,Global
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma,,,Chiba University,Oncology, Malignant Pleural Mesothelioma,Phase I,Japan
HB-0025,,,Huabo Biopharm (Shanghai) Co Ltd,Oncology, Solid Tumor,Phase I,China; United States
HLX-06,,,Shanghai Henlius Biotech Inc,Oncology, Solid Tumor,Phase I,China; Taiwan; United States
HLX-06,,,Shanghai Henlius Biotech Inc,Oncology, Metastatic Hepatocellular Carcinoma (HCC),Inactive,Taiwan
HPV-19,,,Suzhou Stainwei Biotech Inc,Oncology, Breast Cancer; Colon Cancer; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Ovarian Cancer,Phase I,China
hRESCAP,,,Amrif BV,Immunology, Rheumatoid Arthritis,Phase I,Global
HZB-1006,,,Heilongjiang ZBD Pharmaceutical Co Ltd,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Hepatocellular Carcinoma; Neuroendocrine Tumors; Solid Tumor; Thyroid Cancer; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Phase I,China
IBI-304,,,Tiantai Yinkang Biological Medicine Co Ltd,Ophthalmology, Macular Edema,Phase I,China
IBI-324,,,Innovent Biologics Inc,Metabolic Disorders, Diabetic Macular Edema,Phase I,China
IMM-2510,,,ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd,Oncology, Solid Tumor,Phase I,China
INCB-106385,,,Incyte Corp,Oncology, Solid Tumor,Phase I,Australia
INCB-106385,,,Incyte Corp,Oncology," Anal Cancer; Bladder Cancer; Colorectal Cancer; Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Head And Neck Cancer Squamous Cell Carcinoma; Hepatocellular Carcinoma; Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Triple-Negative Breast Cancer (TNBC)",Phase I,Global
INXN-4001,,,Triple-Gene LLC,Cardiovascular, Congestive Heart Failure (Heart Failure),Phase I,United States
ixoberogene soroparvovec,ixoberogene soroparvovec,,Adverum Biotechnologies Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,EU; United States
ixoberogene soroparvovec,ixoberogene soroparvovec,,Adverum Biotechnologies Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Discontinued,United States
JY-025,,,Beijing Eastern Biotech Co Ltd,Oncology, Non-Small Cell Lung Cancer; Solid Tumor,Phase I,China
KC-1036,,,Beijing Konruns Pharmaceutical Co Ltd,Oncology, Solid Tumor,Phase I,China
KC-1036,,,Beijing Konruns Pharmaceutical Co Ltd,Oncology, Gastrointestinal Tumor,Preclinical,China
KD-035,,,Oncon,Oncology, Metastatic Colorectal Cancer; Solid Tumor,Phase I,Global
KH-906,conbercept [INN],,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Ophthalmology, Corneal Neovascularization,Phase I,China
KH-906,conbercept [INN],,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,China
KX-2361,,,Xiangxue Pharmaceutical Co Ltd,Oncology, Gastrointestinal Tumor; Glioblastoma Multiforme (GBM); Malignant Glioma,Phase I,China
KX-2361,,,Athenex Inc,Oncology, Hematological Tumor; High-Grade Glioma; Lymphoma; Solid Tumor,Inactive,Global
KX-2361,,,Athenex Inc,Oncology, Glioblastoma Multiforme (GBM),Inactive,Global; United States
lenalidomide,lenalidomide,,Starton Therapeutics Inc,Oncology, Multiple Myeloma (Kahler Disease),Phase I,Netherlands
lenalidomide,lenalidomide,,Starton Therapeutics Inc,Oncology, Chronic Lymphocytic Leukemia (CLL),Phase I,United States
lenalidomide,lenalidomide,,Starton Therapeutics Inc,Oncology, Multiple Myeloma (Kahler Disease),Preclinical,United States
lenalidomide,lenalidomide,,Starton Therapeutics Inc,Oncology, Mantle Cell Lymphoma; Myelodysplastic Syndrome,Inactive,United States
MG-021,,,North China Pharmaceutical Group New Drug Research and Development Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,China
Monoclonal Antibody to Inhibit VEGF for Unspecified Indication,,,Central South University Xiangya Hospital 3,Undisclosed, Unspecified,Phase I,China
MT-0814,,,Mitsubishi Tanabe Pharma Corp,Ophthalmology, Age Related Macular Degeneration,Phase I,Japan
MT-0814,,,Mitsubishi Tanabe Pharma Corp,Ophthalmology, Age Related Macular Degeneration,Inactive,North America
ramucirumab biosimilar,,,Sichuan Kelun Pharmaceutical Co Ltd,Oncology, Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer,Phase I,China
ramucirumab biosimilar,,,Chia Tai Tianqing Pharmaceutical Group Co Ltd,Oncology, Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer,Phase I,China
ranibizumab biosimilar,,,Shanghai United Cell Biotechnology Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Global
ranibizumab biosimilar,,,Shanghai United Cell Biotechnology Co Ltd,Ophthalmology, Choroidal Neovascularization; Retinal Vascular Occlusion,Inactive,Global
RG-6120,,,F. Hoffmann-La Roche Ltd,Ophthalmology, Choroidal Neovascularization; Wet (Neovascular / Exudative) Macular Degeneration,Phase I,Global
SOLOT-Eye,,,Suzhou Stainwei Biotech Inc,Ophthalmology, Age Related Macular Degeneration; Wet (Neovascular / Exudative) Macular Degeneration,Phase I,China
SOLOT-Eye,,,Suzhou Stainwei Biotech Inc,Metabolic Disorders, Diabetic Macular Edema,IND/CTA Filed,China
terameprocol,terameprocol,,Erimos Pharmaceuticals LLC,Oncology, High-Grade Glioma,Phase I,Global
terameprocol,terameprocol,,Erimos Pharmaceuticals LLC,Oncology, Glioma; Head And Neck Cancer; Leukemia; Solid Tumor,Inactive,Global
terameprocol,terameprocol,,Erimos Pharmaceuticals LLC,Infectious Disease, Viral Infections,Inactive,Global
terameprocol,terameprocol,,Erimos Pharmaceuticals LLC,Cardiovascular, Ischemia Reperfusion Injury,Inactive,Global
terameprocol,terameprocol,,Erimos Pharmaceuticals LLC,Women's Health, Cervical Intraepithelial Neoplasia (CIN),Inactive,Global
THR-687,,,Oxurion NV,Metabolic Disorders, Non-Proliferative Diabetic Retinopathy (NPDR); Proliferative Diabetic Retinopathy (PDR),Phase I,Global
THR-687,,,Oxurion NV,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
THR-687,,,Oxurion NV,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
vanucizumab,vanucizumab,,F. Hoffmann-La Roche Ltd,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Metastatic Ovarian Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer; Solid Tumor,Phase I,Global
vanucizumab,vanucizumab,,F. Hoffmann-La Roche Ltd,Oncology, Metastatic Colorectal Cancer,Discontinued,Global
aflibercept biosimilar,,,Zeen Biotechnology Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,IND/CTA Filed,China
bevacizumab biosimilar,,,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd,Oncology,,IND/CTA Filed,Global
lenalidomide SR,lenalidomide,,Guangzhou Diqi Pharmaceutical Technology Co Ltd,Oncology, Myelodysplastic Syndrome,IND/CTA Filed,China
Monoclonal Antibody to Inhibit VEGF for Colorectal Cancer and Non-Small Cell Lung Cancer,,,3SBio Inc,Oncology, Colorectal Cancer; Non-Small Cell Lung Carcinoma,IND/CTA Filed,Global
OSI-930,,,Simcere Pharmaceutical Group Ltd,Oncology, Colorectal Cancer; Gastric Cancer; Glioblastoma Multiforme (GBM); Head And Neck Cancer; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Small-Cell Lung Cancer,IND/CTA Filed,China
OSI-930,,,Astellas Pharma Inc,Oncology, Colorectal Cancer; Gastric Cancer; Glioblastoma Multiforme (GBM); Head And Neck Cancer; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Small-Cell Lung Cancer,Inactive,United States
PORT-7,,,Portage Biotech Inc,Oncology, Solid Tumor,IND/CTA Filed,Global
PORT-7,,,Portage Biotech Inc,Oncology, Bladder Cancer; Colorectal Cancer; Gastric Cancer; Hepatocellular Carcinoma; Metastatic Lung Cancer; Metastatic Pancreatic Cancer; Triple-Negative Breast Cancer (TNBC),Preclinical,Global
SYN-001,,,Synactix Pharmaceuticals Inc,Undisclosed, Unspecified,IND/CTA Filed,China
SYN-001,,,Synactix Pharmaceuticals Inc,Oncology," Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia); Chronic Myelomonocytic Leukemia (CMML); Medullary Thyroid Cancer; Non-Small Cell Lung Cancer; Papillary Thyroid Cancer",Preclinical,Global
SYN-001,,,Synactix Pharmaceuticals Inc,Oncology, Breast Cancer,Discovery,Global
ZGGS-18,,,Suzhou Zelgen Biopharmaceutical Co Ltd,Oncology, Solid Tumor,IND/CTA Filed,China
(paclitaxel + siVEGF),paclitaxel,,China Pharmaceutical University,Oncology,,Preclinical,Global
A-006,,,MeiraGTx Holdings Plc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
ABP-201,,,Abpro Corp,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
ABP-201,,,Abpro Corp,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
ADO-514,,,Adamed Pharma SA,Oncology, Adenocarcinoma; Colorectal Cancer; Lung Cancer; Pancreatic Cancer,Preclinical,Global
ADO-514,,,Adamed Pharma SA,Oncology, Sarcomas; Uterine Cancer,Inactive,Global
aflibercept biosimilar,,,PharmAbcine Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
aflibercept biosimilar,,,PharmAbcine Inc,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
aflibercept biosimilar,,,Shilpa Medicare Ltd,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
aflibercept biosimilar,,,Shilpa Medicare Ltd,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
aflibercept biosimilar,,,Prestige BioPharma Ltd,Oncology, Metastatic Colorectal Cancer,Preclinical,EU; United States
aflibercept biosimilar,,,Prestige BioPharma Ltd,Ophthalmology, Macular Edema; Retinopathy,Preclinical,EU; United States
aflibercept biosimilar,,,Synermore Biologics Co Ltd,Oncology, Unspecified Cancer,Preclinical,Global
aflibercept biosimilar,,,Rophibio Inc,Ophthalmology, Macular Degeneration,Preclinical,Global
aflibercept biosimilar,,,Rophibio Inc,Oncology, Colorectal Cancer,Preclinical,Global
aflibercept SR,aflibercept,,Ocular Therapeutix Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
aflibercept SR,aflibercept,,Ocular Therapeutix Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
AG-67650,,,Allgenesis Biotherapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
AGN-151200,,,AbbVie Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
AIT-102,,,AI Therapeutics Inc,Oncology, Atypical Teratoid Rhabdoid Tumor; Central Nervous System (CNS) Cancer; Colon Cancer; Colorectal Cancer; Ewing Sarcoma; Liposarcoma ; Lung Adenocarcinoma; Melanoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Solid Tumor; Synovial Sarcoma; Triple-Negative Breast Cancer (TNBC),Preclinical,Global
AK-antiVEGF,,,Akouos Inc,Oncology, Vestibular Schwannoma (Acoustic Neuroma),Preclinical,United States
AL-201AB,,,AngioLab Inc,Ophthalmology,,Preclinical,Global
AL-201AB,,,AngioLab Inc,Oncology,,Preclinical,Global
ALK-1/VEGF bispecific antibody,,,Kintor Pharmaceutical Ltd,Oncology, Solid Tumor,Preclinical,Global
Allo-Aca,,,Allysta Pharmaceuticals Inc,Ophthalmology, Choroidal Neovascularization,Preclinical,Global
AMD-101,,,AMD Therapeutics LLC,Ophthalmology, Age Related Macular Degeneration,Preclinical,United States
AMD/DR,,,OliPass Corporation,Metabolic Disorders, Diabetic Retinopathy,Preclinical,Global
AMD/DR,,,OliPass Corporation,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
aNRP-214,,,aTyr Pharma Inc,Immunology, Inflammation,Preclinical,Global
aNRP-214,,,aTyr Pharma Inc,Oncology, Unspecified Cancer,Preclinical,Global
Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology,,,University of Utah,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization; Corneal Neovascularization,Preclinical,Global
Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology,,,University of Utah,Immunology, Corneal Graft Rejection,Preclinical,Global
Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology,,,University of Utah,Oncology, Adenocarcinoma; Breast Cancer; Colon Cancer,Inactive,Global
"Antisense RNAi Oligonucleotide to Inhibit NET-1, EMS1 and VEGF for Hepatocellular Carcinoma",,,Biomics Biotechnologies Co Ltd,Oncology, Hepatocellular Carcinoma,Preclinical,Global
Antisense RNAi Oligonucleotide to Inhibit VEGF for Age Related Macular Degeneration,,,Phio Pharmaceuticals Corp,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
Antisense RNAi Oligonucleotide to Inhibit VEGF for Unspecified Cancer,,,Nano Intelligent Biomedical Engineering Corp,Oncology, Unspecified Cancer,Preclinical,Global
Antisense RNAi Oligonucleotides to Inhibit sFLT-1 for Pre-Eclampsia,,,UMass Chan Medical School,Cardiovascular, Pre-Eclampsia,Preclinical,Global
AP-505,,,AP Biosciences Inc,Oncology, Hepatocellular Carcinoma; Lung Cancer,Preclinical,Global
APL-2006,,,Apellis Pharmaceuticals Inc,Ophthalmology, Geographic Atrophy; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
Apratoxin S10,,,Oceanyx Pharmaceuticals Inc,Oncology, Pancreatic Cancer,Preclinical,Global
Apratoxin S8,,,Oceanyx Pharmaceuticals Inc,Oncology, Colorectal Cancer,Preclinical,Global
ATYR-2810,,,aTyr Pharma Inc,Musculoskeletal Disorders, Muscle Relaxation,Preclinical,Global
ATYR-2810,,,aTyr Pharma Inc,Oncology, Non-Small Cell Lung Cancer; Solid Tumor; Triple-Negative Breast Cancer (TNBC),Preclinical,Global
ATYR-2810,,,aTyr Pharma Inc,Immunology, Inflammation,Discovery,Global
ATYR-2810,,,aTyr Pharma Inc,Oncology, Unspecified Cancer,Discovery,Global
axitinib SR,axitinib,,Aerie Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,United States
axitinib SR,axitinib,,Aerie Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,United States
bevacizumab,bevacizumab,,Pleryon Therapeutics Ltd,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
bevacizumab,bevacizumab,,Pleryon Therapeutics Ltd,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
bevacizumab biosimilar,,,BioXpress Therapeutics SA,Oncology, Colon Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Preclinical,Global
bevacizumab biosimilar,,,BioXpress Therapeutics SA,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
bevacizumab biosimilar,,,BioIntegrator,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Preclinical,Global
bevacizumab biosimilar,,,Kidswell Bio Corp,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Preclinical,Global
bevacizumab biosimilar,,,Epygen Biotech Pvt Ltd,Oncology, Cervical Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Recurrent Glioblastoma Multiforme (GBM),Preclinical,Global
bevacizumab biosimilar,,,Epygen Biotech Pvt Ltd,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
bevacizumab biosimilar,,,Aprogen Inc,Oncology, Colorectal Cancer,Preclinical,Global
bevacizumab biosimilar,,,PharmAbcine Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Ovarian Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer; Recurrent Malignant Glioma ; Squamous Non-Small Cell Lung Cancer,Preclinical,Global
bevacizumab biosimilar,,AiNEX,Mycenax Biotech Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Preclinical,Global
Bi-specific Monoclonal Antibodies to Inhibit VEGF and IL-8 for Renal Cell Carcinoma,,,Immune Pharmaceuticals Inc,Oncology, Renal Cell Carcinoma,Preclinical,Global
Bi-specific Monoclonal Antibodies to Target TfR and VEGF for Age Related Macular Degeneration,,,Abzyme Therapeutics LLC,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
"Bi-specific Monoclonal Antibody to Target VEGF and PTPRB for Diabetic Macular Edema, Wet Macular Degeneration and Oncology",,,Aadi Bioscience Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
"Bi-specific Monoclonal Antibody to Target VEGF and PTPRB for Diabetic Macular Edema, Wet Macular Degeneration and Oncology",,,Aadi Bioscience Inc,Oncology,,Preclinical,Global
"Bi-specific Monoclonal Antibody to Target VEGF and PTPRB for Diabetic Macular Edema, Wet Macular Degeneration and Oncology",,,Aadi Bioscience Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
BIO-201,,,Biophytis SA,Ophthalmology, Juvenile Macular Degeneration (Stargardt Disease),Preclinical,Global
BIO-201,,,Biophytis SA,Ophthalmology, Dry (Atrophic) Macular Degeneration,Preclinical,EU
BIO-201,,,Biophytis SA,Ophthalmology, Dry (Atrophic) Macular Degeneration; Retinopathy,Inactive,Global
BIO-203,,,Biophytis SA,Ophthalmology, Dry (Atrophic) Macular Degeneration; Retinopathy,Preclinical,Global
Biologic to Inhibit VEGF for Choroidal Neovascularization,,,Chinese Academy of Sciences,Ophthalmology, Choroidal Neovascularization,Preclinical,Global
Biologics for Acute Respiratory Distress Syndrome and Sepsis,,,Medical University of South Carolina,Respiratory, Acute Respiratory Distress Syndrome,Preclinical,Global
Biologics for Acute Respiratory Distress Syndrome and Sepsis,,,Medical University of South Carolina,Infectious Disease, Sepsis,Preclinical,Global
Biologics for Prostate Cancer,,,Cells for Cells SA,Oncology, Prostate Cancer,Preclinical,Global
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications,,,University of Montreal,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
BT-2180,,,Beta Therapeutics Pty Ltd,Ophthalmology, Dry (Atrophic) Macular Degeneration; Retinopathy; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
CBT-005,,,Cloudbreak Therapeutics LLC,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,United States
Cell Therapy for Ischemia,,,University of Texas Health Science Center at Houston,Cardiovascular, Ischemia,Preclinical,Global
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers,,,Mallinckrodt Plc,Dermatology, Venous Leg Ulcers (Crural Ulcer),Preclinical,Global
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers,,,Mallinckrodt Plc,Metabolic Disorders, Diabetic Foot Ulcers,Preclinical,Global
CIGB-247,,,Center for Genetic Engineering and Biotechnology,Oncology, Hepatocellular Carcinoma,Preclinical,Global
CIGB-247,,,Center for Genetic Engineering and Biotechnology,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
CIGB-247,,,Center for Genetic Engineering and Biotechnology,Oncology, Breast Cancer; Carcinomas; Colon Carcinoma; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Lung Cancer; Peritoneal Cancer,Inactive,Global
CLM-94,,,University of Pisa,Oncology, Medullary Thyroid Cancer,Preclinical,Global
CLM-94,,,University of Pisa,Oncology, Anaplastic Thyroid Cancer,Inactive,Global
DA-3131,,,Dong-A Socio Holdings Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,South Korea
decorin,,,University of Birmingham Medical School,Ophthalmology, Open-Angle Glaucoma,Preclinical,Global
decorin,,,University of Birmingham Medical School,Oncology, Glioblastoma Multiforme (GBM),Preclinical,Global
decorin,,,University of Birmingham Medical School,Dermatology, Scar,Inactive,Global
DR-30121,,,Zhejiang Doer Biologics Corp,Ophthalmology, Age Related Macular Degeneration; Dry (Atrophic) Macular Degeneration,Preclinical,Global
DR-30206,,,Zhejiang Doer Biologics Corp,Oncology, Solid Tumor,Preclinical,Global
Drug to Inhibit VEGFR-1 and VEGFR-2 for Oncology,,,National Cancer Institute US,Oncology,,Preclinical,Global
Drugs to Agonize ATP1A1 for Prostate Cancer,,,Marshall University,Oncology, Prostate Cancer,Preclinical,Global
EB-203,,,Eye Bio Korea Co Ltd,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
EC-7072,,,EntreChem SL,Oncology, Chronic Lymphocytic Leukemia (CLL),Preclinical,Global
EC-7072,,,EntreChem SL,Oncology, Bladder Cancer; Colon Cancer; Melanoma; Prostate Cancer,Inactive,Global
EG-12021,,,EirGenix Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Preclinical,Global
ELB-011,,,Mediolanum farmaceutici SpA,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
ELB-011,,,MABLife SAS,Ophthalmology, Choroidal Neovascularization,Inactive,Global
EYS-609,,,Eyevensys SAS,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
EYS-609,,,Eyevensys SAS,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
EYS-609,,,Eyevensys SAS,Ophthalmology, Central Retinal Vein Occlusion,Inactive,Global
EYS-809,,,Eyevensys SAS,Ophthalmology, Central Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
EYS-809,,,Eyevensys SAS,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
FB-216A12,,,Frontbio Co Ltd,Metabolic Disorders, Diabetic Retinopathy,Preclinical,Global
FP-002,,,Foresee Pharmaceuticals Co Ltd,Hormonal Disorders, Acromegaly,Preclinical,United States
FP-002,,,Foresee Pharmaceuticals Co Ltd,Oncology, Carcinoid Tumor,Inactive,United States
FP-002,,,Foresee Pharmaceuticals Co Ltd,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
FSEC,,,University of Chicago,Oncology, Breast Cancer; Lung Cancer; Neuroblastoma; Pancreatic Cancer,Preclinical,Global
Fusion Protein for Melanoma and Pancreatic Cancer,,,German Cancer Research Center,Oncology, Melanoma; Pancreatic Cancer,Preclinical,Global
"Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors",,,Clayton Biotechnologies Inc,Oncology, Solid Tumor,Preclinical,Global
"Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors",,,Clayton Biotechnologies Inc,Metabolic Disorders, Diabetic Retinopathy,Preclinical,Global
"Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors",,,Clayton Biotechnologies Inc,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
Fusion Protein to Inhibit VEGF for Glioblastoma and Lung Cancer,,,University of California San Francisco,Oncology, Glioblastoma Multiforme (GBM),Preclinical,Global
Fusion Protein to Inhibit VEGF for Glioblastoma and Lung Cancer,,,University of California San Francisco,Oncology, Lung Cancer,Inactive,Global
Fusion Protein to Target VEGFR1 and VEGFR2 for Oncology,,,University of Texas MD Anderson Cancer Center,Oncology,,Preclinical,Global
Fusion Proteins for Oncology,,,National Health Research Institutes,Oncology,,Preclinical,Global
GB-103,,,Graybug Vision Inc,Metabolic Disorders, Diabetic Retinopathy,Preclinical,Global
GB-103,,,Graybug Vision Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
Gene Therapies for Geographic Atrophy and  Wet Macular Degeneration,,,Apellis Pharmaceuticals Inc,Ophthalmology, Geographic Atrophy; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
Gene Therapy to Activate BMP2 and VEGF for Bone Fracture,,,Kazan Federal University,Musculoskeletal Disorders, Bone Fracture,Preclinical,Global
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers,,,Canton Biotechnologies Inc,Dermatology, Wounds,Preclinical,Global
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers,,,Canton Biotechnologies Inc,Metabolic Disorders, Diabetic Foot Ulcers,Preclinical,Global
Gene Therapy to Activate PEDF for Age Related Macular Degeneration,,,University of Geneva,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
Gene Therapy to Activate Raver-2 Protein for Ophthalmology Disorders,,,University of Utah,Ophthalmology, Choroidal Neovascularization; Corneal Neovascularization; Vision Disorders,Preclinical,Global
Gene Therapy to Activate Vascular Endothelial Growth Factor for Neurological Disorders,,,University of the Basque Country,Central Nervous System, Alzheimer's Disease; Parkinson's Disease,Preclinical,Global
Gene Therapy to Inhibit VEGF-A for Corneal Neovascularization,,,University of Utah School of Medicine,Ophthalmology, Corneal Neovascularization,Preclinical,Global
Gene Therapy to Inhibit VEGFA for Wet Age Related Macular Degeneration,,,Seoul National University,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
GFB-204,,,Yale University,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
GFB-204,,,Yale University,Oncology,,Preclinical,Global
GFB-204,,,Kirax Corporation (Inactive),Oncology, Lung Cancer,Inactive,Global
GLB-2002,,,GeneLeap Biotech,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
GNE-947,,,Genentech USA Inc,Ophthalmology, Choroidal Neovascularization,Preclinical,Global
GRFKDR-13,,,Tubitak Marmara Research Center,Oncology,,Preclinical,Global
GRFKDR-26,,,Tubitak Marmara Research Center,Oncology,,Preclinical,Global
GTC-2380,,,Gismo Therapeutics Inc,Immunology, Rheumatoid Arthritis,Preclinical,Global
HG-203,,,Huida (Shanghai) Biotechnology Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
HS-1793,,,Dong-A University,Oncology, Breast Cancer,Preclinical,Global
HuVE-1,,,Galaxy Biotech LLC,Oncology, Hepatocellular Carcinoma,Preclinical,Global
IDB-0076,,,Ildong Pharmaceutical Co Ltd,Oncology, Solid Tumor,Preclinical,Global
IGT-427,,,Ingenia Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
IGT-427,,,Ingenia Therapeutics Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
IHP-102,,,IHP Therapeutics Inc,Oncology, Unspecified Cancer,Preclinical,Global
IHP-102,,,IHP Therapeutics Inc,Hematological Disorders, Sickle Cell Disease,Preclinical,Global
IMM-0207,,,ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd,Oncology, Solid Tumor,Preclinical,Japan; United States
IMM-3202,,,ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd,Oncology, Glioblastoma Multiforme (GBM),Preclinical,Global
IMM-3202,,,ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd,Oncology, Solid Tumor,Inactive,Global
IN-02,,,In3bio Ltd,Oncology, Solid Tumor,Preclinical,Global
IS-217,,Soriacare,Issar Pharmaceuticals Pvt Ltd,Immunology, Psoriasis,Preclinical,United States
IS-217,,,Issar Pharmaceuticals Pvt Ltd,Gastrointestinal, Inflammatory Bowel Disease,Preclinical,Global
IVMED-50,,,iVeena Delivery Systems Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
IVMED-55,,,iVeena Delivery Systems Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
JDE-006,,,Kiora Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
JDE-006,,,Kiora Pharmaceuticals Inc,Ophthalmology, Age Related Macular Degeneration; Corneal Neovascularization,Preclinical,Global
JT-07,,,Jyant Technologies Inc,Oncology, Solid Tumor,Preclinical,Global
JT-07,,,Jyant Technologies Inc,Gastrointestinal, Crohn's Disease (Regional Enteritis),Preclinical,Global
JZB-05,,,Shanghai Jing Ze Biotechnology Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Preclinical,China
KAL-821,,,Kala Pharmaceuticals Inc,Ophthalmology, Age Related Macular Degeneration,Preclinical,Global
KN-024,,,AlphaMab Co Ltd,Ophthalmology, Unspecified Ophthalmological Disorders,Preclinical,Global
KNP-301,,,Kanaph Therapeutics Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
KNP-301,,,Kanaph Therapeutics Inc,Ophthalmology, Dry (Atrophic) Macular Degeneration; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
KSI-501,,,Kodiak Sciences Inc,Ophthalmology, Uveitis; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
KSI-501,,,Kodiak Sciences Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
KSI-501,,,Kodiak Sciences Inc,Infectious Disease, Coronavirus Disease 2019 (COVID-19),Discovery,Global
KTH-223,,,Kalos Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
KTH-223,,,Kalos Therapeutics Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Discovery,Global
KV-123833,,,Kalvista Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
lenalidomide CR,lenalidomide,,Nanexa AB,Oncology, Multiple Myeloma (Kahler Disease),Preclinical,Global
LYN-103,,,LynkCell Inc,Oncology,,Preclinical,Global
melittin,,,Catholic University of Daegu,Genito Urinary System And Sex Hormones, Kidney Fibrosis,Preclinical,Global
melittin,,,Catholic University of Daegu,Gastrointestinal, Cholangitis; Liver Fibrosis,Preclinical,Global
melittin,,,Catholic University of Daegu,Immunology, Inflammation,Discovery,Global
melittin,,,Catholic University of Daegu,Oncology,,Inactive,Global
melittin,,,Catholic University of Daegu,Cardiovascular, Atherosclerosis,Inactive,Global
melittin,,,Catholic University of Daegu,Dermatology, Skin Inflammation,Inactive,Global
metformin,metformin,,Curative Biotechnology Inc,Ophthalmology, Age Related Macular Degeneration; Choroideremia; Geographic Atrophy; Juvenile Macular Degeneration (Stargardt Disease); Retinal Degeneration; Retinitis Pigmentosa (Retinitis),Preclinical,United States
metformin,metformin,,Curative Biotechnology Inc,Metabolic Disorders, Diabetic Retinopathy,Preclinical,United States
Monoclonal Antibodies To Antagonize Neuropilin-1 Receptor for Solid Tumors,,,Sonata Therapeutics Inc,Oncology, Solid Tumor,Preclinical,Global
Monoclonal Antibodies to Inhibit VEGF for Age Related Macular Degeneration and Macular Edema,,,Sustained Nano Systems LLC,Ophthalmology, Age Related Macular Degeneration; Macular Edema,Preclinical,Global
Monoclonal Antibody Conjugate to Target Galectin 3 Binding Protein for Melanoma,,,MediaPharma SRL,Oncology, Melanoma,Preclinical,Global
Monoclonal Antibody to Antagonoze LRP6 for Idiopathic Pulmonary Fibrosis,,,Panorama Researchama Research,Respiratory, Idiopathic Pulmonary Fibrosis,Preclinical,Global
Monoclonal Antibody to Inhibit ADAM15 for Oncology and Ophthalmology,,,Vasgen Ltd,Oncology, Breast Cancer; Prostate Cancer,Preclinical,Global
Monoclonal Antibody to Inhibit ADAM15 for Oncology and Ophthalmology,,,Vasgen Ltd,Ophthalmology,,Preclinical,Global
Monoclonal Antibody to Inhibit CD146 for Melanoma and Pancreatic Cancer,,,Aix-Marseille University,Oncology, Melanoma; Pancreatic Cancer,Preclinical,Global
Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia,,,Takeda Pharmaceutical Co Ltd,Respiratory, Bronchopulmonary Dysplasia,Preclinical,Global
Monoclonal Antibody to Inhibit VEGF for Unspecified Cancer,,,Beijing Sanyuan Gene Pharmaceutical Co Ltd,Oncology, Unspecified Cancer,Preclinical,Global
NAV-838,,,A6 Pharmaceuticals LLC,Infectious Disease, Endotoxemia; Sepsis,Preclinical,Global
NAV-838,,,A6 Pharmaceuticals LLC,Ophthalmology,,Discovery,Global
ND-1001,,,Nanode Therapeutics Inc,Oncology, Chondrosarcoma,Preclinical,Global
NEV-AD1,,,Neovia Oncology Inc,Oncology,,Preclinical,Global
New Chemical Entities,,,OM Pharma Ltd,Oncology, Unspecified Cancer,Preclinical,Global
New Chemical Entities,,,OM Pharma Ltd,Metabolic Disorders, Diabetic Nephropathy; Diabetic Retinopathy,Preclinical,Global
New Chemical Entities,,,OM Pharma Ltd,Gastrointestinal, Pancreatitis,Preclinical,Global
NFS-10,,,Neurophth Therapeutics Inc,Ophthalmology, Retinopathy,Preclinical,Global
NG-101,,,Neuracle Genetics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,United States
NK-4,,,Kringle Pharma Inc,Oncology, Breast Cancer; Colon Cancer; Gallbladder Cancer; Gastric Cancer; Glioblastoma Multiforme (GBM); Lung Cancer; Lymphoma; Melanoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer,Preclinical,Global
NXC-310,,,Nextgen Bioscience,Ophthalmology, Macular Degeneration,Preclinical,Global
Ocu-110,,,Ocugenix Corp,Ophthalmology,,Preclinical,Global
Oligonucleotides for Unspecified Indication,,,PharmaResearch Co Ltd,Undisclosed, Unspecified,Preclinical,Global
ONCR-201,,,OncoResponse Inc,Oncology, Endometrial Cancer; Glioblastoma Multiforme (GBM); Ovarian Cancer; Triple-Negative Breast Cancer (TNBC),Preclinical,United States
OSX-001,,,OncoSenX Inc,Metabolic Disorders, Ageing,Preclinical,Global
OSX-001,,,OncoSenX Inc,Oncology, Solid Tumor,Preclinical,Global
P-52,,,Hokkaido University,Immunology, Psoriasis,Preclinical,Global
pazopanib,pazopanib [INN],,Lotus Pharmaceutical Co Ltd,Oncology, Hepatocellular Carcinoma; Thyroid Cancer,Preclinical,Global
pazopanib,pazopanib [INN],,Lotus Pharmaceutical Co Ltd,Oncology, Renal Cell Carcinoma,Preclinical,EU
pazopanib,pazopanib [INN],,Lotus Pharmaceutical Co Ltd,Oncology, Soft Tissue Sarcoma,Inactive,Asia-Pacific; EU
pazopanib,pazopanib [INN],,Lotus Pharmaceutical Co Ltd,Oncology, Renal Cell Carcinoma,Inactive,Asia-Pacific
PB-101,,,Panolos Bioscience,Oncology, Solid Tumor,Preclinical,Global
PD-L1/VEGF Trap,,,Immunowake Inc,Oncology, Unspecified Cancer,Preclinical,Global
pegylated doxorubicin,,,Graybug Vision Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
pegylated doxorubicin,,,Graybug Vision Inc,Ophthalmology, Choroidal Neovascularization,Inactive,Global
PMC-201,,,PharmAbcine Inc,Oncology, Colorectal Cancer,Preclinical,Global
PMC-404,,,PharmAbcine Inc,Undisclosed, Unspecified,Preclinical,Global
Polymer to Target P-selectin and VEGF for Oncology,,,National Cancer Center,Oncology,,Preclinical,Global
propranolol hydrochloride,propranolol hydrochloride,,Spanish National Research Council,Genetic Disorders, Von Hippel-Lindau Syndrome,Preclinical,EU
Protein to Inhibit VEGF for Ophthalmology,,,Ocular Therapeutix Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
Protein to Inhibit VEGF for Ophthalmology,,,Ocular Therapeutix Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
Q-922,,,Medicon Inc,Oncology, Epithelial Ovarian Cancer,Preclinical,Global
QR-214,,,Qrono Inc,Oncology, Unspecified Cancer,Preclinical,Global
R-916562,,,Rigel Pharmaceuticals Inc,Oncology,,Preclinical,Global
ramucirumab biosimilar,,,Eden Biologics Inc,Oncology, Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer,Preclinical,Global
ranibizumab biobetter,,,Ildong Pharmaceutical Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
ranibizumab biosimilar,,,Clonz Biotech Pvt Ltd,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,India
ranibizumab biosimilar,,,Clonz Biotech Pvt Ltd,Metabolic Disorders, Diabetic Macular Edema,Preclinical,India
ranibizumab biosimilar,,,HK inno.N Corp,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
ranibizumab biosimilar,,,HK inno.N Corp,Ophthalmology, Retinopathy,Inactive,United States
ranibizumab biosimilar,,,Celon Pharma SA,Ophthalmology, Age Related Macular Degeneration; Macular Edema,Preclinical,Global
ranibizumab biosimilar,,,Celon Pharma SA,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
ranibizumab biosimilar,,,Mabion SA,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
ranibizumab biosimilar,,,Mabion SA,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization; Macular Edema; Vision Disorders; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
ranibizumab biosimilar,,,Profarma,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
ranibizumab biosimilar,,,Profarma,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
Recombinant Peptide for Acute Ischemic Stroke and Alzheimer's Disease,,,Stream Biomedical Inc,Central Nervous System, Alzheimer's Disease,Preclinical,Global
Recombinant Peptide for Acute Ischemic Stroke and Alzheimer's Disease,,,Stream Biomedical Inc,Cardiovascular, Acute Ischemic Stroke,Preclinical,Global
Recombinant Protein to Agonize PEDF for Women's Health,,,Tel Aviv University,Women's Health, Endometriosis; Ovarian Hyperstimulation Syndrome; Polycystic Ovarian Syndrome,Preclinical,Global
"Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology",,,Stanford University,Oncology,,Preclinical,Global
Recombinant Protein to Inhibit PDGF and VEGF for Wet Age Related Macular Degeneration,,,AbbVie Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
Recombinant Protein to Target FLT1 for Pre-Eclampsia,,,Aggamin LLC,Cardiovascular, Pre-Eclampsia,Preclinical,EU; United States
RO-101,,,RevOpsis Therapeutics Corp,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
RO-101,,,RevOpsis Therapeutics Corp,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
RP-1400,,,Rhizen Pharmaceuticals SA,Oncology, Non-Small Cell Lung Cancer,Preclinical,Global
RS-201,,,RiniSight Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
RS-201,,,RiniSight Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
SAUG-1,,,Portage Biotech Inc,Oncology, Solid Tumor,Preclinical,Global
SCR-101,,,AMD Therapeutics LLC,Dermatology, Acne Vulgaris; Hypertrophic Scars,Preclinical,United States
SCT-520F,,,SinoCelltech Group Ltd,Oncology, Solid Tumor,Preclinical,Global
SCT-520FF,,,SinoCelltech Group Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
SGL-10060,,,Seagull Therapeutics,Oncology,,Preclinical,Global
SHLP-6,,,CohBar Inc,Oncology, Breast Cancer; Liver Cancer; Ovarian Cancer; Prostate Cancer,Preclinical,Global
SJP-1601,,,Samjin Pharm Co Ltd,Oncology, Colorectal Cancer,Preclinical,Global
SK-216,,,Hiroshima University,Oncology, Metastatic Lung Cancer,Preclinical,Global
Small Molecule for Dry Eye and Meibomian Blepharitis,,,Aerie Pharmaceuticals Inc,Ophthalmology, Keratoconjunctivitis Sicca (Dry Eye); Meibomian Blepharitis,Preclinical,Global
Small Molecule for Ophthalmology,,,Eyemedix Inc,Ophthalmology,,Preclinical,Global
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis,,,Impetis Biosciences Ltd,Gastrointestinal, Liver Fibrosis,Preclinical,Global
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis,,,Impetis Biosciences Ltd,Ophthalmology,,Inactive,Global
Small Molecule to Inhibit FTase and GGTase I for Pancreatic Cancer,,,H. Lee Moffitt Cancer Center & Research Institute Inc,Oncology, Pancreatic Cancer,Preclinical,Global
Small Molecule to Inhibit VEGF for Diabetic Macular Edema and Wet Macular Degeneration,,,Kubota Vision Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
Small Molecule to Inhibit VEGF for Diabetic Macular Edema and Wet Macular Degeneration,,,Kubota Vision Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
Small Molecule to Inhibit VEGF for Solid Tumors,,,Interprotein Corp,Oncology, Solid Tumor,Preclinical,Global
Small Molecule to Inhibit VEGF-A and IL6 for Inflammation and Oncology,,,Kyung Hee University,Oncology, Blood Cancer,Preclinical,Global
Small Molecule to Inhibit VEGF-A and IL6 for Inflammation and Oncology,,,Kyung Hee University,Immunology, Inflammation,Preclinical,Global
Small Molecule to Inhibit VEGFA for Oral Cancer,,,Kyung Hee University,Oncology, Oral Cancer,Preclinical,Global
Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction,,,Vanderbilt University,Cardiovascular, Myocardial Infarction,Preclinical,Global
Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction,,,Vanderbilt University,Respiratory, Asthma,Inactive,Global
Small Molecules to Inhibit VEGFR2 for Breast Cancer,,,Nova Southeastern University,Oncology, Breast Cancer,Preclinical,Global
SPHINX-31,,,Exonate Ltd,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)",Preclinical,Global
SPHINX-31,,,Exonate Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
ST-102,,,Semathera Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
ST-1898,,,Beijing Scitech-MQ Pharmaceuticals Ltd,Oncology, Gastric Cancer; Hepatocellular Carcinoma; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer,Preclinical,China
Stem Cell Therapy for Critical Limb Ischemia,,,University of California Davis,Cardiovascular, Critical Limb Ischemia,Preclinical,Global
"Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain",,,Stem Cell Medicine Ltd,Central Nervous System, Neuropathic Pain (Neuralgia); Peripheral Nerve Injury,Preclinical,Global
STIA-0168,,,Sorrento Therapeutics Inc,Oncology,,Preclinical,Global
STP-355,,,Sirnaomics Ltd,Oncology, Breast Cancer; Colorectal Cancer; Melanoma,Preclinical,United States
Synthetic Peptide to Antagonise VEGFR for Wounds,,,Yale University,Dermatology, Wounds,Preclinical,Global
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology,,,Xavier University of Louisiana,Oncology, Breast Cancer,Preclinical,Global
Synthetic Peptides for Oncology,,,The Cleveland Clinic Foundation,Oncology,,Preclinical,Global
Synthetic Proteins to Inhibit VEGFA for Wet Macular Degeneration and Oncology,,,Reflexion Pharmaceuticals Inc,Oncology,,Preclinical,Global
Synthetic Proteins to Inhibit VEGFA for Wet Macular Degeneration and Oncology,,,Reflexion Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Unknown,Global
taurolidine,taurolidine [INN],,CorMedix Inc,Oncology, Neuroblastoma,Preclinical,United States
taurolidine,taurolidine [INN],,CorMedix Inc,Infectious Disease, Fungal Infections,Discovery,Global
taurolidine,taurolidine [INN],,CorMedix Inc,Oncology, Osteosarcoma,Discovery,Global
thalidomide,thalidomide,Taldo,PlumeStars Srl,Genetic Disorders, Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease),Preclinical,EU; United States
TJO-054,,,TaeJoon Pharmaceuticals Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
TO-O-1002,,,Theratocular Biotek Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
TO-O-1002,,,Theratocular Biotek Co Ltd,Ophthalmology, Retinal Vein Occlusion,Preclinical,Global
TO-O-1002,,,Theratocular Biotek Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,United States
TR-764,,,University of Padova,Oncology, Hepatocellular Carcinoma; Melanoma,Preclinical,Global
TRV-32R,,,Teraclon IDF SL,Ophthalmology, Glaucoma,Preclinical,Global
TRV-32R,,,Teraclon IDF SL,Metabolic Disorders, Diabetic Retinopathy,Preclinical,Global
TRV-32R,,,Teraclon IDF SL,Ophthalmology, Age Related Macular Degeneration; Central Retinal Vein Occlusion,Inactive,Global
TY-011,,,Nanjing Tianyi Bioscience Co Ltd,Oncology, Gastric Cancer,Preclinical,Global
UB-925,,,United BioPharma Inc,Oncology, Colorectal Cancer; Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Non-Small Cell Lung Cancer,Preclinical,Global
UBS-109,,,Emory University,Oncology, Colorectal Cancer; Head And Neck Cancer Squamous Cell Carcinoma,Preclinical,Global
UBS-109,,,Emory University,Musculoskeletal Disorders, Bone Disorders,Preclinical,Global
UBS-109,,,Emory University,Central Nervous System, Depression,Inactive,Global
V-10,,,Nangiotx Inc,Cardiovascular, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Preclinical,Global
v-DOS,,,Helix BioPharma Corp,Oncology, Breast Cancer,Preclinical,Global
Vaccine to Target CD147 for Lung Cancer and Autoimmune Diseases,,,The Rappaport Institute,Oncology, Lung Cancer,Preclinical,Global
Vaccine to Target CD147 for Lung Cancer and Autoimmune Diseases,,,The Rappaport Institute,Immunology, Autoimmune Disorders,Inactive,Global
Variants of IGT-427,,,Ingenia Therapeutics Inc,Metabolic Disorders, Diabetic Macular Edema,Preclinical,Global
Variants of IGT-427,,,Ingenia Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
varisacumab,varisacumab [INN],,OncXerna Therapeutics Inc,Oncology, Pancreatic Cancer,Preclinical,Global
varisacumab,varisacumab [INN],Apagin,Generium,Oncology, Metastatic Colorectal Cancer,Inactive,Russia
VB-211,,,Vascular Biogenics Ltd,Cardiovascular, Ischemia,Preclinical,Global
VLTR-557,,,Valitor Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Preclinical,Global
VLTR-557,,,Valitor Inc,Ophthalmology, Age Related Macular Degeneration; Retinal Vein Occlusion,Preclinical,Global
Wet AMD,,,Generation Bio Co,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Preclinical,Global
Wnt-001,,,Wntgen LLC,Metabolic Disorders, Diabetic Retinopathy,Preclinical,Global
Wnt-001,,,Wntgen LLC,Ophthalmology, Corneal Neovascularization,Preclinical,Global
Wnt-001,,,Wntgen LLC,Metabolic Disorders, Diabetic Nephropathy,Inactive,Global
Wnt-001,,,Wntgen LLC,Immunology, Systemic Sclerosis (Scleroderma),Inactive,Global
Wnt-001,,,Wntgen LLC,Genetic Disorders,Polycystic Kidney Disease,Inactive,Global
Wnt-001,,,Wntgen LLC,Gastrointestinal, Cirrhosis; Non-Alcoholic Steatohepatitis (NASH),Inactive,Global
Wnt-001,,,Wntgen LLC,Genito Urinary System And Sex Hormones,Chronic Kidney Disease (Chronic Renal Failure); Kidney Fibrosis,Inactive,Global
Wnt-001,,,Wntgen LLC,Respiratory, Idiopathic Pulmonary Fibrosis,Inactive,Global
Wnt-001,,,Wntgen LLC,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
xB-3002,,,Bioasis Technologies Inc,Oncology, Glioblastoma Multiforme (GBM),Preclinical,Global
YZ-129,,,Texas A&M University,Oncology, Glioblastoma Multiforme (GBM),Preclinical,Global
aflibercept biosimilar,,,Kidswell Bio Corp,Ophthalmology, Unspecified Ophthalmological Disorders,Discovery,Global
aflibercept biosimilar,,,GlycoNex Inc,Ophthalmology,,Discovery,Global
aflibercept biosimilar,,,GlycoNex Inc,Oncology,,Discovery,Global
aflibercept biosimilar,,,Huons Global Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discovery,Global
AIC-104,,,Ailon Co Ltd,Oncology, Unspecified Cancer,Discovery,Global
AIC-104,,,Ailon Co Ltd,Metabolic Disorders, Diabetic Retinopathy,Discovery,Global
B-733,,,Larix Bioscience LLC,Cardiovascular, Pre-Eclampsia,Discovery,Global
bevacizumab biosimilar,,,IMGENEX India Pvt Ltd,Oncology, Colorectal Cancer,Discovery,Global
bevacizumab biosimilar,,,Clonz Biotech Pvt Ltd,Oncology, Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Discovery,India
bevacizumab biosimilar,,,Avesthagen Ltd,Oncology, Colorectal Cancer; Glioblastoma Multiforme (GBM); Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer; Ovarian Cancer,Discovery,India
bevacizumab biosimilar,,,Huons Global Co Ltd,Oncology, Solid Tumor,Discovery,Global
Bi-specific Monoclonal Antibody to Inhibit PD-L1 and VEGFR for Oncology,,,Kadmon Holdings Inc,Oncology,,Discovery,Global
Bi-specific Monoclonal Antibody to Inhibit VEGF and Semaphorin 3A for Age Related Macular Degeneration and Diabetic Macular Edema,,,Semathera Inc,Ophthalmology, Age Related Macular Degeneration,Discovery,Global
Bi-specific Monoclonal Antibody to Inhibit VEGF and Semaphorin 3A for Age Related Macular Degeneration and Diabetic Macular Edema,,,Semathera Inc,Metabolic Disorders, Diabetic Macular Edema,Discovery,Global
DNX-214,,,DNX Biopharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discovery,Global
fenofibrate,fenofibrate,,Charlesson LLC,Metabolic Disorders, Diabetic Retinopathy,Discovery,Global
FP-008,,,Foresee Pharmaceuticals Co Ltd,Metabolic Disorders, Diabetic Retinopathy,Discovery,United States
Gene Therapy to Inhibit Transforming Growth Factor Beta (TGFb) for Breast and Lung Cancers,,,MultiVir Inc,Oncology, Breast Cancer; Lung Cancer,Discovery,Global
HuA-2T,,,Galaxy Biotech LLC,Oncology,,Discovery,Global
IBX-13,,,Ibex Biosciences LLC,Infectious Disease, Malaria,Discovery,Global
IBX-13,,,Ibex Biosciences LLC,Oncology, Lung Cancer,Inactive,Global
LQ-015,,,Shanghai Novamab Biopharmaceuticals Co Ltd,Ophthalmology, Age Related Macular Degeneration,Discovery,Global
LYN-00101,,,LynkCell Inc,Oncology, Solid Tumor,Discovery,Global
necuparanib,necuparanib,,Johnson & Johnson,Infectious Disease, Coronavirus Disease 2019 (COVID-19),Discovery,Global
necuparanib,necuparanib,,Momenta Pharmaceuticals Inc,Oncology, Lung Cancer; Metastatic Melanoma,Inactive,Global
necuparanib,necuparanib,,Momenta Pharmaceuticals Inc,Oncology, Colorectal Cancer; Metastatic Breast Cancer; Ovarian Cancer,Discontinued,Global
necuparanib,necuparanib,,Momenta Pharmaceuticals Inc,Oncology, Metastatic Pancreatic Cancer,Discontinued,United States
OGB-23501,,,Onegene Biotechnology Inc,Oncology, Solid Tumor,Discovery,Global
OGB-23502,,,Onegene Biotechnology Inc,Oncology, Solid Tumor,Discovery,Global
OGB-23503,,,Onegene Biotechnology Inc,Oncology, Solid Tumor,Discovery,Global
PPB-4010,,,Paras Biopharmaceuticals Finland Oy,Oncology, Metastatic Breast Cancer,Discovery,Global
ramucirumab biosimilar,,,Prestige BioPharma Ltd,Oncology, Adenocarcinoma Of The Gastroesophageal Junction,Discovery,Global
RBTKi,,,Rebio Technologies Ltd,Metabolic Disorders, Diabetic Macular Edema,Discovery,Global
Recombinant Protein for Age Related Macular Degeneration,,,Affilogic SAS,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discovery,Global
SL-186,,,i2 Pharmaceuticals Inc,Oncology,,Discovery,Global
SL-188,,,i2 Pharmaceuticals Inc,Oncology,,Discovery,Global
Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer,,,China Pharmaceutical University,Oncology, Breast Cancer,Discovery,Global
Small Molecule to Antagonize VEGFR2 for Oncology,,,Nanjing University,Oncology,,Discovery,Global
Small Molecule to Inhibit c-Met and VEGFR-2 for Oncology,,,China Pharmaceutical University,Oncology,,Discovery,Global
Small Molecule to Inhibit VEGF for Oncology,,,FUDAN University,Oncology,,Discovery,Global
Small Molecules for Hereditary Hemorrhagic Telangiectasia,,,Starfish Innovations,Genetic Disorders, Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease),Discovery,Global
Small Molecules to Inhibit EGFR and VEGFR-2 for Oncology,,,China Pharmaceutical University,Oncology,,Discovery,Global
Small Molecules to Inhibit VEGFR-2 for Oncology,,,Xi'an Jiaotong University,Oncology,,Discovery,Global
SPI-0500,,,Score Pharma Inc,Oncology, Colorectal Cancer,Discovery,Global
Synthetic Peptide to Inhibit VIP for Oncology,,,Interprotein Corp,Oncology,,Discovery,Global
SYP-5,,,Shenyang Pharmaceutical University,Oncology,,Discovery,Global
TGT-101,,,ToolGen Inc,Metabolic Disorders, Diabetic Retinopathy,Discovery,Global
TGT-101,,,ToolGen Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discovery,Global
Tie2/VEGF bi-specific,,,Unity Biotechnology Inc,Ophthalmology, Age Related Macular Degeneration,Discovery,Global
Tie2/VEGF bi-specific,,,Unity Biotechnology Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Discovery,Global
VEGF,,,Imugene Ltd,Oncology, Unspecified Cancer,Discovery,Global
VEGF and ANG2 Tetravalent Bispecific Antibody,,,China Medical System Holdings Ltd,Ophthalmology, Unspecified Ophthalmological Disorders,Discovery,China
YHC-1104,,,Yuhan Corp,Oncology, Non-Small Cell Lung Cancer,Discovery,Global
aflibercept biosimilar,,,Oncosimis Biotech Pvt Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Unknown,Global
AP-216,,,Aprogen Inc,Oncology, Lung Cancer; Ovarian Cancer,Unknown,Global
AP-216,,,Aprogen Inc,Ophthalmology, Choroidal Neovascularization; Retinopathy Of Prematurity,Inactive,Global
bevacizumab biosimilar,,,Karyo Biologics LLC,Oncology, Breast Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Unknown,United States
Gene Therapy 2 to Activate p53 for Oncology,,,Shenzen SiBiono GeneTech Co Ltd,Oncology,,Unknown,Global
ND-01,,,Therabest Co Ltd,Oncology, Unspecified Cancer,Unknown,Global
(aflibercept + rinucumab),(aflibercept + rinucumab),,Regeneron Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,United States
2H-10,,,CSL Ltd,Metabolic Disorders, Type 2 Diabetes,Inactive,Global
A-3914,,,Albireo Pharma Inc,Gastrointestinal,,Inactive,Global
A-3914,,,Albireo Pharma Inc,Dermatology, Atopic Dermatitis (Atopic Eczema); Scar,Inactive,Global
A-3914,,,Albireo Pharma Inc,Immunology, Psoriasis,Inactive,Global
A-5425,,,Albireo Pharma Inc,Immunology, Psoriasis,Inactive,Global
A-5425,,,Albireo Pharma Inc,Dermatology, Atopic Dermatitis (Atopic Eczema); Scar,Inactive,Global
A-5425,,,Albireo Pharma Inc,Gastrointestinal,,Inactive,Global
AA-98,,,MicroConstants China Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
AA-98,,,MicroConstants China Inc,Oncology, Melanoma; Pancreatic Cancer,Inactive,Global
AA-98,,,MicroConstants China Inc,Central Nervous System, Multiple Sclerosis,Inactive,Global
AAA-225,,,Actinium Pharmaceuticals Inc,Oncology, Breast Cancer; Glioblastoma Multiforme (GBM); Solid Tumor,Inactive,Global
AB-393,,,Aparna Biosciences Corp (Inactive),Oncology,,Inactive,Global
AB-7,,,Suzhou Stainwei Biotech Inc,Oncology, Solid Tumor,Inactive,Global
ABP-200,,,Abpro Corp,Oncology, Solid Tumor,Inactive,Global
ABT-468,,,Abtelum Biomedical Inc (Inactive),Oncology, Pancreatic Ductal Carcinoma,Inactive,Global
ABT-468,,,Abtelum Biomedical Inc (Inactive),Central Nervous System, Intracerebral Hemorrhage,Inactive,Global
ABT-510,,,AbbVie Inc,Oncology, Head And Neck Cancer; Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Metastatic Melanoma; Non-Hodgkin Lymphoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Soft Tissue Sarcoma,Inactive,Global
ABT-526,,,AbbVie Inc,Oncology, Lymphoma,Inactive,Global
AC-301,,,TWi Biotechnology Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
AC-301,,,TWi Biotechnology Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
AC-607,,,AlloCure Inc. (Inactive),Genito Urinary System And Sex Hormones, Acute Renal Failure (ARF) (Acute Kidney Injury),Inactive,Global
acrizanib,acrizanib [INN],,Novartis AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
ACT-3673,,,Clanotech AB,Oncology, Solid Tumor,Inactive,Global
ACT-3673,,,Clanotech AB,Ophthalmology, Age Related Macular Degeneration; Macular Edema,Inactive,Global
ACT-3673,,,Clanotech AB,Cardiovascular, Atherosclerosis; Myocardial Ischemia; Stroke,Inactive,Global
ACT-3673,,,Clanotech AB,Immunology, Chronic Inflammation,Inactive,Global
ACT-3673,,,Clanotech AB,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
ACU-6151,,,Kubota Vision Inc,Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Inactive,Global
ACU-6151,,,Kubota Vision Inc,Ophthalmology, Geographic Atrophy; Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
ACUO-2,,,Accuitis Pharmaceuticals Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
AdeVasc,,AdeVasc,NT Pharma LLC,Central Nervous System, Amyotrophic Lateral Sclerosis,Inactive,Global
ADVM-032,,,Adverum Biotechnologies Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
AE-941,,Neovastat,Aeterna Zentaris Inc,Oncology, Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Inactive,Global
aflibercept biosimilar,,,Clover Biopharmaceuticals Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,China
aflibercept biosimilar,,,Lupin Ltd,Ophthalmology, Central Retinal Vein Occlusion; Choroidal Neovascularization; Macular Edema; Myopia; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
aflibercept biosimilar,,,Lupin Ltd,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Inactive,Global
AG-30/5C,,,AnGes Inc,Dermatology, Skin Ulcers; Wounds,Inactive,Global
AG-30/5C,,,AnGes Inc,Infectious Disease, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections; Pseudomonas aeruginosa Infections,Inactive,Global
AKB-6899,,,Akebia Therapeutics Inc,Hematological Disorders, Anemia,Inactive,Global
AKB-6899,,,Akebia Therapeutics Inc,Ophthalmology,,Inactive,Global
AKB-6899,,,Akebia Therapeutics Inc,Oncology,,Inactive,United States
AKB-6899,,,Akebia Therapeutics Inc,Gastrointestinal, Colitis,Inactive,Global
AL-39324,,,Novartis AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
AL-78898A,,,Novartis AG,Ophthalmology, Geographic Atrophy; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
alacizumab pegol,alacizumab pegol [INN],,UCB SA,Oncology, Non-Small Cell Lung Cancer,Inactive,Global
albendazole,albendazole,,PharmAust Ltd,Oncology, Malignant Neoplasms; Ovarian Cancer; Peritoneal Cancer,Inactive,Global
AM-001,,,amcure GmbH,Oncology, Pancreatic Cancer,Inactive,Global
AM-1101,,,Kemin Industries Inc,Cardiovascular, Restenosis,Inactive,Global
AM-1101,,,Kemin Industries Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
AM-133,,,Takeda Pharmaceutical Co Ltd,Cardiovascular, Coronary Artery Disease (CAD) (Ischemic Heart Disease); Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Inactive,Global
andecaliximab,andecaliximab,,Gilead Sciences Inc,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Lung Adenocarcinoma; Metastatic Adenocarcinoma of The Pancreas; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Pancreatic Cancer; Squamous Non-Small Cell Lung Carcinoma,Inactive,Global
andecaliximab,andecaliximab,,Gilead Sciences Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction,Inactive,Global; Japan
andecaliximab,andecaliximab,,Gilead Sciences Inc,Respiratory, Chronic Obstructive Pulmonary Disease (COPD),Inactive,Global
andecaliximab,andecaliximab,,Gilead Sciences Inc,Oncology, Gastric Cancer,Inactive,Global; Japan; United States
andecaliximab,andecaliximab,,Gilead Sciences Inc,Respiratory, Cystic Fibrosis,Discontinued,Global
andecaliximab,andecaliximab,,Gilead Sciences Inc,Immunology, Rheumatoid Arthritis,Discontinued,Global
andecaliximab,andecaliximab,,Gilead Sciences Inc,Gastrointestinal, Crohn's Disease (Regional Enteritis); Ulcerative Colitis,Discontinued,Global
"Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology",,,FairJourney Biologics SA,Oncology,,Inactive,Global
"Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology",,,The Rappaport Institute,Dermatology, Alopecia,Inactive,Global
"Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology",,,The Rappaport Institute,Gastrointestinal, Colitis,Inactive,Global
"Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology",,,The Rappaport Institute,Immunology, Bone Marrow Transplant Rejection,Inactive,Global
"Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology",,,The Rappaport Institute,Metabolic Disorders, Diabetic Nephropathy,Inactive,Global
Antisense Oligonucleotide to Antagonize NRP1 for Ophthalmology,,,Secarna Pharmaceuticals GmbH & Co KG,Ophthalmology,,Inactive,Global
Antisense RNAi Oligonucleotide to Inhibit Angiopoietin 2 for Acute Lung Injury,,,Alnylam Pharmaceuticals Inc,Respiratory, Acute Lung Injury,Inactive,Global
apricoxib,apricoxib,Capoxigem,Adastra Pharmaceuticals Inc,Immunology, Inflammation,Inactive,Global
apricoxib,apricoxib,Capoxigem,Adastra Pharmaceuticals Inc,Oncology, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Non-Small Cell Lung Cancer; Pancreatic Cancer,Inactive,Global
apricoxib,apricoxib,Capoxigem,Adastra Pharmaceuticals Inc,Central Nervous System, Pain,Inactive,Global
APX-004,,,Apexigen Inc,Oncology,,Inactive,Global
ART-101,,,ArtGen Inc,Cardiovascular, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Inactive,Global
ART-160,,,Teva Pharmaceutical Industries Ltd,Oncology, Solid Tumor,Inactive,Global
atiprimod,atiprimod[INN],,Synergy Pharmaceuticals Inc (Inactive),Oncology, Neuroendocrine Carcinoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma,Inactive,United States
atiprimod,atiprimod[INN],,Synergy Pharmaceuticals Inc (Inactive),Immunology, Rheumatoid Arthritis,Inactive,Global
AZD-2932,,,AstraZeneca Plc,Oncology, Solid Tumor,Inactive,EU
AZD-2932,,,AstraZeneca Plc,Central Nervous System, Abdominal Pain,Inactive,United States
BAY-872243,,,Bayer AG,Oncology, Advanced Malignancy,Inactive,Global
BB-201,,,Benitec Biopharma Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
BB-202,,,Benitec Biopharma Inc,Ophthalmology, Dry (Atrophic) Macular Degeneration; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
Beta-LGND2,,,Oncternal Therapeutics,Metabolic Disorders, Diabetic Retinopathy; Obesity,Inactive,Global
Beta-LGND2,,,Oncternal Therapeutics,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
bevacizumab,bevacizumab,,Lee's Pharmaceutical Holdings Ltd,Ophthalmology, Macular Degeneration,Inactive,Global
bevacizumab biobetter,,,Prestige BioPharma Ltd,Oncology, Solid Tumor,Inactive,Global
bevacizumab biobetter,,,Ildong Pharmaceutical Co Ltd,Oncology, Solid Tumor,Inactive,Global
bevacizumab biosimilar,,,Harvest Moon Pharmaceuticals USA Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,Zenotech Laboratories Ltd,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Colorectal Cancer,Inactive,Global
bevacizumab biosimilar,,,Jiangsu Aosaikang Pharmaceutical Co Ltd,Oncology, Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Inactive,China
bevacizumab biosimilar,,,Sun Pharma Advanced Research Company Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,3SBio Inc,Oncology, Non-Small Cell Lung Cancer,Inactive,Global
bevacizumab biosimilar,,,3SBio Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
bevacizumab biosimilar,,,PharmaResearch BIO Co Ltd,Oncology, Breast Cancer; Cervical Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer,Inactive,Global
bevacizumab biosimilar,,,Anew Oncology Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Ovarian Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer; Recurrent Malignant Glioma ; Squamous Non-Small Cell Lung Cancer,Inactive,Global
bevacizumab biosimilar,,,Anew Oncology Inc,Ophthalmology, Macular Edema,Inactive,Global
bevacizumab biosimilar,,,Coherus BioSciences Inc,Oncology, Cervical Cancer; Kidney Cancer (Renal Cell Cancer); Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Ovarian Cancer; Recurrent Glioblastoma Multiforme (GBM),Inactive,Global
bevacizumab biosimilar,,,Alteogen Inc,Oncology, Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Inactive,Global
bevacizumab biosimilar,,,InSight Biopharmaceuticals Ltd (Inactive),Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Ovarian Cancer; Metastatic Renal Cell Carcinoma; Peritoneal Cancer; Recurrent Malignant Glioma ; Squamous Non-Small Cell Lung Cancer,Inactive,Global
bevacizumab biosimilar,,,Siam Bioscience Co Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,United BioPharma Inc,Oncology, Colorectal Cancer,Inactive,Global
bevacizumab biosimilar,,,Mabion SA,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,Protheragen Inc,Oncology, Colorectal Cancer,Inactive,Global
bevacizumab biosimilar,,,Kashiv BioSciences LLC,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,STC Biologics Inc,Oncology, Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Inactive,Global
bevacizumab biosimilar,,,Panacea Biotec Ltd,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,EB Sub Inc,Oncology, Cervical Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Peritoneal Cancer,Inactive,Global
bevacizumab biosimilar,,,AlphaMab Co Ltd,Oncology,,Inactive,Global
bevacizumab biosimilar,,,PlantForm Corp,Oncology, Colorectal Cancer,Inactive,Global
bevacizumab SR,,,Critical Pharmaceuticals Ltd (Inactive),Ophthalmology, Age Related Macular Degeneration,Inactive,Global
bevacizumab SR,,,Ocular Therapeutix Inc,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
bevacizumab SR,,,Ocular Therapeutix Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
bevasiranib sodium,bevasiranib sodium,,Phio Pharmaceuticals Corp,Ophthalmology,,Inactive,Global
bevasiranib sodium,bevasiranib sodium,,OPKO Health Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Inactive,Global
bevasiranib sodium,bevasiranib sodium,,OPKO Health Inc,Ophthalmology, Age Related Macular Degeneration,Discontinued,Global
Bi-specific Monoclonal Antibodies to Inhibit CXCL-12 and VEGF for Renal Cell Carcinoma,,,Cytovia Holdings Inc,Oncology, Renal Cell Carcinoma,Inactive,Global
BioBypass-CAD,,,Precigen Inc,Cardiovascular, Coronary Artery Disease (CAD) (Ischemic Heart Disease),Inactive,Global
Biosimilar to Inhibit VEGF for Non-Small Cell Lung Cancer,,,3SBio Inc,Oncology, Non-Small Cell Lung Cancer,Inactive,Global
BIW-8556,,,Kyowa Kirin Co Ltd,Oncology, Breast Cancer; Colon Cancer,Inactive,Global
BL-012,,,Beijing Labsolutions Pharmaceuticals Co Ltd,Oncology,,Inactive,Global
BL-2050,,,BioLineRx Ltd,Cardiovascular, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Inactive,Global
BMS-817378,,,Simcere Pharmaceutical Group Ltd,Oncology,,Inactive,China
BMS-817378,,,Bristol-Myers Squibb Co,Oncology," Esophageal Cancer; Gastric Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Solid Tumor",Inactive,Global
BO-011,,,Highlight Therapeutics SL,Oncology, Colon Cancer; Lung Cancer; Melanoma; Pancreatic Cancer,Inactive,Global
Bryosomes,,,Aphios Corp,Oncology, Esophageal Cancer,Inactive,Global
bucillamine,bucillamine [INN],,Keystone Biomedical Inc (Inactive),Cardiovascular, Ischemia; Reperfusion Injury,Inactive,Global
carlumab,carlumab,,Johnson & Johnson,Oncology, Pancreatic Cancer,Inactive,United States
carlumab,carlumab,,Johnson & Johnson,Gastrointestinal, Inflammatory Bowel Disease,Inactive,Global
carlumab,carlumab,,Johnson & Johnson,Respiratory, Idiopathic Pulmonary Fibrosis,Discontinued,Global
carlumab,carlumab,,Johnson & Johnson,Oncology," Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Ovarian Cancer; Solid Tumor",Discontinued,Global
CBI-101,,,"Carolina BioPharm, Inc. (Inactive)",Oncology, Bone Sarcoma; Breast Cancer; Lung Cancer; Soft Tissue Sarcoma,Inactive,Global
CCX-662,,,ChemoCentryx Inc,Oncology, Glioblastoma Multiforme (GBM),Inactive,Global
Cell Therapy for Critical Limb Ischemia,,,University Hospital of Reims,Cardiovascular, Critical Limb Ischemia,Inactive,Global
CIGB-166,,,Center for Genetic Engineering and Biotechnology,Oncology,,Inactive,Global
CIGB-166,,,Center for Genetic Engineering and Biotechnology,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
cimetidine,cimetidine,,Mayne Pharma Group Ltd,Gastrointestinal,,Inactive,Global
CLT-002,,,Charlesson LLC,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
CLT-002,,,Charlesson LLC,Ophthalmology, Age Related Macular Degeneration; Ocular Inflammation,Inactive,Global
CLT-003,,,Charlesson LLC,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,United States
CLT-003,,,Charlesson LLC,Metabolic Disorders, Diabetic Macular Edema,Inactive,United States
CLT-005,,,Charlesson LLC,Metabolic Disorders, Diabetic Retinopathy,Inactive,United States
CLT-005,,,Charlesson LLC,Ophthalmology, Dry (Atrophic) Macular Degeneration; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,United States
CLT-010,,,Charlesson LLC,Ophthalmology,,Inactive,Global
CLT-010,,,Charlesson LLC,Oncology,,Inactive,Global
CLT-01001,,,Charlesson LLC,Oncology,,Inactive,Global
CLT-01001,,,Charlesson LLC,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
CLT-01007,,,Charlesson LLC,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
CLT-01007,,,Charlesson LLC,Oncology,,Inactive,Global
CLT-01012,,,Charlesson LLC,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
CLT-01012,,,Charlesson LLC,Oncology,,Inactive,Global
CLT-28643,,,Clanotech AB,Ophthalmology, Choroidal Neovascularization; Retinopathy Of Prematurity; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
CLT-28643,,,Clanotech AB,Respiratory, Pulmonary Fibrosis,Inactive,Global
CLT-28643,,,Clanotech AB,Dermatology, Scar,Inactive,EU; United States
CS-3158,,,Shenzhen Chipscreen Biosciences Co Ltd,Oncology, Breast Cancer; Colorectal Cancer; Lung Cancer; Solid Tumor,Inactive,Global
CTP-221,,,Concert Pharmaceuticals Inc,Oncology, Blood Cancer; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Inactive,Global
CTX-033,,,CytomX Therapeutics Inc,Oncology, Pancreatic Cancer,Inactive,Global
CVE-199,,,Chugai Pharmaceutical Co Ltd,Oncology, Neuroblastoma,Inactive,Global
CVX-045,,,Pfizer Inc,Oncology, Advanced Malignancy; Solid Tumor,Inactive,Global
CYC-116,,,Cyclacel Pharmaceuticals Inc,Oncology, Breast Cancer; Colorectal Cancer; Pancreatic Cancer; Solid Tumor,Inactive,United States
DC-101,,,Eli Lilly and Co,Oncology, Hepatocellular Carcinoma; Kidney Cancer (Renal Cell Cancer); Neuroblastoma; Renal Cell Carcinoma; Small-Cell Lung Cancer,Inactive,Global
DC-101,,,Eli Lilly and Co,Ophthalmology, Retinopathy,Inactive,Global
deferoxamine,deferoxamine,,DiaMedica Therapeutics Inc,Central Nervous System, Dementia Associated With Alzheimer's Disease,Inactive,Global
DEL-1 antibody,,,Bristol-Myers Squibb Co,Oncology,,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Musculoskeletal Disorders, Dupuytren Contracture,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Genito Urinary System And Sex Hormones, Kidney Fibrosis,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Toxicology, Radiation Injury,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,United States
DFN-529,,,Diffusion Pharmaceuticals Inc,Infectious Disease, Human Immunodeficiency Virus (HIV) Infections (AIDS),Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Respiratory, Idiopathic Pulmonary Fibrosis,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Immunology, Psoriasis,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Central Nervous System, Epilepsy; Huntington Disease; Parkinson's Disease,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Oncology, Glioblastoma Multiforme (GBM),Inactive,United States
DFN-529,,,Diffusion Pharmaceuticals Inc,Oncology, Breast Cancer; Lung Cancer; Prostate Cancer,Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Ophthalmology, Proliferative Vitreoretinopathy (PVR),Inactive,Global
DFN-529,,,Diffusion Pharmaceuticals Inc,Dermatology, Actinic (Solar) Keratosis; Alopecia; Atopic Dermatitis (Atopic Eczema); Bullous Pemphigoid; Keloids; Rosacea,Inactive,Global
DLX-903,,,Kuur Therapeutics Ltd,Oncology,,Inactive,Global
DM-512,,,Dermadis SAS,Immunology, Psoriasis,Inactive,Global
DN-9693,,,Daiichi Sankyo Co Ltd,Oncology,,Inactive,Global
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy,,,Stanford University,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy,,,Stanford University,Oncology,,Inactive,Global
Drug to Inhibit Tyrosine Kinase for AMD,,,Allergan Ltd,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Drug to Inhibit VEGFR/PDGFR for Oncology,,,Beta Pharma Inc,Oncology,,Inactive,Global
"Drug to Inhibit VEGFR1, VEGFR2 and VEGFR3 for Age Related Macular Degeneration",,,AVEO Pharmaceuticals Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Drug to Inhibit VEGFR2 for Age Related Macular Degeneration,,,Allostera Pharma Inc. (Inactive),Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Drugs to Inhibit HIF1 Alpha for Obesity and Type 2 Diabetes,,,National Cancer Institute US,Metabolic Disorders, Obesity; Type 2 Diabetes,Inactive,Global
Drugs to Inhibit VEGF and ANG 2 for Age Related Macular Degeneration,,,Ambrx Biopharma Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
E-804,,,Hallym University Medical Center,Oncology, Colon Cancer,Inactive,Global
EG-00144,,,Trizell Ltd,Oncology, Solid Tumor,Inactive,Global
EG-01257,,,Trizell Ltd,Oncology, Lung Cancer,Inactive,Global
EG-013,,,Trizell Ltd,Women's Health, Intrauterine Growth Restriction,Inactive,Global
EG-014,,,Trizell Ltd,Oncology, Solid Tumor,Inactive,Global
EG-015,,,Trizell Ltd,Dermatology, Wounds,Inactive,Global
EG-016,,,Trizell Ltd,Cardiovascular, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Inactive,Global
EG-3287,,,Trizell Ltd,Oncology, Solid Tumor,Inactive,Global
EI-014,,,Elixiron Immunotherapeutics Inc,Oncology, Hepatocellular Carcinoma,Inactive,Global
ELB-012,,,Elsalys Biotech SA,Ophthalmology, Neovascular Glaucoma; Retinopathy,Inactive,Global
elpamotide,elpamotide [INN],,OncoTherapy Science Inc,Oncology, Bile Duct Cancer (Cholangiocarcinoma) ; Pancreatic Cancer; Solid Tumor,Inactive,Japan
EM-400,,,Emiliem Inc,Undisclosed, Unspecified,Inactive,Global
Endothelin-1,,,China Sky One Medical Inc,Oncology,,Inactive,Global
ENV-1305,,,Envisia Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
ESBA-903 SR,,,Novartis AG,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
EW-A-401,,,Sangamo Therapeutics Inc,Cardiovascular, Critical Limb Ischemia; Intermittent Claudication; Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Inactive,Global
F-2K3,,,Suzhou Stainwei Biotech Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
fenretinide,fenretinide,,ReVision Therapeutics Inc,Ophthalmology, Choroidal Neovascularization; Geographic Atrophy; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
FG-4497,,,FibroGen Inc,Metabolic Disorders, Obesity,Inactive,Global
FG-4497,,,FibroGen Inc,Central Nervous System, Cerebral Edema; Traumatic Brain Injury,Inactive,Global
FG-4497,,,FibroGen Inc,Immunology, Kidney Transplant Rejection,Inactive,Global
FG-4497,,,FibroGen Inc,Genito Urinary System And Sex Hormones, Acute Renal Failure (ARF) (Acute Kidney Injury),Inactive,Global
FP-1039,,,Five Prime Therapeutics Inc,Oncology, Endometrial Cancer; Malignant Pleural Mesothelioma; Squamous Non-Small Cell Lung Cancer,Inactive,Global
Gene Therapy to Activate FLT1 for Brain Arteriovenous Malformation,,,BioMarin Pharmaceutical Inc,Central Nervous System, Brain Hemorrhage,Inactive,Global
Gene Therapy to Activate IL-12 for Head and Neck Cancer Squamous Cell Carcinoma,,,Dana-Farber Cancer Institute Inc,Oncology, Head And Neck Cancer Squamous Cell Carcinoma; Recurrent Head And Neck Cancer Squamous Cell Carcinoma,Inactive,Global
Gene Therapy to Activate Plasminogen kringle 5 for Diabetic Retinopathy,,,Charlesson LLC,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
"Gene Therapy to Activate VEGF for Cardiovascular Diseases, Diabetic Neuropathy and Thromboangiitis obliterans",,,Madrigal Pharmaceuticals Inc,Cardiovascular, Angina (Angina Pectoris); Cardiovascular Disease; Thromboangiitis obliterans (Buerger disease),Inactive,United States
"Gene Therapy to Activate VEGF for Cardiovascular Diseases, Diabetic Neuropathy and Thromboangiitis obliterans",,,Madrigal Pharmaceuticals Inc,Metabolic Disorders, Diabetic Neuropathy,Inactive,Global
"Gene Therapy to Activate VEGF for Cardiovascular Diseases, Diabetic Neuropathy and Thromboangiitis obliterans",,,Madrigal Pharmaceuticals Inc,Cardiovascular, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Inactive,Global
Gene Therapy to Activate VEGF for Critical Limb Ischemia and Diabetic Neuropathy,,,Northwestern University,Cardiovascular, Critical Limb Ischemia,Inactive,Global
Gene Therapy to Activate VEGF for Critical Limb Ischemia and Diabetic Neuropathy,,,Northwestern University,Metabolic Disorders, Diabetic Neuropathy,Inactive,Global
Gene Therapy to Activate VEGF for Ischemia,,,Biosidus SA,Cardiovascular, Coronary Artery Disease (CAD) (Ischemic Heart Disease),Inactive,Global
Gene Therapy to Activate VEGF-A and bFGF for Coronary Artery Disease,,,Institute of Cardiology Warsaw,Cardiovascular, Coronary Artery Disease (CAD) (Ischemic Heart Disease),Inactive,Global
Gene Therapy to Activate VEGF-D for Placental Insufficiency,,,Magnus Life Ltd (Inactive),Women's Health,,Inactive,Global
Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma,,,Hyogo College Of Medicine,Immunology, Rheumatoid Arthritis,Inactive,Global
Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma,,,Hyogo College Of Medicine,Oncology, Hepatocellular Carcinoma,Inactive,Global
GLV-1h164,,,Genelux Corp,Oncology, Hepatocellular Carcinoma; Triple-Negative Breast Cancer (TNBC),Inactive,Global
golvatinib tartrate  +  lenvatinib mesylate,golvatinib tartrate +  lenvatinib mesylate,,Eisai Co Ltd,Oncology, Melanoma; Recurrent Glioblastoma Multiforme (GBM); Solid Tumor,Inactive,Global
GT-053,,,HEC Pharma Co Ltd,Oncology, Solid Tumor,Inactive,Global
HC-1144,,,Hinova Pharmaceuticals Co Ltd,Oncology,,Inactive,Global
HIV vaccine,,,Emory University,Infectious Disease, Human Immunodeficiency Virus (HIV) Infections (AIDS),Inactive,Global
HP-802247,,,Smith & Nephew Plc,Dermatology, Venous Leg Ulcers (Crural Ulcer); Wounds,Inactive,Global
HPV-19K,,,Suzhou Stainwei Biotech Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
HST-001,,,Histogen Inc,Dermatology, Androgenic Alopecia,Inactive,Global
HST-001,,,Histogen Inc,Gastrointestinal, Crohn's Disease (Regional Enteritis); Ulcerative Colitis,Inactive,Global
HST-001,,,Histogen Inc,Dermatology, Androgenic Alopecia,Discontinued,United States
HuMax-VEGF,,HuMax-VEGF,Genmab AS,Oncology,,Inactive,Global
HuMc-3 mAB,,,Abeona Therapeutics Inc,Oncology, Breast Cancer,Inactive,Global
hydroxychloroquine + sorafenib tosylate,hydroxychloroquine [INN] + sorafenib tosylate,,VG Life Sciences Inc,Oncology, Colon Cancer; Hepatocellular Carcinoma; Lung Adenocarcinoma; Metastatic Ovarian Cancer; Pancreatic Cancer; Solid Tumor; Triple-Negative Breast Cancer (TNBC),Inactive,Global
IMM-2503,,,ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd,Oncology, Solid Tumor,Inactive,Global
IMM-2504,,,ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd,Oncology, Solid Tumor,Inactive,Global
IMMU-101,,,Immunomedics Inc,Oncology, Ovarian Cancer,Inactive,United States
IMMU-101,,,Immunomedics Inc,Oncology, Colorectal Cancer; Pancreatic Cancer,Inactive,Global
INTI-1,,,Intica Biomedical Inc,Oncology, Glioblastoma Multiforme (GBM); Pancreatic Cancer; Triple-Negative Breast Cancer (TNBC),Inactive,Global
IPS-04 series,,,InnoPharmaScreen Inc,Central Nervous System, Alzheimer's Disease,Inactive,Global
IRCR-101,,,Samsung Medical Center,Oncology, Solid Tumor,Inactive,Global
IXS-312,,,InNexus Biotechnology Inc. (Inactive),Metabolic Disorders, Diabetic Retinal Dysplasia,Inactive,Global
IXS-312,,,InNexus Biotechnology Inc. (Inactive),Ophthalmology, Age Related Macular Degeneration,Inactive,Global
K-106,,,Kala Pharmaceuticals Inc,Ophthalmology,,Inactive,Global
KI-10F,,,Inha University,Oncology, Colon Cancer,Inactive,Global
KN-014,,,AlphaMab Co Ltd,Oncology, Bladder Cancer; Colorectal Cancer; Lung Cancer; Metastatic Cancer,Inactive,Global
KN-014,,,AlphaMab Co Ltd,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
KPI-287,,,Kala Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
KPI-287,,,Kala Pharmaceuticals Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
LAU-8080,,,Louisiana State University,Ophthalmology, Corneal Neovascularization,Inactive,Global
linifanib,linifanib,,AbbVie Inc,Oncology, Colorectal Cancer; Metastatic Breast Cancer; Renal Cell Carcinoma,Inactive,Global
linifanib,linifanib,,AbbVie Inc,Oncology, Non-Small Cell Lung Cancer; Solid Tumor,Inactive,Global; Japan
linifanib,linifanib,,AbbVie Inc,Oncology, Hepatocellular Carcinoma,Inactive,EU; United States
linifanib,linifanib,,AbbVie Inc,Oncology, Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia,Inactive,United States
Lm-LLO-Flk1,,,Advaxis Inc,Oncology, Breast Cancer; Solid Tumor,Inactive,Global
LMG-324,,,Novartis AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
LT-1009,,ASONEP,Apollo Endosurgery Inc,Central Nervous System, Multiple Sclerosis,Inactive,Global
LT-1009,,ASONEP,Apollo Endosurgery Inc,Oncology, Renal Cell Carcinoma; Solid Tumor,Inactive,Global
LT-1009,,ASONEP,Apollo Endosurgery Inc,Gastrointestinal, Colitis,Inactive,Global
LT-1009,,iSONEP,Apollo Endosurgery Inc,Metabolic Disorders, Diabetic Retinopathy,Discontinued,Global
LT-1009,,iSONEP,Apollo Endosurgery Inc,Ophthalmology, Choroidal Neovascularization; Retinal Pigment Epithelial (RPE) Detachment; Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
metuzumab,,,Pacific Meniuoke Biopharmaceutical Company,Oncology, Non-Small Cell Lung Carcinoma,Inactive,China
Modulin,,,Novation Pharmaceuticals Inc,Oncology,,Inactive,Global
Modulin,,,Novation Pharmaceuticals Inc,Immunology, Inflammation,Inactive,Global
Monoclonal Antibodies for Oncology,,,Avid Bioservices Inc,Oncology,,Inactive,Global
Monoclonal Antibodies to Target hCG for Oncology,,,"CG Therapeutics, Inc. (Inactive)",Oncology,,Inactive,Global
Monoclonal Antibody to Antagonize Neuropilin for Solid Tumor,,,Eli Lilly and Co,Oncology, Solid Tumor,Inactive,Global
Monoclonal Antibody to Antagonize VEGFR-1 for Oncology and Inflammatory Disorders,,,PharmAbcine Inc,Oncology,,Inactive,Global
Monoclonal Antibody to Antagonize VEGFR-1 for Oncology and Inflammatory Disorders,,,PharmAbcine Inc,Immunology, Inflammation,Inactive,Global
Monoclonal Antibody to Antagonize VEGFR-2 for Age Related Macular Degeneration and Oncology,,,Protelica Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Monoclonal Antibody to Antagonize VEGFR-2 for Age Related Macular Degeneration and Oncology,,,Protelica Inc,Oncology,,Inactive,Global
Monoclonal Antibody to Antagonize VEGFR-3 for Inflammatory Disorders and Oncology,,,PharmAbcine Inc,Oncology,,Inactive,Global
Monoclonal Antibody to Antagonize VEGFR-3 for Inflammatory Disorders and Oncology,,,PharmAbcine Inc,Immunology, Inflammation,Inactive,Global
Monoclonal Antibody to Inhibit AXL for Breast Cancer and Non-Small Cell Lung Cancer,,,Genentech USA Inc,Oncology, Breast Cancer; Non-Small Cell Lung Cancer,Inactive,Global
Monoclonal Antibody to Inhibit DLL4 for Inflammatory Disorders and Oncology,,,PharmAbcine Inc,Immunology, Inflammation,Inactive,Global
Monoclonal Antibody to Inhibit DLL4 for Inflammatory Disorders and Oncology,,,PharmAbcine Inc,Oncology,,Inactive,Global
Monoclonal Antibody to Inhibit VEGF for Oncology,,,LG Chem Ltd,Oncology,,Inactive,Global
Monoclonal Antibody to Inhibit VEGF for Oncology,,,Center of Molecular Immunology,Oncology, Breast Cancer; Colorectal Cancer; Kidney Cancer (Renal Cell Cancer); Lung Cancer,Inactive,Global
Monoclonal Antibody to Inhibit VEGF-A for Wet Macular Degeneration,,,Genentech USA Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
Monoclonal Antibody to Inhibit VEGFA for Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer,,,Beijing Luzhu Biotechnology Co Ltd,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Inactive,China
Monoclonal Antibody to Inhibit VEGFR2 for Metastatic Breast Cancer and Metastatic Adenocarcinoma of the Pancreas,,,Avid Bioservices Inc,Oncology, Metastatic Adenocarcinoma of The Pancreas; Metastatic Breast Cancer,Inactive,Global
Monoclonal Antibody to Target CD147 for Oncology and Immunology,,,The Rappaport Institute,Immunology, Autoimmune Disorders,Inactive,Global
Monoclonal Antibody to Target CD147 for Oncology and Immunology,,,The Rappaport Institute,Oncology, Solid Tumor,Inactive,Global
Monoclonal Antobody to Inhibit Vascular Endothelial Growth Factor for Inflammation,,,CytomX Therapeutics Inc,Immunology, Inflammation,Inactive,Global
MORAb-050,,,Eisai Co Ltd,Oncology, Metastatic Melanoma; Pancreatic Cancer,Inactive,Global
motesanib diphosphate,motesanib diphosphate,,Takeda Pharmaceutical Co Ltd,Oncology, Advanced Malignancy; Esophageal Cancer; Lung Cancer; Metastatic Colorectal Cancer; Pancreatic Cancer; Solid Tumor; Thyroid Cancer,Inactive,Global
motesanib diphosphate,motesanib diphosphate,,Takeda Pharmaceutical Co Ltd,Oncology, Gastrointestinal Stromal Tumor (GIST),Inactive,Japan; United States
motesanib diphosphate,motesanib diphosphate,,Takeda Pharmaceutical Co Ltd,Oncology, Non-Small Cell Lung Cancer,Inactive,Japan; South Korea
motesanib diphosphate,motesanib diphosphate,,Amgen Inc,Oncology, Breast Cancer,Discontinued,United States
motesanib diphosphate,motesanib diphosphate,,Takeda Pharmaceutical Co Ltd,Oncology, Non-Small Cell Lung Cancer,Discontinued,EU; United States
MPBF-001,,,MediaPharma SRL,Genetic Disorders, Von Hippel-Lindau Syndrome,Inactive,Global
MPBF-001,,,MediaPharma SRL,Oncology, Epithelial Tumor; Kidney Cancer (Renal Cell Cancer); Pancreatic Endocrine Tumor; Pheochromocytoma,Inactive,Global
MPC-MICROIO,,,Mesoblast Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
MPHE-001A,,,MediaPharma SRL,Cardiovascular, Ischemic Stroke,Inactive,Global
MPHE-001A,,,MediaPharma SRL,Metabolic Disorders, Diabetic Ischemic Foot Ulcers,Inactive,Global
MPHE-001C,,,MediaPharma SRL,Oncology, Renal Cell Carcinoma,Inactive,Global
MPT-0B098,,,Taipei Medical University,Oncology, Non-Small Cell Lung Cancer,Inactive,Global
MSB-001,,,Transcenta Holding Ltd,Oncology, Gastric Cancer,Inactive,Global
muparfostat sodium,muparfostat sodium,,Medigen Biotechnology Corp,Oncology, Metastatic Melanoma; Non-Small Cell Lung Cancer,Inactive,Global
muparfostat sodium,muparfostat sodium,,TBG Diagnostics Ltd,Oncology," Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer",Inactive,Global
muparfostat sodium,muparfostat sodium,,Medigen Biotechnology Corp,Oncology, Hepatocellular Carcinoma,Discontinued,Global
NM-3,,,Sanofi,Oncology, Solid Tumor,Inactive,Global
NM-3,,,Sanofi,Metabolic Disorders, Diabetic Nephropathy,Inactive,Global
NOV C-ter,,,Sisene Biotechnology (Inactive),Oncology, Colorectal Cancer; Glioblastoma Multiforme (GBM); Non-Small Cell Lung Cancer,Inactive,Global
NOV C-ter,,,Sisene Biotechnology (Inactive),Ophthalmology, Corneal Neovascularization,Inactive,Global
NOV-110201,,,National OncoVenture,Oncology, Glioblastoma Multiforme (GBM),Inactive,Global
NOV-110401,,,National OncoVenture,Oncology, Colon Cancer; Gastric Cancer,Inactive,Global
NPI-1342,,,"Nereus Pharmaceuticals, Inc. (Inactive)",Immunology, Inflammation,Inactive,Global
NPI-1342,,,"Nereus Pharmaceuticals, Inc. (Inactive)",Oncology, Carcinomas; Multiple Myeloma (Kahler Disease); Pancreatic Cancer,Inactive,Global
NPI-1387,,,Triphase Accelerator Corp,Oncology, Carcinomas; Multiple Myeloma (Kahler Disease); Pancreatic Cancer,Inactive,Global
NPI-1387,,,Triphase Accelerator Corp,Immunology, Inflammation,Inactive,Global
NPI-1390,,,Triphase Accelerator Corp,Immunology, Inflammation,Inactive,Global
NPI-1390,,,Triphase Accelerator Corp,Oncology, Carcinomas; Multiple Myeloma (Kahler Disease); Pancreatic Cancer,Inactive,Global
NT-506,,,Neurotech Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
oglufanide disodium,oglufanide disodium,,Cytran Inc. (Inactive),Oncology, Ovarian Cancer; Peritoneal Cancer,Inactive,Global
oglufanide disodium,oglufanide disodium,,Implicit Bioscience Ltd,Infectious Disease, Community-Acquired Infections; Hepatitis C,Inactive,Global
oglufanide disodium,oglufanide disodium,,Cytran Inc. (Inactive),Infectious Disease, Kaposi Sarcoma,Discontinued,Global
OHR-3031,,,NeuBase Therapeutics Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
OMN-54,,Aneustat,Omnitura Therapeutics Inc,Oncology, Breast Cancer; Colorectal Cancer; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Head And Neck Cancer; Liver Cancer; Lymphoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Small-Cell Lung Cancer,Inactive,Global
Oncolytic Virus for Melanoma and Renal Cell Carcinoma,,,Xuzhou Medical College,Oncology, Melanoma; Renal Cell Carcinoma,Inactive,Global
Oncolytic Viruses to Inhibit VEGF for Solid Tumors,,,PsiOxus Therapeutics Ltd,Oncology, Solid Tumor,Inactive,Global
OPK-10050,,,TheraKine Inc (Inactive),Ophthalmology,,Inactive,Global
OSI-632,,,Astellas Pharma Inc,Ophthalmology,,Inactive,Global
OSI-632,,,Pfizer Inc,Oncology, Epithelial Ovarian Cancer; Fallopian Tube Cancer; Non-Small Cell Lung Cancer; Peritoneal Cancer,Discontinued,Global
OSI-817,,,Astellas Pharma Inc,Oncology,,Inactive,Global
OXB-103,,MoNuDin,Oxford BioMedica Plc,Central Nervous System, Amyotrophic Lateral Sclerosis,Inactive,Global
OXB-203,,,Oxford BioMedica Plc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
PBF-1350,,,Palo BioFarma SL,Oncology, Lung Cancer,Inactive,Global
pegdinetanib,pegdinetanib,,Bristol-Myers Squibb Co,Oncology, Solid Tumor,Inactive,Global; Japan
pegdinetanib,pegdinetanib,,Bristol-Myers Squibb Co,Oncology, Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Non-Hodgkin Lymphoma; Non-Small Cell Lung Cancer,Inactive,Global
Pegylated Arginine Deiminase,,,AngioLab Inc,Musculoskeletal Disorders, Arthritis,Inactive,Global
Pegylated Arginine Deiminase,,,AngioLab Inc,Immunology, Psoriasis,Inactive,Global
Pegylated Arginine Deiminase,,,AngioLab Inc,Ophthalmology,,Inactive,Global
PEGylated Recombinant Proteins to Inhibit VEGF for Rheumatoid Arthritis and Cancer,,,Bolder Biotechnology Inc,Oncology,,Inactive,Global
PEGylated Recombinant Proteins to Inhibit VEGF for Rheumatoid Arthritis and Cancer,,,Bolder Biotechnology Inc,Immunology, Rheumatoid Arthritis,Inactive,Global
Peptide for Oncology and Ophthalmology,,,Trizell Ltd,Ophthalmology,,Inactive,Global
Peptide for Oncology and Ophthalmology,,,Trizell Ltd,Oncology,,Inactive,Global
Peptide for Wounds,,,Universidade de Coimbra,Dermatology, Wounds,Inactive,Global
Peptide to Agonize Prokineticin Receptor for Women Health,,,Takeda Pharmaceutical Co Ltd,Women's Health,,Inactive,Global
PF-337210,,,Pfizer Inc,Oncology, Solid Tumor,Inactive,Global
PF-655,,,Pfizer Inc,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
PF-655,,,Pfizer Inc,Ophthalmology, Open-Angle Glaucoma; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
PGF,,,Suzhou Stainwei Biotech Inc,Dermatology, Wounds,Inactive,Global
PLG-101,,,PhiloGene Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
PLG-101,,,PhiloGene Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
PLG-201,,,PhiloGene Inc,Oncology, Ewing Sarcoma; Melanoma; Prostate Cancer; Renal Cell Carcinoma; Solid Tumor,Inactive,Global
PLG-202,,,PhiloGene Inc,Oncology, Solid Tumor,Inactive,Global
PMX-290,,,Pharminox Ltd (Inactive),Oncology, Breast Cancer; Colon Cancer; Kidney Cancer (Renal Cell Cancer),Inactive,Global
POS-001,,,Kedem Pharmaceuticals Inc,Dermatology,,Inactive,Global
PR-11,,,University of Texas Health Science Center at Houston,Immunology, Inflammation,Inactive,Global
PR-39,,,University of Texas Health Science Center at Houston,Immunology, Inflammation,Inactive,Global
propranolol hydrochloride,propranolol hydrochloride,,InfectoPharm Arzneimittel und Consilium GmbH,Non Malignant Disorders, Infantile Hemangiomas,Inactive,EU
Protein to Inhibit VEGF for Cardiovascular Disease,,,Beth Israel Deaconess Medical Center,Cardiovascular, Cardiovascular Disease,Inactive,Global
Protein to Inhibit VEGF for Ophthalmology,,,Lotus Innovative Health Ltd,Ophthalmology, Age Related Macular Degeneration; Neovascular Glaucoma,Inactive,Global
Protein to Inhibit VEGF for Ophthalmology,,,Lotus Innovative Health Ltd,Metabolic Disorders, Proliferative Diabetic Retinopathy (PDR),Inactive,Global
Protein to Inhibit VEGF for Ophthalmology 1,,,Lotus Innovative Health Ltd,Ophthalmology,,Inactive,Global
PRS-055,,,Pieris Pharmaceuticals Inc,Ophthalmology,,Inactive,Global
PS-388023,,,Pharmacopeia Inc,Ophthalmology, Corneal Neovascularization,Inactive,Global
PTX-004,,,PepTx Inc,Oncology, Breast Cancer; Colon Carcinoma; Glioma; Lung Cancer; Melanoma; Ovarian Cancer,Inactive,Global
PTZ-329,,,Astellas Pharma Inc,Oncology, Melanoma,Inactive,Global
PTZ-329,,,Astellas Pharma Inc,Oncology, Breast Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Ovarian Cancer; Pancreatic Cancer,Discontinued,Global
PTZ-329,,,Astellas Pharma Inc,Oncology," Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Non-Small Cell Lung Cancer",Discontinued,Global; Japan
PX-12,,,Seagen Inc,Oncology, Gastrointestinal Tract Cancer; Metastatic Cancer; Pancreatic Cancer,Inactive,Global
ramucirumab biosimilar,,,Shanghai Henlius Biotech Inc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Inactive,China
ranibizumab biosimilar,,,AlphaMab Co Ltd,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
ranibizumab biosimilar,,,AlphaMab Co Ltd,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
ranibizumab biosimilar,,,Zenotech Laboratories Ltd,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
ranibizumab biosimilar,,,Pelican Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
ranibizumab biosimilar,,,BioXpress Therapeutics SA,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
Recombinant Peptides for Oncology and Ophthalmology,,,Northwestern University,Oncology,,Inactive,Global
Recombinant Peptides for Oncology and Ophthalmology,,,Northwestern University,Ophthalmology,,Inactive,Global
Recombinant Protein for Amyotrophic Lateral Sclerosis,,,Royal College of Surgeons Ireland,Central Nervous System, Amyotrophic Lateral Sclerosis,Inactive,Global
Recombinant Protein to Activate VEGF for Respiratory Distress Syndrome,,,Flanders Institute for Biotechnology,Respiratory, Neonatal Respiratory Distress Syndrome,Inactive,Global
Recombinant Protein to Antagonize VEGF and PDGF for Thyroid Cancer and Wound Healing,,,Trophogen Inc,Dermatology, Wounds,Inactive,Global
Recombinant Protein to Antagonize VEGF and PDGF for Thyroid Cancer and Wound Healing,,,Trophogen Inc,Oncology, Thyroid Cancer,Inactive,Global
Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology,,,PhiloGene Inc,Oncology, Colon Carcinoma; Ewing Sarcoma; Prostate Cancer; Renal Cell Carcinoma,Inactive,Global
Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology,,,PhiloGene Inc,Metabolic Disorders, Diabetic Nephropathy,Inactive,Global
Recombinant Protein to Inhibit PD1 and VEGF-A for Hematological Malignancies and Solid Tumor,,,Molecular Partners AG,Oncology, Hematological Tumor; Solid Tumor,Inactive,Global
Recombinant Protein to Inhibit VEGFB Receptor for Oncology and Ophthalmology,,,PhiloGene Inc,Oncology, Melanoma,Inactive,United States
Recombinant Protein to Inhibit VEGFB Receptor for Oncology and Ophthalmology,,,PhiloGene Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
Recombinant Protein to Inhibit VEGFB Receptor for Oncology and Ophthalmology,,,PhiloGene Inc,Oncology, Bladder Cancer; Breast Cancer; Colon Cancer; Kidney Cancer (Renal Cell Cancer); Prostate Cancer; Sarcomas; Solid Tumor,Inactive,Global
Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration,,,Sesen Bio Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
RERF,,,National Cancer Institute US,Oncology,,Inactive,Global
RNAi Oligonucleotide to Inhibit VEGFR2 for Oncology and Ophthalmology,,,Silence Therapeutics plc,Ophthalmology, Corneal Neovascularization,Inactive,Global
RNAi Oligonucleotide to Inhibit VEGFR2 for Oncology and Ophthalmology,,,Silence Therapeutics plc,Oncology, Glioma; Neuroblastoma,Inactive,Global
RPI-4610,,,"Actis Biologics, Inc (Inactive)",Oncology, Colorectal Cancer; Kidney Cancer (Renal Cell Cancer); Lung Cancer,Inactive,Global
SA-981,,,Santen Pharmaceutical Co Ltd,Immunology, Rheumatoid Arthritis,Inactive,Global
SB-267268,,,GSK plc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
SCT-501A,,,SinoCelltech Group Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
scVEGF/Lu-177,,,SibTech Inc,Oncology, Triple-Negative Breast Cancer (TNBC),Inactive,Global
SD-282,,,Johnson & Johnson,Respiratory, Asthma; Chronic Obstructive Pulmonary Disease (COPD),Inactive,Global
SD-282,,,Johnson & Johnson,Immunology, Inflammation; Rheumatoid Arthritis,Inactive,Global
SD-282,,,Johnson & Johnson,Hematological Disorders, Neutrophilia,Inactive,Global
SD-282,,,Johnson & Johnson,Central Nervous System, Hyperalgesia,Inactive,Global
SD-282,,,Johnson & Johnson,Oncology, Breast Cancer; Leukemia; Multiple Myeloma (Kahler Disease); Myelodysplastic Syndrome,Inactive,Global
semaxanib,semaxanib,,Pfizer Inc,Genetic Disorders, Von Hippel-Lindau Syndrome,Inactive,Global
semaxanib,semaxanib,,Pfizer Inc,Infectious Disease, Kaposi Sarcoma,Inactive,Global
semaxanib,semaxanib,,Pfizer Inc,Oncology, Metastatic Colorectal Cancer,Discontinued,Global
SL-002,,,i2 Pharmaceuticals Inc,Oncology,,Inactive,Global
Small Molecule for Dry (Atrophic) Macular Degeneration and Geographic Atrophy,,,Aerie Pharmaceuticals Inc,Ophthalmology, Dry (Atrophic) Macular Degeneration; Geographic Atrophy,Inactive,Global
Small Molecule to Antagonize PDGFR and VEGFR-2 for Oncology,,,Takeda Pharmaceutical Co Ltd,Oncology, Lung Cancer; Prostate Cancer,Inactive,Global
Small Molecule to Inhibit Hypoxia Inducible Factor 1 for Asthma,,,University of California Los Angeles,Respiratory, Asthma,Inactive,Global
Small Molecule to Inhibit Hypoxia inducible factor-1 for Ophthalmology,,,LegoChem Biosciences Inc,Ophthalmology,,Inactive,Global
Small Molecule to Inhibit Hypoxia-Sensing Transcriptional Regulator for Oncology,,,Epigenetix Inc (Inactive),Oncology,,Inactive,Global
Small Molecule to Inhibit IGF-1 Receptor for Colorectal Cancer,,,Astellas Pharma Inc,Oncology, Colorectal Cancer; Fibrosarcoma,Inactive,Global
Small Molecule To Inhibit Kinase Insert Domain Receptor For Oncology,,,Sentinel Oncology Ltd,Oncology,,Inactive,Global
Small Molecule to Inhibit S6K1 For Breast Cancer,,,Sentinel Oncology Ltd,Oncology, Breast Cancer,Inactive,Global
Small Molecule to Inhibit Vascular Endothelial Growth Factor for Oncology,,,Women and Infants Hospital of Rhode Island,Oncology,,Inactive,Global
Small Molecule to Inhibit VEGFR for Colorectal Cancer,,,Ascendis Pharma AS,Oncology, Colorectal Cancer,Inactive,Global
Small Molecule to Inhibit VEGFR2 for Kidney Cancer,,,AB Science SA,Oncology, Kidney Cancer (Renal Cell Cancer),Inactive,Global
Small Molecules 5 for Oncology,,,Instituto Biomar SA,Oncology,,Inactive,Global
Small Molecules for Ischemic Stroke,,,University of Queensland,Cardiovascular, Ischemic Stroke,Inactive,Global
"Small Molecules to Antagonize CXCR4 for HIV, Rheumatoid Arthritis and Carcinomas",,,Kyoto University,Oncology, Carcinomas,Inactive,Global
"Small Molecules to Antagonize CXCR4 for HIV, Rheumatoid Arthritis and Carcinomas",,,Kyoto University,Infectious Disease, Human Immunodeficiency Virus (HIV) Infections (AIDS),Inactive,Global
"Small Molecules to Antagonize CXCR4 for HIV, Rheumatoid Arthritis and Carcinomas",,,Kyoto University,Immunology, Rheumatoid Arthritis,Inactive,Global
Small Molecules to Antagonize VEGF-R and PDGF-R for Multiple Sclerosis,,,Cotinga Pharmaceuticals Inc,Central Nervous System, Multiple Sclerosis,Inactive,Global
Small Molecules to Antagonize VEGFR for Retinal Neovascularization,,,Charlesson LLC,Ophthalmology,,Inactive,Global
Small Molecules to Antagonize VEGFR2 for Solid Tumors,,,Novartis AG,Oncology, Solid Tumor,Inactive,Global
"Small Molecules to Inhibit Cyclin D1, CDK6, EGFR and VEGF for Oncology",,,University of Granada,Oncology, Breast Cancer; Colorectal Cancer; Lung Cancer; Melanoma; Myeloproliferative Disorders; Pancreatic Cancer,Inactive,Global
Small Molecules to Inhibit FGFR for Oncology,,,"Proacta, Inc. (Inactive)",Oncology,,Inactive,Global
Small Molecules to Inhibit HIF1A for Oncology and Metabolic Syndrome,,,Lead Discovery Center GmbH,Oncology,,Inactive,Global
Small Molecules to Inhibit HIF1A for Oncology and Metabolic Syndrome,,,Lead Discovery Center GmbH,Metabolic Disorders, Metabolic Syndrome,Inactive,Global
Small Molecules to Inhibit Integrin and Vascular Endothelial Growth Factor Receptor for Age Related Macular Degeneration and Oncology,,,Clanotech AB,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Small Molecules to Inhibit Integrin and Vascular Endothelial Growth Factor Receptor for Age Related Macular Degeneration and Oncology,,,Clanotech AB,Oncology,,Inactive,Global
Small Molecules to Inhibit Multi-Target Tyrosine kinase for Oncology,,,MI.TO. Technology SrL,Oncology,,Inactive,Global
Small Molecules to Inhibit S6K for Oncology,,,ArQule Inc,Oncology,,Inactive,Global
Small Molecules to Inhibit SRPK1 for Prostate Cancer,,,Exonate Ltd,Oncology, Prostate Cancer,Inactive,Global
"Small Molecules to Target eNOS, nNOS and NO Synthase for Oncology",,,University of California Santa Cruz,Oncology,,Inactive,Global
somatostatin,somatostatin [INN],,BCN Peptides SA,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
squalamine lactate,squalamine lactate,,Ohr Pharmaceutical Inc (Inactive),Metabolic Disorders, Diabetic Macular Edema; Proliferative Diabetic Retinopathy (PDR),Inactive,Global
squalamine lactate,squalamine lactate,,Ohr Pharmaceutical Inc (Inactive),Oncology, Non-Small Cell Lung Cancer; Ovarian Cancer; Prostate Cancer,Inactive,Global
squalamine lactate,squalamine lactate,,Ohr Pharmaceutical Inc (Inactive),Musculoskeletal Disorders, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva),Inactive,Global
squalamine lactate,squalamine lactate,,Ohr Pharmaceutical Inc (Inactive),Ophthalmology, Retinal Vein Occlusion,Inactive,Global
squalamine lactate,squalamine lactate,Evizon,Ohr Pharmaceutical Inc (Inactive),Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
SR-16388,,,SRI International,Oncology," Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Multiple Myeloma (Kahler Disease)",Inactive,Global
ST-101,,,Northwestern University,Oncology,,Inactive,Global
Stem Cell Therapy for Acute Myocardial Infarction,,,Medestea Research & Production SpA,Cardiovascular, Myocardial Infarction,Inactive,Global
STP-523,,,Sirnaomics Ltd,Oncology, Glioblastoma Multiforme (GBM),Inactive,Global
STP-601,,Acurita,Sirnaomics Ltd,Ophthalmology, Age Related Macular Degeneration; Corneal Neovascularization; Herpetic Keratitis,Inactive,United States
STP-601,,Acurita,Sirnaomics Ltd,Metabolic Disorders, Proliferative Diabetic Retinopathy (PDR),Inactive,United States
STP-801,,,Sirnaomics Ltd,Oncology, Glioblastoma Multiforme (GBM); Non-Small Cell Lung Cancer,Inactive,Global
STP-801,,,Sirnaomics Ltd,Immunology, Transplant Rejection,Inactive,Global
sunitinib malate CR,sunitinib malate,,Graybug Vision Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Inactive,Global
sunitinib malate CR,sunitinib malate,,Graybug Vision Inc,Metabolic Disorders, Diabetic Macular Edema,Inactive,Global
suramin hexasodium,suramin hexasodium,,Optimum Therapeutics LLC,Oncology, Bladder Cancer; Non-Small Cell Lung Cancer,Inactive,Global
SVN-002,,,Eloxx Pharmaceuticals Inc,Oncology, Metastatic Renal Cell Carcinoma,Inactive,Global
SYN-20112312RU,,,SynBio,Cardiovascular, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD),Inactive,Global
Synthetic Peptide for Age-Related Macular Degeneration and Diabetic Retinopathy,,,Xequel Bio Inc,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Synthetic Peptide for Age-Related Macular Degeneration and Diabetic Retinopathy,,,Xequel Bio Inc,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
Synthetic Peptide For Cardiovascular Disease,,,Meytav Technological Incubator,Cardiovascular, Cardiovascular Disease; Ischemia,Inactive,Global
Synthetic Peptide to Antagonize Neuropilin-1 Receptor for Glioma,,,French National Institute of Health and Medical Research,Oncology, Glioma,Inactive,Global
Synthetic Peptide to Antagonize Vascular Endothelial Growth Factor for Age Related Macular Degeneration,,,Cosmix Molecular Biologicals GmbH (Inactive),Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Synthetic Peptide to Antagonize VPAC1 for Breast and Colon Cancer,,,Longevity Biotech Inc,Oncology, Breast Cancer; Colon Cancer,Inactive,Global
Synthetic Peptides for Wound Healing and Neurodegenerative Diseases,,,Boston Children's Hospital,Central Nervous System, Neurodegenerative Diseases,Inactive,Global
Synthetic Peptides for Wound Healing and Neurodegenerative Diseases,,,Boston Children's Hospital,Dermatology, Wounds,Inactive,Global
Synthetic Peptides to Inhibit PAMP for Oncology,,,Panorama Researchama Research,Oncology,,Inactive,Global
Synthetic Peptides to Target VEGF for Choroidal Neovascularization,,,The Cleveland Clinic Foundation,Ophthalmology, Choroidal Neovascularization,Inactive,Global
Synthetic Protein for Diabetic Retinopathy,,,Johns Hopkins University,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
T-1840383,,,Takeda Pharmaceutical Co Ltd,Oncology, Gastric Cancer,Inactive,Global
taberminogene vadenovec,taberminogene vadenovec [INN],Trinam,Trizell Ltd,Cardiovascular, Intimal Hyperplasia,Inactive,Global
talmapimod,talmapimod,,Johnson & Johnson,Oncology, Multiple Myeloma (Kahler Disease),Inactive,Global
talmapimod,talmapimod,,Johnson & Johnson,Oncology, Myelodysplastic Syndrome,Discontinued,Global
talmapimod,talmapimod,,Johnson & Johnson,Immunology, Rheumatoid Arthritis,Discontinued,Global
TAS-2913,,,Taiho Pharmaceutical Co Ltd,Oncology, Non-Small Cell Lung Cancer,Inactive,Global
TAS-2985,,,Taiho Pharmaceutical Co Ltd,Oncology, Gastric Cancer,Inactive,Global
tesetaxel,tesetaxel [INN],,Genta Incorporated (Inactive),Oncology, Gastric Cancer,Inactive,EU; United States
tesetaxel,tesetaxel [INN],,Genta Incorporated (Inactive),Oncology," Bladder Cancer; Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Metastatic Transitional (Urothelial) Tract Cancer",Inactive,Global
tesetaxel,tesetaxel [INN],,Daiichi Sankyo Co Ltd,Oncology, Advanced Malignancy; Solid Tumor,Inactive,Japan
tesetaxel,tesetaxel [INN],,Genta Incorporated (Inactive),Oncology, Melanoma,Inactive,United States
tesetaxel,tesetaxel [INN],,Odonate Therapeutics Inc,Oncology, Triple-Negative Breast Cancer (TNBC),Discontinued,Global
tesetaxel,tesetaxel [INN],,Odonate Therapeutics Inc,Oncology, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer),Discontinued,EU; United States
tigapotide triflutate,tigapotide triflutate,,Kotinos Pharmaceuticals Inc,Oncology, Metastatic Prostate Cancer,Inactive,Global
TLK-60404,,,MabVax Therapeutics Holdings Inc,Oncology, Colon Cancer; Leukemia; Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer,Inactive,Global
TLK-60596,,,MabVax Therapeutics Holdings Inc,Oncology, Colon Cancer,Inactive,Global
TM-601,,,Eisai Co Ltd,Oncology, Anaplastic Astrocytoma; Central Nervous System (CNS) Tumor; Glioblastoma Multiforme (GBM); High-Grade Glioma; Melanoma; Oligodendroglioma; Recurrent Malignant Glioma ; Solid Tumor,Inactive,Global
TM-601,,,Eisai Co Ltd,Oncology, Glioma,Inactive,EU
TW-01003,,,United Biomedical Inc,Oncology,,Inactive,Global
U-94,,,Medestea Research & Production SpA,Oncology, Metastatic Cancer,Inactive,Global
UB-924,,,United BioPharma Inc,Oncology, Brain Cancer; Colorectal Cancer; Kidney Cancer (Renal Cell Cancer); Non-Small Cell Lung Cancer,Inactive,Global
UBP-1212,,,Shanghai Junshi Bioscience Co Ltd,Oncology, Metastatic Colorectal Cancer,Inactive,Global
UBP-1212,,,Shanghai Junshi Bioscience Co Ltd,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
V-1932,,,Teraclon IDF SL,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
Vaccine for Non-Small Cell Lung Cancer,,,Fukushima Medical University,Oncology, Non-Small Cell Lung Cancer,Inactive,Global
Vaccine for Pancreatic Cancer,,,University of Tokyo,Oncology, Pancreatic Cancer,Inactive,Global
Vaccine to Target VEGF-Alpha for Age Related Macular Degeneration and Solid Tumors,,,Neovacs SA,Oncology, Colorectal Cancer; Ovarian Cancer,Inactive,Global
Vaccine to Target VEGF-Alpha for Age Related Macular Degeneration and Solid Tumors,,,Neovacs SA,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Vaccine to Target VEGFR-1 and VEGFR-2 for Ophthalmology,,,Osaka University,Ophthalmology, Age Related Macular Degeneration; Ophthalmology,Inactive,Global
Vaccine to Target VEGFR1 for Oncology,,,Kinki University School of Medicine,Oncology," Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer; Renal Cell Carcinoma",Inactive,Japan
vatalanib,vatalanib,,Novartis AG,Genetic Disorders, Von Hippel-Lindau Syndrome,Inactive,Global
vatalanib,vatalanib,,Novartis AG,Non Malignant Disorders, Hemangiomas,Inactive,Global
vatalanib,vatalanib,,Novartis AG,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Meningioma; Myelodysplastic Syndrome",Inactive,Global
vatalanib,vatalanib,,Novartis AG,Oncology, Colorectal Cancer; Diffuse Large B-Cell Lymphoma; Glioma; Non-Small Cell Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumor,Discontinued,Global
vatalanib,vatalanib,,Novartis AG,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
VEGF Mimetic,,,Trizell Ltd,Cardiovascular, Atherosclerosis,Inactive,Global
VEGF/rGel,,,Targa Therapeutics Corp,Ophthalmology, Age Related Macular Degeneration,Inactive,Global
VEGF/rGel,,,Targa Therapeutics Corp,Oncology, Bladder Cancer; Bone Metastasis; Breast Cancer; Melanoma; Metastatic Lung Cancer; Pancreatic Cancer; Prostate Cancer; Solid Tumor,Inactive,Global
VEGF/rGel,,,Targa Therapeutics Corp,Metabolic Disorders, Diabetic Retinopathy,Inactive,Global
VEGI-192A,,,"ProteomTech, Inc. (Inactive)",Oncology,,Inactive,Global
VEGI-192A,,,"ProteomTech, Inc. (Inactive)",Ophthalmology, Age Related Macular Degeneration,Inactive,Global
Veglin,,,VasGene Therapeutics Inc,Oncology, Malignant Mesothelioma; Renal Cell Carcinoma,Inactive,Global
VEL-015,,,Velacor Therapeutics Pty Ltd (Inactive),Central Nervous System, Alzheimer's Disease,Inactive,Global
VEL-015,,,Velacor Therapeutics Pty Ltd (Inactive),Oncology," Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer",Inactive,Global
VGX-100,,,Opthea Ltd,Immunology, Corneal Graft Rejection,Inactive,Global
VGX-100,,,Opthea Ltd,Oncology, Breast Cancer; Cervical Cancer; Colon Cancer; Glioblastoma Multiforme (GBM); Ovarian Cancer; Renal Cell Carcinoma; Solid Tumor,Inactive,Global
VGX-100,,,Opthea Ltd,Ophthalmology, Keratoconjunctivitis Sicca (Dry Eye),Inactive,Global
VGX-200,,,Opthea Ltd,Respiratory, Lymphangioleiomyomatosis,Inactive,Global
VGX-200,,,Opthea Ltd,Oncology, Solid Tumor,Inactive,Global
VMDA-3601,,,Helixmith Co Ltd,Cardiovascular, Coronary Artery Disease (CAD) (Ischemic Heart Disease),Inactive,Global
VMDA-3601,,,Helixmith Co Ltd,Cardiovascular, Critical Limb Ischemia,Inactive,South Korea
VX-35,,,Vaccinex Inc,Oncology, Breast Cancer,Inactive,Global
VX-70,,,Vaccinex Inc,Oncology, Rhabdomyosarcoma,Inactive,Global
WSD-1227,,,Wayshine Biopharma Inc,Oncology, Colorectal Cancer; Glioblastoma Multiforme (GBM); Metastatic Brain Tumor; Ovarian Cancer,Inactive,United States
XD-001,,,AlphaMab Co Ltd,Oncology,,Inactive,Global
YBL-008,,,Y-Biologics Inc,Oncology,,Inactive,South Korea
(aflibercept + nesvacumab),(aflibercept + nesvacumab),,Regeneron Pharmaceuticals Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Discontinued,United States
(aflibercept + nesvacumab),(aflibercept + nesvacumab),,Regeneron Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,United States
4SC-203,,,4SC AG,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)",Discontinued,Global
ABT-100,,,AbbVie Inc,Oncology, Solid Tumor,Discontinued,Global
aflibercept biosimilar,,,Coherus BioSciences Inc,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
aflibercept biosimilar,,,Coherus BioSciences Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Discontinued,Global
AG-13958,,,Pfizer Inc,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization,Discontinued,Global
AGN-745,,,Merck & Co Inc,Ophthalmology, Age Related Macular Degeneration; Choroidal Neovascularization,Discontinued,Global
ALN-VEG01,,,Alnylam Pharmaceuticals Inc,Ophthalmology, Age Related Macular Degeneration,Discontinued,Global
AVA-101,,,Adverum Biotechnologies Inc,Ophthalmology, Retinal Vein Occlusion; Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
AVA-201,,,Adverum Biotechnologies Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
AZD-9935,,,AstraZeneca Plc,Oncology, Solid Tumor,Discontinued,Global
bevacizumab biosimilar,,,Momenta Pharmaceuticals Inc,Oncology, Glioblastoma Multiforme (GBM); Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer,Discontinued,Global
bevacizumab biosimilar,,,Eden Biologics Inc,Oncology, Colorectal Cancer,Discontinued,EU
bevacizumab biosimilar,,,Eden Biologics Inc,Oncology, Non-Small Cell Lung Cancer; Ovarian Cancer,Discontinued,China; EU
bevacizumab biosimilar,,,Eden Biologics Inc,Oncology, Cervical Cancer; Glioblastoma Multiforme (GBM); Metastatic Colorectal Cancer; Renal Cell Carcinoma,Discontinued,China
BMOV,,,GHO Holding BV,Cardiovascular, Ischemic Stroke,Discontinued,Global
BMOV,,,GHO Holding BV,Dermatology, Burns,Discontinued,Global
CVX-241,,,Pfizer Inc,Oncology, Advanced Malignancy; Solid Tumor,Discontinued,Global
DE-120,,,Santen Pharmaceutical Co Ltd,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,United States
F-200,,,PDL BioPharma Inc,Ophthalmology, Age Related Macular Degeneration,Discontinued,Global
foretinib,foretinib,,GSK plc,Oncology, Adenocarcinoma Of The Gastroesophageal Junction; Gastric Cancer; Hepatocellular Carcinoma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Papillary Renal Cell Carcinoma; Recurrent Head And Neck Cancer Squamous Cell Carcinoma,Discontinued,Global
GW-824575,,,GSK plc,Respiratory, Asthma,Discontinued,Global
GW-824575,,,GSK plc,Ophthalmology, Age Related Macular Degeneration,Discontinued,Global
GZ-402663,,,Sanofi,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
H-409/22,,,AstraZeneca Plc,Cardiovascular, Coronary Artery Disease (CAD) (Ischemic Heart Disease),Discontinued,Global
iCo-007,,,Satellos Bioscience Inc,Metabolic Disorders, Diabetic Macular Edema,Discontinued,Global
icrucumab,icrucumab,,Eli Lilly and Co,Oncology, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Metastatic Colorectal Cancer; Transitional Cell Carcinoma (Urothelial Cell Carcinoma),Discontinued,Global
interferon alfa-2b + lovastatin,interferon alfa-2b + lovastatin,,NeoPlas Innovation,Oncology, Melanoma,Discontinued,Global
LY-3022856,,,Eli Lilly and Co,Oncology, Advanced Malignancy; Colorectal Cancer; Solid Tumor,Discontinued,Global
MK-0888,,,Merck & Co Inc,Oncology,,Discontinued,Global
NT-503,,,Neurotech Pharmaceuticals Inc,Ophthalmology, Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,Global
OCV-101,,,Otsuka Holdings Co Ltd,Oncology, Pancreatic Cancer,Discontinued,Japan
parsatuzumab,parsatuzumab,,Genentech USA Inc,Oncology, Solid Tumor,Discontinued,Global; Japan
parsatuzumab,parsatuzumab,,Genentech USA Inc,Oncology, Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Discontinued,Global
PF-04605412,,,Pfizer Inc,Oncology, Metastatic Cancer; Solid Tumor,Discontinued,Global
phVEGF,,,Fornix BioSciences N.V. (Inactive),Metabolic Disorders, Diabetes,Discontinued,Global
phVEGF,,,Fornix BioSciences N.V. (Inactive),Cardiovascular, Ischemia,Discontinued,Global
PRS-050,,Angiocal,Pieris Pharmaceuticals Inc,Oncology, Solid Tumor,Discontinued,Global
ranibizumab biosimilar,,,Coherus BioSciences Inc,Metabolic Disorders, Diabetic Macular Edema; Diabetic Retinopathy,Discontinued,United States
ranibizumab biosimilar,,,Coherus BioSciences Inc,Ophthalmology, Macular Edema; Wet (Neovascular / Exudative) Macular Degeneration,Discontinued,United States
S-646240,,,Shionogi & Co Ltd,Ophthalmology, Age Related Macular Degeneration,Discontinued,Japan
SB-509,,,Sangamo Therapeutics Inc,Metabolic Disorders, Diabetic Neuropathy,Discontinued,Global
SB-509,,,Sangamo Therapeutics Inc,Central Nervous System, Amyotrophic Lateral Sclerosis; Spinal Cord Injury; Traumatic Brain Injury,Discontinued,Global
SB-509,,,Sangamo Therapeutics Inc,Cardiovascular, Stroke,Discontinued,Global
sNN-0029,,,Newron Pharmaceuticals SpA,Central Nervous System, Amyotrophic Lateral Sclerosis,Discontinued,Global
suramin hexasodium,suramin hexasodium,,Pfizer Inc,Oncology," Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer",Discontinued,United States
TAK-593,,,Takeda Pharmaceutical Co Ltd,Oncology, Solid Tumor,Discontinued,Global
telbermin,telbermin,,Genentech USA Inc,Metabolic Disorders, Diabetic Foot Ulcers,Discontinued,Global
vesencumab,vesencumab,,F. Hoffmann-La Roche Ltd,Oncology, Solid Tumor,Discontinued,Global
XL-820,,,Exelixis Inc,Oncology, Gastrointestinal Stromal Tumor (GIST); Solid Tumor,Discontinued,Global
XL-999,,,Symphony Evolution Inc,Oncology," Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Colorectal Cancer; Metastatic Renal Cell Carcinoma; Multiple Myeloma (Kahler Disease); Non-Small Cell Lung Cancer; Ovarian Cancer",Discontinued,Global
